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Abstract 
Throughout ontogeny the mammalian brain shows windows of time during which there is an 
increased sensitivity towards the programming effects of external and endogenous signals. The 
general assumption is that such phases of increased sensitivity correspond to dynamic phases 
of brain development and maturation. Programming of neuronal pathways and functions takes 
place during phases of ontogeny which are characterized by high susceptibility to noxious 
stimuli and may comprise numerous mechanisms. With regard to the programming of 
neuroendocrine mechanisms of adaptation, the perinatal period in rodents offers the unique 
opportunity to examine the effect of stress and steroid hormones during a phase characterized 
by high vulnerability and underdeveloped (immature) capacity of neuroendocrine adaptation. 
Thus, inadequate signals, leading to disturbed homeostasis can result in mal-programming of 
brain functions, therefore leading to increased vulnerability to the development of disorders of 
the central nervous, but also peripheral systems. While both physiological and pathological 
programming have been associated with altered brain structure, gene expression and function, 
the mechanisms through which these effects are established and maintained throughout life are 
not well understood.  
In the present work, we focused on the mechanisms of programming and mal-programming of 
the hypothalamus-pituitary-adrenal (HPA) axis and their structural, behavioral and 
neuroendocrine correlates. We have identified several mechanisms through which stress, 
glucocorticoids but also sex-steroids during early ontogeny can affect brain function in later life 
by altering HPA axis function. As dysregulation of HPA axis function has been associated with 
many disorders of the brain, such as depression and cognitive disorders, studying the factors 
contributing to the physiological and pathological programming of the HPA axis could contribute 
to a better understanding of the pathophysiology of CNS disorders.   
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Sumário 
Ao longo da ontogenia o cérebro dos mamíferos apresenta janelas temporais nas quais há 
maior sensibilidade para os efeitos programadores de sinais externos e internos. A ideia 
generalizada é a de que estas fases de maior sensibilidade correspondem a fases mais 
dinâmicas do desenvolvimento e maturação cerebral. A programação das vias neuronais e das 
suas funções ocorre durante fases ontogénicas que se caracterizam por uma elevada 
sensibilidade a estímulos nóxicos e pode envolver diversos mecanismos. Com respeito aos 
efeitos programadores sobre os mecanismos neuroendócrinos de adaptação, o período 
perinatal nos roedores oferece uma oportunidade única para examinar os efeitos do stress e 
das hormonas esteroides durante uma fase caracterizada por uma elevada vulnerabilidade e 
imaturidade da adaptação neuroendócrina. Assim, sinais inadequados, induzem distúrbios 
homeostáticos que podem resultar em má programação das funções cerebrais, e 
consequentemente numa maior vulnerabilidade para o desenvolvimento de doenças do sistema 
nervoso central, mas também dos sistemas periféricos. Os efeitos programadores fisiológicos e 
patológicos têm sido associados com alterações da estrutura cerebral, mas os mecanismos 
pelos quais estes efeitos ocorrem e são mantidos ao longo da vida não são ainda bem 
conhecidos. 
Neste trabalho, centramos a nossa atenção nos mecanismos programadores do eixo 
hipotalâmico-hipofisário-adrenal (HPA) e nos seus correlatos estruturais, comportamentais e 
neuroendócrinos. Identificamos vários mecanismos pelos quais a exposição ao stress, aos 
glucocorticóides mas também aos esteroides sexuais durante o processo ontogénico, podem 
afetar a função cerebral mais tarde na vida através da alteração da função do eixo HPA. Como 
a desregulação do eixo HPA tem sido associada a várias doenças cerebrais, tais como a 
depressão e perturbações cognitivas, o estudo dos fatores que contribuem para os efeitos 
programadores fisiológicos e patológicos do eixo HPA pode contribuir para um melhor 
entendimento da fisiopatologia das doenças do sistema nervoso central. 
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1. Introduction 
The neuroendocrine regulation of hypothalamus-pituitary-adrenal axis function 
The well-orchestrated secretion of glucocorticoids (GC) by the adrenal cortex represents one of 
the major adaptive responses in the mammalian organism. GC are steroid hormones, and as 
such derivatives of cholesterol. Their de novo production and secretion is induced in the 
fasciculate zone of the adrenal cortex upon stimulation through pituitary derived 
adrenocorticotrophic hormone (ACTH). There are two major ACTH secretagogues released by 
parvocellular neurons of the paraventricular hypothalamic nucleus (PVN) – corticotrophin 
releasing hormone (CRH) and arginine vasopressin (AVP) (Charmandari et al., 2005). Both 
peptide-hormones act on their respective receptors (CRH receptor 1, and Vasopressin receptor 
1b) in corticotroph cells of the anterior pituitary lobe in a synergistic fashion to induce secretion 
of stored ACTH (Charmandari et al., 2005; Aguilera, 2011). In addition both hormones have 
been shown to induce transcription of the proopiomelanocortin (POMC) gene and the 
posttranslational processing of POMC to ACTH. The parvocellular division of the PVN, where 
CRH and AVP are co-expressed, receives regulatory inputs from many intra- and 
extrahypothalamic sites (Sawchenko et al., 2000; Aguilera, 2011; Cole and Sawchenko, 2002).  
However the general assumption is that the regulation of CRH and AVP gene expression in the 
PVN and their secretion into the portal blood stream at the median eminence is governed by 
two major limbic structures: the hippocampal formation and the amygdala (Jankord and 
Herman, 2008). Both structures project to the bed nucleus of the stria terminalis (BNST) which 
plays the role of a functional relay integrating both signals (Jankord and Herman, 2008; Choi et 
al., 2007; Herman et al., 2002; Ventura-Silva et al., 2012). In general, the hippocampal 
formation exerts an inhibitory control on HPA axis function, while the amygdala stimulates 
adrenocortical secretions (Jankord and Herman, 2008). In the neural control of PVN activity, the 
BNST exerts the role of a functional relay which toggles the input of superimposed regulatory 
centers. Hippocampal glutamate and amygdaloid GABA-ergic pathways project onto the GABA-
ergic efferent BNST neurons, which innervate the PVN (Choi et al., 2007; Herman et al., 2002; 
Jankord and Herman, 2008). The corresponding excitation and inhibition of BNST perikarya 
underlie the mechanisms of hippocampal suppression and amygdaloid stimulation of PVN 
activity.  
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GC regulate HPA axis activity through negative feedback loops which occur at all of the above 
described levels. A major role for autocrine regulation at the level of the adrenal cortex seems 
unlikely as glucocorticoid receptors (GR) are mostly (but not exclusively) expressed in the cells 
of the androgen-producing reticular zone (Paust et al., 2006; Gummow et al., 2006). GR 
expression has been shown in pituitary corticotroph cells, and recent studies suggest a role for 
the balance between pituitary and adrenocortical GR expression as one of the reasons for high 
inter-individual variability of HPA axis function in humans (Briassoulis et al., 2011). While 
pituitary GR can negatively affect POMC gene expression through a negative GR response 
element (GRE) (Drouin et al., 1989; Drouin et al., 1987), glucocorticoids – as small lipophilic 
molecules – readily pass the blood-brain barrier (BBB) and affect CRH and AVP expression in 
the PVN (Charmandari et al., 2005).  
Numerous studies have suggested that GC regulate CRH gene expression, however, direct 
actions of GC at a GRE on the CRH promoter have so far only been shown in vitro in the AtT20 
pituitary tumor cell line (Malkoski et al., 1997; Malkoski and Dorin, 1999). The current data 
suggest that GC signaling in CRH neurons in the PVN interacts with other (e.g. neurotransmitter) 
signaling cascades originating at the cell membrane (Kageyama et al., 2010; Aguilera and Liu, 
2012; Kageyama and Suda, 2009). Similarly, while GC have been implicated in the direct 
regulation of AVP gene expression and mRNA stability (Volpi et al., 2004; Yoshida, 2008), the 
interaction with other signaling cascades seems crucial for GC negative feedback on AVP. 
Interestingly, to this date it is not clear to what extent the direct interaction of activated GR with 
CRH and AVP gene expression is involved in the regulation of the negative GC feedback 
(Yoshida, 2008). There are striking contrasts in the literature due to experimental models used 
(in vitro vs. in vivo, tumor cell lines vs. primary neuronal and organotypic slice cultures).  
Studies in adrenalectomized and GC-supplemented rodents have suggested direct inhibitory 
effects of GC on CRH and AVP expression and secretion, as well as differential sensitivity of both 
genes to the inhibitory actions of GC (Albeck et al., 1994; Makino et al., 1995). However studies 
from our lab have shown, that dexamethasone, a highly potent and selective synthetic GR 
agonist, actually increases CRH secretion from cultured hypothalamic neurons, while at the 
same time AVP secretion is suppressed (Hellbach et al., 1998). In contrast, studies in the AtT20 
cell line suggest a direct negative action of activated GR on CRH gene expression (Malkoski and 
Dorin, 1999). Experiments using organotypic slice cultures suggest that the activational state of 
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the parvocellular PVN neurons determines the extent (quality and quantity of) GC effects on 
CRH and AVP expression and secretion (Kuwahara et al., 2003; Arima et al., 2001; Aguilera 
and Liu, 2012).  
Taken together there seems to be certain involvement of GR in parvocellular PVN neurons in the 
regulation of the negative GC feedback, however it is evident that neuronal signals from other 
GC-sensitive brain structures (i.e. the above mentioned limbic areas as well as brain stem 
monoaminergic neuronal populations) are the main regulators of CRH and AVP production and 
secretion from the PVN. The direct signals from brainstem catecholaminergic neuronal 
populations to the PVN are mostly driving HPA axis activity and represent an immediate 
response to physical stressors (such as pain, hemorrhage or metabolic challenges) (Pacák and 
Palkovits, 2001).  
In contrast, the role of limbic structures in HPA axis activity regulation becomes manifest when 
psychological stressors are imposed. The perception of such psychological stressors is highly 
subjective and the quality and magnitude of the behavioral and endocrine response to these 
stressors is mostly dependent on previous experience and mnemonic processes (Jankord and 
Herman, 2008; Sousa and Almeida, 2012). Therefore it is not surprising that both, the 
hippocampal formation and the extended amygdala are implicated in learning and conditioning 
processes as well as the “mnemonic” and “emotional” control of HPA axis regulation (Jankord 
and Herman, 2008; Pacák and Palkovits, 2001).  
The assumption of a major role of the hippocampal formation in regulating HPA axis function 
and GC negative feedback is derived from rodent studies, where subiculum lesions lead to a 
disinhibition of HPA axis activity (Herman and Mueller, 2006; Herman et al., 2003), however 
the anatomical route of the hippocampal output seems to determine its involvement in negative 
feedback regulation (Bradbury et al., 1993). Additionally the hippocampus is the one site in the 
brain which shows the highest expression of corticosteroid receptors (Reul and de Kloet, 1986) 
as well as the highest amount of binding of radio-labeled corticosteroids (De Kloet et al., 1975). 
The hippocampus therefore has been ascribed the role of the major site of GC negative 
feedback.  
The effects of GC on hippocampal structure and function are numerous and highly dependent 
on the dose and duration of the GC and will be discussed below. Besides direct transcriptional 
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effects, the neural GC-mediated regulation of hypothalamic neuropeptide secretion is 
accomplished largely by the above-described hippocampal glutamate and amygdaloid GABA-
ergic projections onto BNST efferent neurons (Choi et al., 2007; Herman et al., 2002). GR 
activation in hippocampal neurons is associated with a glutamatergic surge, which, via BNST 
stimulation, ultimately conveys suppression of PVN secretory output. On the contrary, GR 
activation in amygdaloid neurons results in enhanced GABA-ergic output to the BNST and, 
eventually, disinhibition of PVN neurosecretory cells.  
Further amygdaloid “drive” originates from CRH neurons located in its central nucleus, which 
bolster the PVN activation through activation of glutamate and CRH-releasing efferents located 
in the anteromedial BNST (Makino et al., 1994a; Cole and Sawchenko, 2002). It is pertinent to 
note that, unlike in the PVN, activation of GR in amygdaloid CRH-producing neurons increases 
the expression of this neuropeptide (Makino et al., 1994b). The molecular mechanisms 
underlying this phenomenon are not well understood, however it seems plausible that also in 
the CeA GC interact with other signaling cascades, probably differently than in the PVN. Another 
possibility could be that the CRH gene in the amygdala has a functional positive GRE, while that 
is not the case in the PVN; one possible explanation for this disparity could be local differences 
in the epigenetic control of CRH gene expression, however to date this is mere speculation. As 
is the case for the hippocampus, the effects of GC on amygdaloid neurons highly depend on 
timing (onset and duration) and dose of GC exposure as well as on other (e.g. neurotransmitter) 
signals converging on these structures (Joëls et al., 2009; Krishnan and Nestler, 2010; 
Sarabdjitsingh et al., 2012).  
In a very simplified cascade the events of HPA response to a psychological stressor we believe 
the following occurs:  
Sensory information of the stressor is projected from the primary sensory cortical areas through 
thalamic gating mechanisms to the hippocampus and the amygdala, where we believe that the 
information is processed in terms of comparison with previous life experience (memory 
processes) and the emotional evaluation of this information.  
The outcome of this “evaluation”, which also involves reciprocal interactions between 
hippocampus, amygdala and prefrontal cortex (PFC) (Radley and Sawchenko, 2011; Radley et 
al., 2006) is the disinhibition of the PVN by the BNST leading to surge firing and release of CRH 
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and AVP. It should be noted that the duration and quality of the stress exposure determines the 
balance between the synergistic molecules CRH and AVP: while in acute settings CRH 
expression and release are strongly increased, in chronic (or repeated) stress situations CRH 
expression is “normalized” while AVP expression and secretion are further increased.  
CRH and AVP are released into the portal blood stream of the anterior pituitary where they lead 
to the release of stored ACTH from corticotroph cells as well to the induction of POMC gene 
expression and its posttranslational processing. At this stage it should be noted that additional 
factors secreted from hypothalamic and brainstem neurons at the median eminence (such as 
dopamine, noradrenaline, serotonin but also glutamate and GABA) also affect corticotroph cell 
function (Labrie et al., 1987).  
ACTH in turn binds to its receptor on adrenocortical cells (although GC are mainly produced in 
the fasciculate zone of the adrenal cortex, ACTH receptors are also expressed in the glomerular 
and reticular zone, where they have also been shown to govern steroidogenesis (production of 
mineralocorticoids and androgens respectively). As steroidogenic cells can not store their 
secretory product, all steroids are synthesized and secreted de novo on demand, which takes a 
considerable amount of time – up to several minutes.  
GC are not primarily involved in the immediate stress response (which is mainly mediated by 
catecholamines), but rather in the adaptive response to a stressor, aiming to restore 
homeostasis (Charmandari et al., 2005). These effects include metabolic alterations aiming to 
mobilize energy from internal stores, reduction of energy expenditure by suppression of 
processes not immediately necessary for survival (e.g. immunomodulation) and alteration of 
brain functions (including behavioral and endocrine alterations and adaptation) (Sternberg et al., 
1992; Patchev and Patchev, 2006).  
The classic view is that in their nature as ligand activated transcription factors, corticosteroid 
receptors mediate GC actions by altering gene expression, which again requires more time 
(minutes to hours). While this underlines the importance of GC action to the mounting of an 
adaptive response to stress by governing the so called “late” phase of the response (de Kloet et 
al., 2005), over the last decades evidence of rapid (within milliseconds to few minutes) GC 
effects which are independent of gene transcription and de novo protein synthesis has 
accumulated , however we are still far away from understanding how these “rapid” GC effects 
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integrate into the adaptive response to stress (Riedemann et al., 2010). In addition the 
molecular mechanisms involved in rapid GC signaling are not well understood; for instance it 
still remains to be shown beyond doubt if there is a membrane receptor for corticosteroids and 
what the nature of this receptor might be. It is however plausible to assume, that the slowly 
increasing amounts of GC secreted by the adrenal cortex upon activation by ACTH act via these 
rapid signaling mechanisms to affect behavioral and endocrine functions (including a role in 
mediating negative GC feedback) before the effects of classical GC signaling cascade (i.e. 
altered gene expression and protein synthesis) can be observed.  
For the sake of simplicity and brevity, rapid GC signaling will be neglected in this introduction, 
especially as there still is more discordance than consensus on its mechanisms and biological 
functions (see Riedemann et al., 2010 for a review on this topic).  
It is important to point out that HPA axis function is different between both sexes. Females 
(rodents as well as higher primates) display substantially higher amounts of circulating ACTH 
and GCs, as well as higher expression of hypothalamic CRH and AVP (Patchev and Almeida, 
1998). Interestingly however at the same time females display higher GC negative feedback 
sensitivity than males and higher expression of corticosteroid receptors in relevant limbic and 
hypothalamic brain areas (Patchev and Almeida, 1996). Previous studies from our lab have 
ascribed a significant role for the early ontogenetic sex-steroid milieu in the sex-specific 
organization of HPA axis function (Patchev et al., 1999) and part of the present work has 
attempted to dissect the distinct roles of estrogen receptor isoforms in this process.  
The biology of corticosteroid receptor function 
There are two types of corticosteroid receptors – the glucocorticoid (GR) and the 
mineralocorticoid receptor (MR). As steroid receptors, both share a common structure and act 
as ligand activated transcription factors (Gronemeyer et al., 2004). Both, GR and MR, can bind 
endogenous glucocorticoids (corticosterone in rodents and cortisol in higher primates and 
humans), however with different affinities. While MR binds corticosterone with a 5-7 times 
higher affinity than GR (Reul and de Kloet, 1986), GR is not capable of binding 
mineralocorticoids (aldosterone) in notable quantities (Spencer et al., 1990; Funder, 2012). 
However the amount of aldosterone that can pass the BBB is negligible (Geerling and Loewy, 
2009) as are the amounts of this hormone which have been shown to be produced in loco by 
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some neurons and astrocytes (Gomez-Sanchez et al., 2005; Geerling and Loewy, 2009). 
Therefore, the main corticosteroid in the brain, which participates in the regulation of HPA axis 
function, is corticosterone (in rodents). The differential affinities of MR and GR have led to the 
“balance” hypothesis of corticosteroid signaling (De Kloet et al., 1998): brain MR are already 
occupied and activated by low amounts of corticosterone (i.e. at the circadian through of HPA 
axis activity), while GR are activated when GC levels increase (e.g. at the circadian zenith of HPA 
axis activity or upon exposure to and perception of stress). This finding suggests that shifts in 
the balance between MR and GR activation lead to differential transcriptomic and physiological 
responses, which depend on the availability of corticosterone.  
While the balance hypothesis provides a suitable model to describe the differential effects of low 
and high doses of GC on hippocampal gene expression and function (Datson et al., 2012; De 
Kloet et al., 1998; Evans and Arriza, 1989), it should be noted that there are additional levels of 
fine-tuning GC signaling in the brain (and elsewhere). For instance, many tissues (including 
different limbic brain areas, as the hippocampus and the amygdala) express 11-
Hydroxysteroid-dehydrogenase (11-HSD) type 2, an enzyme which can actively convert the 
active corticosterone (in humans cortisol) to its inactive 11-keto-form 11-dehydrocorticosterone 
(in humans cortisone) (Wyrwoll et al., 2011). The biotransformation of GC by 11-HSD 
(especially type 2) represents an auxiliary mechanism of GC level adjustment in loco and fine 
tuning of GR- and MR-mediated control of HPA activity. Still, it should be noted that the 
expression of 11-HSD itself is subject to regulation by stress and GC (Low et al., 1994; Walker 
et al., 1994; Wyrwoll et al., 2011).  
In addition GR and MR, as all steroid receptors, are involved in complex interactions with the 
transcriptional machinery, e.g. direct and indirect interactions with transcription factors and 
their signaling cofactors. Studies from this lab and others have indicated that MR and GR recruit 
similar co-activators and co-repressors (such as SRC1, TIF-2, NCoR1) (Tirard et al., 2004; van 
der Laan et al., 2008; de Kloet et al., 2009) and it seems plausible that both receptors, when 
co-expressed (which is believed to be mostly the case) are in some degree competing for the 
interaction with these molecules (Meijer, 2002; Lonard and O’Malley, 2012), which would also 
represent a mechanism of fine tuning GC action.  
Upon ligand activation, GR and MR dissociate from their interaction with chaperones (Grad and 
Picard, 2007) (such as hsp90, hsp70), form homodimers and translocate into the nucleus, 
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where they bind to their respective response element, and via their AP1 site also modulate 
cAMP-dependent gene transcription (Yoshida et al., 2006; Díaz-Gallardo et al., 2010). To date it 
is not clear, if GR and MR actually form heterodimers in vivo (Nishi and Kawata, 2007), which 
would add another level of complexity (but also finesse) to the regulation of GC signaling in the 
brain.  
While the GR-MR balance hypothesis surely has contributed to our understanding of 
corticosteroid physiology in the hippocampus, it also bears the danger of misleading. For 
instance, the question to what extent the quantity of a protein is indicative of its functioning, 
remains unanswered. Several studies have disproved the original assumption that in the brain 
MR is exclusively expressed in the hippocampus and some subnuclei of the amygdala (Reul and 
de Kloet, 1986), and we now know that indeed in most brain areas MR and GR are co-
expressed (Geerling and Loewy, 2009), however MR in much lower quantities than GR (and 
both less than in the hippocampus). This leads to the question if the MR-GR balance hypothesis 
is valid also in these structures, i.e. if in these structures GR is the dominating mediator of GC 
actions or if the low quantities of MR are still sufficient to balance and counteract excessive GR 
activation.  
The reasons for our current lack of knowledge are numerous, however the limited molecular 
and pharmacological tools are probably the most prominent. To date there are no antibodies 
with high selectivity for MR, making chromatin immuno-praecipitation (ChIP) assays for MR at 
least not reliable beyond doubt, thus prohibiting the identification of MR and GR specific target 
genes (Geerling and Loewy, 2009; Gomez-Sanchez et al., 2006). Also, our pharmacological tool 
box is rather limited when it comes to highly selective corticosteroid receptor agonists and 
antagonists, especially when BBB penetration is a requirement. Dexamethasone, while highly 
selective for GR with negligible binding at MR, has been shown to not enter the murine, in 
contrast to the rat, brain (de Kloet et al., 2005) (Meijer et al., 1998) (De Kloet et al., 1975). The 
most commonly used GR antagonist mifepristone (RU 486) is actually a potent antigestagen 
(Heikinheimo et al., 1987) with strong antimineralocorticoid activity (Li et al., 1999), whose 
potential to penetrate the BBB is rather low (Heikinheimo and Kekkonen, 1993), thus making 
GR-selective dosing practically impossible.  
Studies in animals with general or brain-specific transgenesis or mutations of corticosteroid 
receptors and their cofactors have shed some light on the distinct roles of GR and MR on brain 
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structure and function (Wintermantel et al., 2004; Charlier and Balthazart, 2005), however 
prompt the question of potential compensatory processes making up for the genetic 
manipulation. Some of these studies will be discussed in greater detail in the course of this 
manuscript, however many of them also report paradoxical phenomena (Tronche et al., 1999; 
Kaufer et al., 2004; Mitra et al., 2009; Patchev et al., 2007) and therefore have not been able 
to answer all questions of corticosteroid signaling in the brain.  
Stress and glucocorticoid actions in the brain  
As described above, GC mediate a major, but not the only response to a stressful stimulus. 
Therefore it is important to point out, that GC and stress might actually have differential effects 
on brain functions, i.e. that not all effects of stress on behavioral and endocrine brain functions 
as well as brain structure can be reproduced by exogenous GC application (Patchev and 
Patchev, 2006). This dissociation is interesting from a physiological point of view, in order to 
understand the mechanisms and effects of basal (non-stress-related) alterations in GC secretion 
(e.g. circadian and ultradian oscillations) (Lightman et al., 2008) vs. those induced by stress, 
where GC actions are only one (even if major) part of the plethora of well orchestrated 
physiological processes. 
In general it should be considered that corticosteroids, while on the one hand absolutely 
necessary for brain function, can exert pathological effects on brain structure and function (de 
Kloet et al., 2005; Sousa et al., 2008; Sousa and Almeida, 2012). The main factors contributing 
to this outcome are: i) timing and duration of the exposure and ii) the quantity of GC. In general 
the same can be applied in respect to the adaptive and mal-adaptive effects of stress, however 
while the chronicity of stress and GC exposure can be compared, the individual (subjective) 
assessment of a potentially stressful situation (i.e. different individuals have different 
perceptions of one and the same stressor) is more difficult to assess, especially in rodents 
(Sousa et al., 2006; Patchev and Patchev, 2006).  
Acute and chronic stress have extensively been shown to affect emotional behaviors in rodents 
and humans, including anxiety-related behavior and fear  as well as coping style and depression-
like behavior  (Bessa et al., 2009; Pêgo et al., 2008; Pêgo et al., 2010). Thus chronic stress 
models employing psychological stressors have been ascribed the role of rodent models of 
human depression (Bessa et al., 2009; Lupien et al., 2009; McEwen, 2005). Indeed, stress in 
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humans has been identified as a major risk factor for CNS disorders such as depression and 
anxiety disorders (Krishnan and Nestler, 2010; Chrousos and Gold, 1992; Meyer et al., 2001), 
as well as cognitive disorders (Sotiropoulos et al., 2008b; Lupien et al., 2009; Koenig et al., 
2011). Studies from our labs and others have shown that chronic unpredictable stress leads to 
cognitive impairments and even activates amyloidogenic pathways believed to be involved in the 
pathogenesis of Alzheimer’s disease (Sotiropoulos et al., 2008b; Sotiropoulos et al., 2011; 
Sotiropoulos et al., 2008a; Catania et al., 2009). However the mechanistic dissection of how 
stress affects emotional and cognitive behaviors and brain structure is not easy, as only some, 
but not all of these effects can be reproduced (quali- and quantitatively) by chronic 
administration of high doses of GC (Patchev and Patchev, 2006; Liberzon and Young, 1997; 
Imaki et al., 1991). In terms of emotional and cognitive behavior as well as neuromorphology 
and physiology GC actions on the brain are dependent on the activation of both MR and GR and 
the balanced interplay between these receptors seems to determine the neuroadaptational 
outcome (de Kloet et al., 2005). Studies from our labs and others have shown that MR activity 
is crucial for maintenance of neuronal structure and function (Reul et al., 2000; Hassan et al., 
1996; Hassan et al., 1999). For instance, patients suffering from adrenocortical insufficiency 
display hippocampal granule cell loss (Maehlen and Torvik, 1990). Correspondingly, 
adrenalectomized animals display strong cell death and dendritic atrophy in the dentate gyrus of 
the hippocampus (Sloviter et al., 1993; Andrés et al., 2006), which can be preserved by low 
dose application of corticosterone or a MR agonist (Sloviter et al., 1993; Hassan et al., 1996). 
On the other side, high doses of the selective GR agonist dexamethasone lead to neuronal 
apoptosis and reduced dendritic arborization in the hippocampus and the prefrontal cortex 
(Sousa et al., 2008; Hassan et al., 1996; Yu et al., 2008), structures crucially involved in 
emotional and cognitive behavioral functions (Sousa and Almeida, 2012; Bessa et al., 2009). 
Interestingly however, GR activation in the amygdala results in increased dendritic branching 
which indicates that not only the interplay between MR and GR, but also the cellular milieu (e.g. 
neuronal input, paracrine environment) influence the effects of GC on neuronal morphology and 
function (Sarabdjitsingh et al., 2012; Pêgo et al., 2008; Roozendaal et al., 2009).  
In addition to the interplay between MR and GR and the cellular environment, the chronicity of 
stress/GC exposure determines their neurophysiological and –structural effects (Sousa and 
Almeida, 2012). Interestingly different behavioral domains seem to be affected differentially by 
acute vs. chronic stress/GC exposure. For instance, while acute stress or GC exposure seems 
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to enhance certain domains of cognition (Yuen et al., 2011), chronic settings lead to 
impairment of cognitive functions (Sousa and Almeida, 2012; Cerqueira et al., 2007; Joëls et 
al., 2006). Similarly stress and GC affect emotional behaviors differentially depending on the 
duration and intensity/dose: while acute, as well as chronic stress/GC application increase 
anxiety-related behaviors (Mitra and Sapolsky, 2008; McEwen et al., 2012), only chronic 
stress/GC exposure have negative effects on depression-like behaviors (Bessa et al., 2009). 
Taken together it seems important to point out, that GC (either fluctuating under basal circadian 
conditions or as an adaptive response to a stressor) are essential for the integrity of brain 
function and structure. However exposure to high doses of GC over longer periods (e.g. 
exogenous or by mal-adaptive response to a stressful situation) lead to alterations in neuronal 
structure and function with a distinct spatio-termporal pattern. 
Programming and mal-programming of the HPA axis and the consequences for 
mental health 
Programming of the brain is a very broad term referring to those physiological processes which 
determine the long-term functioning of neuronal networks (i.e. the “hard wiring” of brain 
circuits). The programming stimuli are both endogenous (e.g. developmental changes in 
hormone secretion) and environmental (e.g. alimentary state, stress) (Dörner, 1983; Hanson et 
al., 2011a). Timing seems to play the most important role for physiological programming and 
brain organization. The general concept is that programming and organization processes take 
place mainly during early ontogeny (embryonal, fetal, neonatal) (Andersen, 2003). However 
recently adolescence and puberty have also been shown to be critical time windows during 
which the brain is not only undergoing maturation, but also organization of neuronal networks 
and therefore seems highly susceptible for programming and mal-programming by endogenous 
and exogenous signals (Schulz et al., 2009; Vigil et al., 2011; Koenig et al., 2011). These 
findings indicate that brain programming is an ongoing process (or a plethora of ongoing 
processes) well beyond early ontogeny and that exogenous impacts can interfere with these 
(possibly throughout the entire lifespan) depending on their timing (onset and duration), quality 
and quantity (strength). Such “mal-programming” refers to the long-term consequences of 
disrupted programming mechanisms through exogenous or endogenous stimuli which have 
occurred “at the wrong time, at the wrong place” and/or with the wrong intensity. Studying the 
programming and mal-programming of the HPA axis is medically relevant due to the 
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pathophysiological involvement of GCs in many brain (e.g. depression, Alzheimer’s disease) (de 
Kloet et al., 2005; Sotiropoulos et al., 2008b), metabolic (e.g. Diabetes mellitus, obesity, 
osteoporosis), immune and hematological disorders (Charmandari et al., 2005; Sternberg et al., 
1992)  
The objective of the present work was to assess the mechanisms of neonatal programming of 
neuronal circuits governing HPA axis function.  
In detail we scrutinized:  
- the epigenetic mechanisms involved in mal-programming effects of neonatal stress on 
HPA axis function and their long-term consequences (Chapter 1, publication by 
Murgatroyd, Patchev et al. 2010). 
- the neuro-morphological, endocrine and behavioral long-term effects of selective 
neonatal GR activation leading to depletion of the neuronal precursor pool (Chapter 2, 
publication by Yu, Patchev et al., 2010). 
- the involvement of estrogen receptor isoforms (ER and ER) in the process of sex-
specific organization of HPA axis function (Chapter 3, publication by Patchev et 
al., 2011). 
In addition, in ongoing studies we have assessed the long-term consequences of peripubertal 
exposure to chronic stress and diet induced obesity. In these studies we show clearly that stress 
and metabolic challenges during puberty have sex-specific sustained (mal-programmed) effects 
on cognitive and emotional behaviors as well as HPA axis function, and we now aim to identify 
the cellular and molecular mechanisms involved in the establishment and maintenance of these 
mal-programmed effects. These findings however illustrate, that programming and mal-
programming of the brain are possible even beyond the neonatal time window (e.g. during 
puberty).  
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2. Results 
2.1 Chapter 1: Dynamic DNA methylation programs persistent adverse 
effects of early life stress 
Murgatroyd C, Patchev AV, Wu Y et al., Nature Neuroscience, 2009 
2.1.1 Rationale 
This study aimed to examine the epigenetic mechanisms involved in programming of HPA axis 
functions through neonatal stress. The stress paradigm (maternal separation) was chosen for its 
well-established long-term behavioral and endocrine phenotype in rodents. Upon verification of 
the presence of hypercorticism and the expression of the tentative aberrant emotional 
behavioral phenotype, we chose a specialized, post-mitotic neuronal population, namely AVP 
neurons in the parvocellular division of the PVN, for the examination of epigenetic changes 
induced by early life stress.   
2.1.2 Major findings 
- early life stress (ELS) in mice has persistent endocrine and behavioral consequences for 
up to 1 year of age 
- these changes are associated with increased expression of AVP in the parvocellular 
division of the PVN 
- increased AVP mRNA expression in ELS mice is associated with reduced  DNA 
methylation in the intergenic enhancer region of the AVP gene 
- ELS-associated AVP enhancer hypomethylation does not occur immediately after 
neonatal stress exposure and is established within certain time lag, with biochemical 
hallmarks in post-mitotic neurons becoming manifest after 10 days of age.  
- The emergence of ELS-induced AVP enhancer hypomethylation is, at least partly, 
dependent on activity-driven intracellular Ca2+-signalling converging onto site-specific 
phosphorylation of MeCP2 
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- CamKII-dependent phosphorylation of MeCP2 at Serine residue 438 is increased in AVP 
neurons of pups exposed to neonatal stress, but not in adult animals with a history of 
ELS 
- MeCP2 phosphorylation at S438 had been shown to be associated with reduced 
MeCP2 binding capacity to methylated CpG islands (Zhou et al., 2006; Flavell and 
Greenberg, 2008); accordingly, we presume that stress-induced MeCP2 
phosphorylation leads to its dissociation form the AVP enhancer, thus enabling active or 
passive de-methylation of this gene locus. This process, however, seems to be time-
dependent, with stress-induced MeCP2-phosphorylation playing a decisive role in its 
initiation. 
2.1.3 Conclusions 
Alterations in DNA methylation can be induced by exogenous noxious influence during early life, 
even in postmitotic, highly specialized neuronal populations. Once established, these epigenetic 
changes can persist throughout life, albeit displaying certain age dynamics (e.g. age-dependent 
decline in overall methylation levels). Activity (experience) driven epigenetic marking can occur 
during early ontogeny and have sustained physiological effects. Stress during early life can mal-
program the HPA axis through epigenetic alterations in neurons of neuroendocrine relevance.  
2.1.4 Outlook / ongoing studies 
- We obtained first evidence for sex-specific differential targeting of neurochemical 
mechanisms by ELS. While the current study showing changes in AVP was carried out 
in males, we observed that in females with a history of ELS also CRH mRNA expression 
was increased. We also noticed that CRH and AVP gene methylation patterns differ 
between the sexes in both control and ELS conditions. Ongoing investigations aim to 
understand the basis of this sex dichotomy and the importance of adult sex hormone 
secretions for the manifestation of HPA axis dysregulation upon ELS exposure. 
- Further work addresses the regulation of GR expression and function in limbic and 
neuroendocrine systems of animals with ELS history. We have first evidence for distinct 
alterations in the spatio-temporal expression patterns of GR mRNA in the brain of ELS 
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mice, which might explain their disturbed glucocorticoid negative feedback efficacy. In 
the PVN of adult mice with ELS history we detected increased GR expression and 
function (as measured by in vivo ChIP assays), despite increased CpG methylation 
within the GR promoter region. Currently we examine the role of the insulator protein YY 
as a crucial regulator of GR expression and function (Bockmühl, Kuczynska, Patchev, et 
al. in preparation). 
- Striking functional alterations associated with ELS were also seen at the pituitary level. 
In pituitary corticotrophs ELS leads to increased expression of POMC mRNA in both 
sexes, with qualitative and quantitative methylation patterns within the POMC gene 
being differentially affected by sex. ELS has also sustained effects on corticotroph 
sensitivity to ACTH secretagogues and glucocorticoid suppression. Ongoing work is 
focusing on ELS-induced alterations in the epigenetic marking of the POMC (Wu, Daniel, 
Patchev et al, in preparation).  
- It remains unclear whether the pharmacological and/or environmental reversibility of 
ELS phenotype (as reported elsewhere (MacQueen et al., 2003; Navailles et al., 2008; 
Francis et al., 2002) is accompanied by changes in epigenetic marking. Future studies 
in our lab will address this issue.  
2.1.5 Contributions 
- involvement in planning and performance of the in vivo studies, including behavioral 
and endocrine phenotyping  
- histological analysis (ISH, ICC, confocal microscopy).  
- elaboration and validation of a method for micropunching of frozen brain tissue en 
block with simultaneous collection of sections for in situ hybridization by adapting the 
Palkovits micro-dissection technique (Palkovits, 1986). This method allowed us to 
concomitantly analyze DNA methylation (in punch specimens) and RNA expression (in 
sections) in each animal, thus permitting individual data monitoring and cross-
validation.  
- Involvement in writing the publication. 
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Figure 1  Summary and proposed model on the mechanisms through which 
neonatal stress alters DNA-methylation at the AVP enhancer region 
Neonatal stress effects on the PVN are exerted through limbic and brainstem monoaminergic signals to the PVN, where 
neuronal activity leads to phosphorylation of MeCP2 at S438, thus causing dissociating of MeCP2 from methylated CpG islands, 
which allows for demethylation. The interactions between limbic, cortical and brainstem neuronal populations under the 
influence of neonatal stress are not well understood, but it is assumed that neonatal stress causes structural and functional 
alterations in these brain areas as well; therefore the here described programming effects of neonatal stress in AVP neurons 
could be the “by proxy” result of these structural and functional rearrangements in limbic monoaminergic neuronal populations.  
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Epigenetic regulation of gene expression allows the integration 
of intrinsic and environmental signals in the genome1. Greater 
emphasis is being placed on the role of epigenetic mechanisms in 
facilitating the adaptation of organisms to changing environments 
through alterations in gene expression. Evidence that dietary or 
pharmacological interventions have the potential to reverse envi-
ronment-induced modification of epigenetic states2–5 has provided 
an additional impetus for understanding the epigenetic basis of 
disease, including disorders of the brain. It has been suggested that 
epigenetic mechanisms underlie brain plasticity, a process requiring 
stable modulation of gene expression6,7. DNA methylation is one of 
the most intensely studied epigenetic mechanisms8 and recent work 
has suggested that this form of gene regulation may determine risk 
for psychiatric disorders3,9,10.
Exposure to stress during neurodevelopment has an effect on the 
quality of physical and mental health11,12. Periodic infant-mother sep-
aration during early postnatal life is one of the most commonly used 
procedures for inducing ELS in rodents. It is characterized by life-
long elevated glucocorticoid secretion, heightened endocrine respon-
siveness to subsequent stressors and disruption of the homeostatic 
mechanisms that regulate the activity of the hypothalamo-pituitary-
adrenal (HPA) axis, all of which are considered to be pathogenetic 
factors in disorders of mood and cognition13–15.
Here we examined the coupling of experience-driven neuronal 
activity with DNA methylation and gene expression6. We focused on 
the expression of the two hypothalamic secretagogues that regulate 
HPA axis activity by increasing the synthesis and release of pitui-
tary adrenocorticotropin, namely, AVP and corticotropin-releasing 
hormone (CRH). Abundant evidence links AVP and CRH to mood 
and cognitive behaviors16,17, making their receptors the targets of 
psychopharmacological agents18,19. In addition to being important 
in the postnatal development and functional maturation of the 
pituitary-adrenal axis, AVP potentiates the actions of CRH under 
circumstances that demand sustained activation of the pituitary and 
adrenal glands20. We found that ELS induces persistent hypomethyla-
tion of the Avp enhancer, accompanied by sustained upregulation of 
Avp expression, increased HPA axis activity and behavioral alterations. 
In the course of exploring the molecular mechanisms underlying 
these changes, we found that MeCP2 is important in the epigenetic 
programming of neuroendocrine and behavioral functions.
RESULTS
ELS-induced phenotypes
Consistent with previous studies15,21, ELS during the first 10 d of 
life led to sustained hyperactivity of the HPA axis, characterized 
by corticosterone hypersecretion under basal conditions, hyper- 
responsiveness to acute stressors applied later in life and escape from 
the inhibitory constraints of dexamethasone (Fig. 1a). Although it 
had no effect on body mass, ELS induced involution of the thymus, 
hypertrophy of the adrenals (Supplementary Fig. 1) and increased 
expression of pituitary pro-opiomelanocortin (Pomc) mRNA, which 
encodes the adrenocorticotropin pro-hormone (Fig. 1b). Pomc 
expression is induced by the hypothalamic neuropeptides AVP 
and CRH, and all of them are under negative feedback control 
by the glucocorticoid receptor. Conspicuously, levels of Nr3c1 
(the gene that encodes the glucocorticoid receptor) mRNA in the 
hippocampus, hypothalamic paraventricular nucleus (PVN) and 
 pituitary were either unchanged or upregulated in ELS-treated mice 
(Supplementary Fig. 1), arguing against impaired corticosterone 
feedback as the primary cause of the observed increases in Pomc 
Max Planck Institute of Psychiatry, Munich, Germany. Correspondence should be addressed to D.S. (spengler@mpipsykl.mpg.de).
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Dynamic DNA methylation programs persistent 
adverse effects of early-life stress
Chris Murgatroyd, Alexandre V Patchev, Yonghe Wu, Vincenzo Micale, Yvonne Bockmühl, Dieter Fischer,  
Florian Holsboer, Carsten T Wotjak, Osborne F X Almeida & Dietmar Spengler
Adverse early life events can induce long-lasting changes in physiology and behavior. We found that early-life stress (ELS) 
in mice caused enduring hypersecretion of corticosterone and alterations in passive stress coping and memory. This 
phenotype was accompanied by a persistent increase in arginine vasopressin (AVP) expression in neurons of the hypothalamic 
paraventricular nucleus and was reversed by an AVP receptor antagonist. Altered Avp expression was associated with sustained 
DNA hypomethylation of an important regulatory region that resisted age-related drifts in methylation and centered on those 
CpG residues that serve as DNA-binding sites for the methyl CpG–binding protein 2 (MeCP2). We found that neuronal activity 
controlled the ability of MeCP2 to regulate activity-dependent transcription of the Avp gene and induced epigenetic marking. 
Thus, ELS can dynamically control DNA methylation in postmitotic neurons to generate stable changes in Avp expression that 
trigger neuroendocrine and behavioral alterations that are frequent features in depression.
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expression and glucocorticoid secretion. Although ELS did not 
influence hypothalamic Crh mRNA expression (Supplementary 
Fig. 1), the procedure resulted in a significant upregulation of Avp 
mRNA (P < 0.05; Fig. 1c). The changes in Avp expression persisted 
for at least 1 year and were restricted to the parvocellular subpopula-
tion of neurons in the PVN, that is, in those neurons that drive the 
 pituitary-adrenal axis (Supplementary Fig. 2).
AVP exerted its regulatory role on Pomc expression levels via acti-
vation of pituitary AVP V1b receptors. Application of SSR149415, 
a selective V1b receptor antagonist, normalized the elevated Pomc 
mRNA levels (Fig. 1b) and corticosterone secretion (data not shown), 
verifying the critical role of AVP in driving the disturbed endocrine 
phenotype in ELS mice.
ELS also produced long-lasting behavioral changes. Adult ELS-
exposed mice showed memory deficits in an inhibitory avoidance 
task (Fig. 1d). In addition, they had increased immobility in the 
forced swim test (Supplementary Fig. 3). In contrast, anxiety-
like behavior was unaffected by ELS in the elevated plus-maze, 
 novelty-induced hypophagia and light-dark avoidance tests (data 
not shown). The ELS-induced behavioral phenotypes were repro-
duced in two further independent replications. Treatment with 
the SSR149415 partially reversed the impaired memory in ELS 
mice (Fig. 1d) and abolished the changes in behavioral stress cop-
ing (Supplementary Fig. 3) without influencing the behavioral 
performance of control mice.
Differential methylation of the Avp gene
Methylation of cytosine residues in CpG dinucleotides can 
result in epigenetic gene silencing; such CpGs are conspicuously 
under-represented in mammalian genomes and typically cluster in 
glucocorticoid-rich regions called CpG islands (CGIs)22. Computa-
tional analysis and a recent genome-wide classification of promoter 
CGIs23 predicted 4 CGIs in Avp: CGI1 (intermediate CpG frequency 
in the promoter region), CGI2 (high CpG frequency covering the 
second and third exons), CGI3 and CGI4 (intermediate CpG frequency 
in the ~3.6-kb downstream region) (Fig. 2a and Supplementary Fig. 4). 
The latter region, also referred to as the intergenic region (IGR), 
separates the neighboring, tail-to-tail–orientated Avp and oxytocin 
genes and includes a composite enhancer region in the first 2.1 kb 
proximal to Avp that is important for expression24.
Sequence analysis of bisulfite-converted DNA isolated from the 
PVN of naive C57BL/6N mice showed sparse methylation in the 
promoter CGI1 and exonic CGI2. In contrast, we found high levels of 
CpG methylation clustered at the more distal enhancer encompassing 
CpG7 to CpG32 and spanning CGI3 (Fig. 2b). The latter region is 
highly conserved between species and is important for Avp regula-
tion24. Less-dense methylation was observed in CGI4 and the adjacent 
oxytocin tissue-specific enhancer region had only a few, irregularly 
spaced and highly methylated CpG residues (Fig. 2b). A similar methyl-
ation of CpG residues at the Avp locus was found in unrelated CD1 
mice, supporting the idea that this pattern is unlikely to be strain 
specific (data not shown). Together, these results support the idea that 
CGIs in intergenic regions are more likely to be methylated than those 
at gene promoters and that CGIs with intermediate CpG densities are 
methylated more frequently25.
Persistent hypomethylation of CGI3 after ELS
We compared PVN tissue from ELS and control mice aged 6 weeks, 
3 months and 1 year and found hypomethylation of multiple CpG 
residues throughout the downstream Avp enhancer region in ELS 
mice (Fig. 3a–c). Analysis of overall methylation of the enhancer 
revealed substantial reductions in methylation in ELS mice of all 
ages (Fig. 3d). Significantly marked (P < 0.05) CpG residues largely 
mapped to CGI3 of the enhancer. For many of these, the degree of 
ELS-induced hypomethylation was consistently greater than that 
observed for overall CGI3 hypomethylation; for example, CpG10 
showed uniformly strong reductions in methylation (by 37% at 
6 weeks, (P < 0.005), 21% at 3 months (P < 0.05) and 66% at 1 year 
(P < 0.005)). This finding reveals that ELS triggers a heterogeneous 
response in CpG hypomethylation and indicates a functional role for 
marked changes.
To obtain a functional measure of those CpG residues that are likely to 
control Avp expression, we sought correlations between Avp mRNA levels 
and the degree of methylation of individual CpG residues that were 
significantly hypomethylated (P < 0.05) in ELS mice. Therefore, in situ 
hybridization (ISH) and DNA methylation analyses were performed on 
tissues from the same individual mice. Of the 11 CpGs that were signifi-
cantly hypomethylated (P < 0.05) in 6-week-old ELS mice (Fig. 3a), only 
seven (CpGs 7, 10, 12, 13, 14, 15 and 17) had methylation patterns that 
were strongly correlated with Avp mRNA levels (Fig. 3e). For example, 
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Figure 1 Endocrine and behavioral consequences of ELS depend on sustained AVP expression. (a) ELS mice had higher serum corticosterone levels at 
6 weeks, 3 months and 1 year of age under basal conditions, at the daily nocturnal peak and after exposure to an acute stressor applied 30 min before 
sampling. An injection of dexamethasone (dex, 6 h before sampling) suppressed corticosterone secretion more effectively in 3-month-old control as 
compared with ELS mice. (b) Pomc mRNA (measured by qualitative PCR, qPCR) was significantly higher in the pituitaries of 3-month-old ELS mice. 
Treatment of 3-month-old control and ELS mice with the AVP V1b receptor antagonist SSR149415 (SSR) reduced Pomc mRNA levels (measured by 
qPCR) in ELS mice. (c) Avp mRNA expression (detected by ISH) was significantly higher in parvocellular PVN neurons of 6-week-old (+31%), 3-month-
old (+13%) and 1-year-old (+15%) ELS mice. (d) ELS mice showed shorter step-down latencies 24 h after learning but not during training (control  
(19 ± 2 s) versus ELS (21 ± 2 s), P > 0.05). Treatment with the AVP V1b receptor antagonist partially reversed memory deficits by increasing step-down 
latencies from 47 ± 3% to 78 ± 7% of vehicle-treated controls, without affecting the behavioral performance of control mice (101 ± 6%). Data are 
presented as mean ± s.e.m. (n = 8–16 mice per group). *P < 0.05, ** P < 0.01 and *** P < 0.001 (t test or ANOVA followed by Newman-Keuls  
post hoc test).
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although residues CpG10 and CpG22 had 
similar levels of methylation (methylation at 
CpG10 in controls and ELS was 60.3 ± 5.9% 
and 37.6%, respectively; methylation at CpG22 in controls and ELS was 
69.5 ± 8.6% and 39 ± 9.8%, respectively; Fig. 3a), the methylation status 
of CpG10, but not of CpG22, correlated strongly with differences in 
Avp expression (CpG10, r2 = 0.44, P < 0.05; CpG22, r2 = 0.07, P > 0.1). 
Thus, ELS-induced alterations in CpG methylation appear to be impor-
tant for Avp mRNA levels, although individual CpG residues located 
in CGI3 seem to contribute, in different degrees, to altered expres-
sion. Those CpGs that failed to show a priori significant differences 
(P > 0.05) in their methylation status in 
response to ELS correlated poorly with Avp 
mRNA levels (data not shown). Notably, dif-
ferential methylation of CGI3 was not evident 
when DNA from the hypothalamic supraoptic 
nucleus of 6-week-old control and ELS mice 
were compared (Supplementary Fig. 5); the 
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Figure 2 Selective methylation of the intergenic 
region of the Avp gene. (a) Schematic diagram 
of the Avp and oxytocin genes orientated tail-
to-tail and separated by the IGR. Exons are 
indicated by open (numbered) boxes and CGIs 
by numbered bars, and the distribution of CpG 
residues and size and position of the respective 
PCR amplicons used for their analyses are 
shown. CpG10 is marked with an asterisk.  
(b) CpG methylation profile in the IGR of 6-week- 
old naive mice. Residues belonging to the  
Avp-Oxt tissue-specific enhancer (Avp/Oxt TSE), 
CpG islands 3 or 4 (CGI3 or CGI4) or the Oxt 
tissue-specific enhancer (Oxt TSE) are color 
coded (inset). CGI3, lying ~0.5 kb downstream 
of the Avp gene, had the highest level of 
methylation. Data are presented as mean ± 
s.e.m. (n = 8 mice per group).
Figure 3 ELS induces hypomethylation of the 
Avp enhancer. (a–c) CpG methylation profiles  
of 6-week-old (a), 3-month-old (b) and  
1-year-old (c) control and ELS mice. The entire 
IGR is shown in a, whereas b and c focus on 
the enhancer. (d) Overall methylation of the 
enhancer decreased significantly in ELS mice 
at all ages. Note the significant age-related 
hypomethylation in control, but not ELS,  
mice. (e) CpG methylation inversely correlated  
with Avp expression, revealed by correlating  
all significantly marked CpGs between  
6-week-old control and ELS mice (shown in a)  
with respective Avp mRNA levels. (f) All 
CpG residues (shown in a–c) that differed 
significantly in methylation at least once (•)  
and by more than 25% (•) at the other two  
ages were defined as methylation landmarks  
(boxed CpGs 10, 12, 13, 14 and 15).  
(g) The composite methylation status of the 
methylation landmarks, in particular CpG10, 
correlated negatively with Avp expression over 
all ages. (h) Differences in methylation (>10%) 
between 6-week-old and 1-year-old control  
and ELS mice for each CpG in the enhancer  
revealed significant changes in both control  
and ELS mice. Methylation landmarks were  
not influenced by age in either group. Data  
are presented as means ± s.e.m. (n = 8–10  
mice per group). # P < 0.01, * P < 0.05,  
** P < 0.005 and *** P < 0.0001 (t test, 
ANOVA followed by Newman-Keuls post hoc  
test or Pearson’s correlation coefficient).
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latter is consistent with the observation that Avp transcript levels in this 
nucleus were not influenced by ELS (Supplementary Fig. 2).
Methylation landmarks correlate with Avp expression
These data led us to hypothesize that ELS-induced changes in the 
methylation status of relevant CpG residues are persistent and 
sustain elevated Avp expression, whereas changes in functionally 
less-significant CpGs (P > 0.05) wane over time. To identify CpGs 
predictive of persistently increased Avp expression, we examined each 
CpG residue in detail. Residues considered to be of predictive value 
were those that were significantly methylation (P < 0.05) marked by 
ELS at one age at least and nominally altered by more than 25% at 
two other ages. By these criteria, CpG residues 10, 12, 13, 14 and 15 
were revealed as methylation landmarks in the Avp enhancer (Fig. 3f). 
The number of CpG residues that were significantly marked by ELS 
decreased with age (11 in 6-week-old, 7 in 3-month-old and 3 in 
1-year-old mice; Fig. 3f). With the exception of CpG10, which localized 
to the upstream boundary (Fig. 2a), all of the emerging methylation 
landmarks mapped to the center of CGI3 (CpGs 12, 13, 14 and 15).
We corroborated the functional role of these residues by correlating 
their individual methylation status with Avp mRNA levels in control 
and ELS 6-week-old, 3-month-old and 1-year-old mice (Fig. 3g). 
This revealed that the composite methylation status of these residues 
faithfully reflected longitudinal Avp expression. 
Poor, if any, correlations were found between 
Avp mRNA expression (at any age) and those 
CpG residues that showed either initial (CpGs 
7, 17, 21, 22, 23 and 32) or otherwise transient (CpGs 11, 20 and 31) 
differences in methylation status (data not shown). This set of find-
ings highlights the functional importance of CpG residues 10, 12, 13, 
14 and 15 in the regulation of Avp expression.
Although significant hypomethylation (P < 0.0001) of the Avp 
enhancer occurred with age in control mice (Fig. 3d), we did not 
observe age-dependent changes in Avp mRNA levels (Fig. 1c). In 
contrast, ELS mice did not show age-related hypomethylation of the 
Avp enhancer (Fig. 3d), but nevertheless maintained higher levels of 
Avp mRNA, as compared to controls (Fig. 1c). This raised the ques-
tion of whether single CpG residues might be differentially sensitive 
to age- versus ELS-induced hypomethylation. Analysis of the effects 
of aging on hypomethylation of all 32 CpGs of the Avp enhancer in 
6-week-old and 1-year-old control and ELS mice showed that age-
associated hypomethylation only occurred in 16% of the CpGs in the 
Avp enhancer region of ELS mice, as compared with 38% in control 
mice (Fig. 3h). Notably, those CpG residues with an assigned regula-
tory role (methylation landmarks 10, 12, 14 and 15) did not show 
significant hypomethylation (P > 0.05) with aging (Fig. 3h).
Enhancer methylation directs Avp expression
An AVP-expressing N6 mouse hypothalamic cell line26 was used to 
examine whether Avp enhancer methylation modulates Avp expression 
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Figure 4 Enhancer methylation represses Avp 
expression as a result of MeCP2 occupancy.  
(a) Reverse-transcription PCR (RT-PCR) analysis  
of Avp expression in mouse PVN, hypothalamic 
N6, neuroblastoma Neuro2a and fibroblast 3T3 
cells. (b) Treatment of N6 cells with 5-azacytidine 
(5-aza, 5 d) prevents CpG methylation and 
induces Avp expression. (c) The parent  
Avp-Gaussia construct contains the entire  
2.1-kb enhancer, ∆10−25 is devoid of CpGs 
10 to 25 and ∆enh lacks the entire enhancer. 
(d) Deletion of either CpGs 10−25 or the entire 
enhancer reduced reporter activity by 37% and 
90%, respectively, in N6 cells. (e) Entire vector or 
site-specific enhancer (CpGs 1−25) methylation 
reduced reporter activity by 90% and 50%, 
respectively. (f) MeCP2 strongly repressed the 
site-specific methylated CGI3 vector; transfection 
with MBD1, MBD2 and MBD3 resulted in weaker 
repression. (g) ChIP analysis revealed that MeCP2 
selectively occupied CGI3 at the Avp locus in  
N6 cells. (h) Treatment with 5-azacytidine  
(5 µM, 5 d) relieved MeCP2 binding and 
enhanced activated RNA polymerase II (Rpol) 
occupancy at the promoter. ChIP data (g,h) are 
presented as means ± s.d. (four independent 
experiments). (i) The oligonucleotides used in 
EMSAs encoded CpG 10, 12 and 14, a mutant 
form of CpG10, and the high-affinity MeCP2-
binding site ds1. (j) MeCP2 bound strongly to 
methylated (m), but not to unmethylated (u), 
CpG10 and ds1. Compared with methylated 
CpG10, MeCP2 bound less to methylated  
CpG12 (12m) and CpG14 (14m). A representative 
autoradiogram and mean DNA-binding values 
(percentage DB, four independent experiments) 
are shown. (k) Dissociation constants (KD) for 
MeCP2 binding.
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(Fig. 4a). We analyzed of the methylation profile in the CGI3 
region that spans CpG10–14 and found a pattern that was similar to 
the one that we observed in the mouse PVN (Supplementary Fig. 6). 
Treatment of N6 cells with 5-azacytidine, a potent inhibitor of DNA 
methylation, reduced the level of methylation of the Avp enhancer and, 
concomitantly, increased Avp expression (Fig. 4b and Supplementary 
Fig. 6). In transfection assays (Fig. 4c), deletion of the CGI3 region 
reduced reporter activity by 37% and deletion of the entire enhancer 
resulted in almost complete abolition of reporter activity (Fig. 4d).
We examined Avp gene reporter activity after in vitro methylation of 
the entire Avp vector, including the promoter and transcribed regions. 
Methylation led to a tenfold decrease in reporter activity (Fig. 4e). 
Moreover, reporter activity was reduced by 50% when methylation 
was targeted specifically to CGI3 (Fig. 4e). Together with the results 
obtained in hypothalamic tissue, this finding suggests that CGI3- 
specific methylation is critical for the control of Avp expression.
MeCP2 selectively binds CGI3 and represses Avp expression
DNA methylation is interpreted by a family of methyl CpG–binding 
domain (MBD) proteins comprising MeCP2, MBD1, MBD2, MBD3 
and MBD4, the first three of which couple DNA methylation to tran-
scriptional repression. Although hypothalamic N6 cells expressed 
MeCP2, MBD1 and MBD2 (Supplementary Fig. 7), we found MeCP2 
to be the most potent repressor of the CGI3 methylated vector in 
co-transfection experiments (Fig. 4f).
We directly assessed the binding of MeCP2 at the Avp locus by 
immunoprecipitation of cross-linked chromatin from N6 cells with 
antibodies to MeCP2 or control IgG, followed by PCR analysis of the 
recovered DNA using seven primer pairs bracketing the Avp locus 
(Fig. 4g). As expected, MeCP2 did not occupy the poorly methylated 
Avp promoter and exonic CpG islands (CGI1 and 2); moreover, MeCP2 
was also absent at CGI4, which is methylated to a relatively high 
extent. In contrast, MeCP2 was strongly enriched at the CGI3 region 
(Fig. 4g). Notably, CGI3, but not CGI4, was poorly recovered when the 
same chromatin samples were immunoprecipitated with antibodies 
to MBD1 and MBD2 (Supplementary Fig. 7). Thus, MeCP2 prefer-
entially and selectively occupies CGI3 of the Avp enhancer.
Pre-treatment of N6 cells with 5-azacytidine robustly decreased 
MeCP2 occupancy at CGI3 and increased promoter binding of acti-
vated (pSer5) RNA polymerase II and Avp transcription in parallel 
(Fig. 4b,h). Therefore, MeCP2 occupancy at the Avp locus is DNA 
methylation-dependent and, once bound, MeCP2 acts to repress 
transcription. High-affinity binding of MeCP2 to methylated DNA 
requires a local sequence context, namely a symmetrical methyl-CpG 
dinucleotide that localizes close to a run of four or more A/T bases 
that facilitate DNA binding27. We identified four CpG dinucleotides 
(CpGs 13, 14 and 21, as well as the highly relevant CpG10) that 
matched the latter criterion in the CGI3 sequence (Fig. 4i). Their 
function in the context of MeCP2 binding was tested by in vitro DNA-
binding electrophoretic mobility shift assays (EMSAs), using recom-
binant MeCP2 and oligonucleotides that spanned CpG10, CpG12 
or CpG14. As anticipated, methylation of these motifs proved to be 
essential for MeCP2 binding and effective self-competition (Fig. 4j 
and Supplementary Fig. 8). MeCP2 specifically bound to the key 
motif CpG10 with a KD of ≈2.6 nM (comparable to that previously 
reported27) and DNA binding was strongly impaired (KD > 50 nM) 
after mutation of the A/T run adjacent to the CpG10 dinucleotide 
(CpG10A/Tmut) (Fig. 4k). Compared with CpG10, the neighboring 
motifs CpG12 and CpG14 bound MeCP2 with lower affinity 
(KD ≈ 9.6 and 10.5 nM, respectively) and competed poorly with CpG10 
for forming a complex with MeCP2 (Supplementary Fig. 8). Together, 
these results indicate that the Avp enhancer contains context-specific, 
high-affinity MeCP2 DNA-binding sites that are important for the 
regulation of Avp.
Phosphorylation of MeCP2 prevents Avp enhancer occupancy
Neuronal depolarization has been shown to trigger Ca2+-dependent 
phosphorylation of MeCP2, causing dissociation of MeCP2 from the 
Bdnf promoter and increased Bdnf transcription28,29. Recently, de novo 
Ca2+/calmodulin-dependent protein kinase II (CaMKII) was shown to 
mediate phosphorylation of rat MeCP2 at serine 421 (S438 in mouse)30. 
Figure 5 CaMKII relieves MeCP2 occupancy and repression of the Avp 
enhancer. (a) CaMKII precludes repression by MeCP2. Transfection of 
CaMKII* and the site-specific methylated CGI3 vector stimulated Avp 
expression and completely reversed repression by transfected MeCP2 in 
N6 cells. (b) CaMKII abolished MeCP2 occupancy at CGI3. Flag-tagged 
forms of MeCP2 or S438A (S438 nonphosphorylatable MeCP2) were 
transfected singly or together with CaMKII* in N6 cells. ChIP experiments 
with an antibody to Flag showed that CaMKII* mediated the release 
of MeCP2 from the Avp enhancer and that enhancer occupancy was 
maintained when MeCP2 (S438A) was transfected. (c) MeCP2 repressed 
endogenous Avp expression in a CaMKII-regulated manner. Flag-tagged 
forms of MeCP2 or S438A (S438A) and CaMKII* were cotransfected 
in N6 cells. RT-PCR analysis of Avp expression revealed that CaMKII* 
attenuated MeCP2-mediated repression; CaMKII* had only minor effects 
in the presence of MeCP2 S438A. (d) Membrane depolarization relieved 
MeCP2 occupancy at the Avp enhancer. N6 cells were depolarized with  
55 mM KCl (30 min). ChIP experiments showed reduced MeCP2 
occupancy at CGI3, paralleled by increased activated Rpol occupancy at 
the promoter (CGI1). Pretreatment of N6 cells with a CaMKII inhibitor 
(KN-93) reversed these effects. (e) Immunoblot analysis of MeCP2-S438 
phosphorylation. Compared with controls, depolarized N6 cells showed 
increased MeCP2-pS438 immunoreactivity; depolarization did not 
influence MeCP2 immunoreactivity. Data (a–d) are presented as means  
± s.d. (four independent experiments).
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To explore whether this mechanism might be 
responsible for regulating MeCP2 occupancy at 
the Avp enhancer, we transfected N6 cells with 
either MeCP2 and/or a constitutively active 
form of CaMKII (CaMKII*) together with 
the CGI3-methlyated Avp vector. Transfection 
of CaMKII* increased Avp reporter activity 
slightly, and completely reversed MeCP2-
mediated repression (Fig. 5a). Furthermore, 
we observed that CaMKII* markedly reduced 
the occupancy of Flag-tagged MeCP2 at the 
Avp enhancer, but failed to release DNA-
bound nonphosphorylatable MeCP2 (S438A; 
Fig. 5b). Subsequently, MeCP2-S438A and (to 
a lesser degree) MeCP2 prevented CaMKII* 
activity–dependent increases in Avp expres-
sion (Fig. 5c); this result is consistent with a 
repressive role of MeCP2.
Additional experiments showed that 
K+-induced depolarization of N6 cells faith-
fully reproduced the effects of CaMKII* 
 transfection, that is, relieved MeCP2 occu-
pancy at the Avp enhancer. A role of CaMKII 
in mediating MeCP2-S438 phosphoryla-
tion was confirmed by the complete reversal 
of this regulation after pretreatment with 
the CaMKII inhibitor KN-93. Moreover, K+-induced depolariza-
tion increased the presence of activated RNA polymerase II at the 
Avp promoter (Fig. 5d), verifying the ability of MeCP2 to repress 
activity-dependent gene expression6. Lastly, an antibody to the 
regulatory MeCP2-S438 phosphorylation site (MeCP2-pS438; 
Supplementary Fig. 9) reacted strongly with extracts from membrane- 
depolarized N6 cells, but only weakly with extracts from nonstimu-
lated N6 cells (Fig. 5e). Thus, membrane depolarization directly leads 
to phosphorylation of MeCP2 at S438.
ELS reduces MeCP2 occupancy at Avp enhancer
We next asked whether the sustained increased expression of Avp after 
ELS is triggered by MeCP2-S438 phosphorylation and subsequent 
relief of MeCP2 occupancy at the Avp enhancer. This hypothesis was 
supported by the observation that MeCP2-S438 phosphorylation 
was prominently increased in parvocellular AVP-expressing neurons 
in the PVN of 10-d-old ELS mice (Fig. 6). In addition, the PVN of 
10-d-old ELS mice had increased phospho-CaMKII immunoreactivity in 
AVP-positive neurons, a finding that is compatible with a role for this 
kinase in the mediation of activity-dependent MeCP2-S438 phospho-
rylation (Supplementary Fig. 10). The extents to which CaMKII and 
MeCP2-S438 were phosphorylated in the parvocellular division of the 
PVN did not differ between 6-week-old control and ELS mice (Fig. 6 
and Supplementary Fig. 10). In addition, neither Mecp2 mRNA nor 
total MeCP2 and CaMKII protein expression differed between the 
two groups (Supplementary Fig. 10). Lastly, MeCP2-pS438 immuno-
reactivity in the supraoptic nucleus did not differ between control and 
ELS mice at all ages, demonstrating the site-specificity of the effects 
(data not shown). These results indicate that there is an age- and cell 
type–specific role for ELS-induced MeCP2-S438 phosphorylation, 
prompting us to examine its relevance for 
enhancer occupancy.
Although RNA polymerase II occupancy 
at the Avp promoter and Avp expression 
Figure 6 ELS induces phosphorylation of MeCP2 in parvocellular PVN neurons. ELS led to 
increased immunostaining of MeCP2-pS438 (pS438) and AVP in the PVN of 10-d-old mice. 
Colocalization of AVP and MeCP2-pS438 in parvocellular neurons in the PVN was apparent. 
Comparable levels of MeCP2-pS438 staining were detected in 6-week-old control and ELS mice. 
The images that are shown are representative of five mice per group and age.
10 d 6 weeks
AVP pS438 AVP/pS438 AVP pS438 AVP/pS438
Control
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50 µm
Figure 7 ELS reduces MeCP2 occupancy at 
the Avp enhancer. (a) ELS upregulated Avp 
expression in the parvocellular PVN (measured 
by ISH) of 10-d-old mice. In vivo ChIP analysis 
revealed increased activated Rpol occupancy at 
the Avp promoter (CGI1) of ELS mice, reflecting 
increased Avp transcription. (b) ELS reduced 
MeCP2 occupancy at CGI3. An in vivo ChIP 
scan of the Avp locus (schematized above) 
revealed selective MeCP2 occupancy at CGI3. 
ELS significantly reduced MeCP2 occupancy 
at this region in both 10-d-old and 6-week-old 
mice. Data are presented as means ± s.e.m. 
(n = 8 mice per group for ISH analysis; ChIP 
analysis based on five groups of pooled PVN).  
* P < 0.05 (t test).
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were markedly increased in 10-d-old ELS mice (Fig. 7a), CGI3 
methylation did not differ between control and ELS mice of this age 
(Supplementary Fig. 11). Notably, in vivo chromatin immunopre-
cipitation (ChIP) experiments on PVN tissue revealed that, of the 
various MBDs, MeCP2 was selectively enriched at CGI3 in 10-d-old 
and 6-week-old control mice (Fig. 7b and data not shown) and that 
binding of MeCP2 to the Avp enhancer was reduced in ELS mice of 
both ages (Fig. 7b). Given that 10-d-old control and ELS mice have 
identical methylation patterns, the measured differences in MeCP2 
occupancy suggest that ELS-induced MeCP2-S438 phosphorylation 
results in relief of MeCP2 occupancy at the Avp enhancer. The repres-
sive function of MeCP2 at the Avp enhancer was substantiated by 
sequential in vivo ChIP experiments, which revealed strong coupling 
of MeCP2 to transcriptionally inactive chromatin marks (data not 
shown), comparable with those reported for Crh occupancy31.
In sum, de-repression of Avp transcription in 10-d-old ELS mice 
appears to involve increased MeCP2-S438 phosphorylation, whereas 
reduced enhancer occupancy in 6-week-old mice most likely reflects 
ELS-induced CGI3 hypomethylation (Figs. 3a and 7b).
DISCUSSION
Adverse experiences during early life contribute to the etiology of 
psychiatric conditions in later life14,32. Our results suggest that ELS 
in mice leads to epigenetic marking (hypomethylation) of a key regu-
latory region of the Avp gene in the PVN. These epigenetic events 
are accompanied by persistent upregulation of Avp expression in the 
parvocellular subdivision of the PVN and, consequently, sustained 
hyperactivity of the HPA axis. Notably, the ELS-induced endocrine 
phenotype lasted for at least 1 year following the initial adverse event 
and could be normalized through administration of an AVP V1b 
receptor antagonist.
Studies in humans and in animal models suggest that stress or 
elevated glucocorticoid secretion are important for the function 
of interdependently regulated behavioral domains33,34. Here, ELS-
treated mice showed increased immobility in the forced-swim test, 
which assesses stress-coping ability35, and had deficits in step-down 
avoidance learning. Although acute rises in glucocorticoid secretion 
can facilitate inhibitory avoidance learning13, our data support the 
notion that sustained elevated glucocorticoid levels impair memory 
performance in ELS mice. Notably, the behavioral phenotypes induced 
by ELS were shown to be partly reversible after antagonism of AVP 
V1b receptors, thus highlighting AVP as an important mediator of 
these processes, but not necessarily the only14.
Our results identify CpG residues in the CGI3 region of the Avp 
enhancer whose persistent hypomethylation after ELS is critical for 
the regulation of Avp expression. Recent work defined these residues as 
being high-affinity, context-specific MeCP2 DNA-binding sites27. On 
the basis of previous reports28,29, we hypothesized that signaling mecha-
nisms controlling MeCP2 occupancy are critical for gene repression 
and the dynamic methylation of CGI3 in response to ELS. Supporting 
this, we found that depolarization of hypothalamic cells can regulate 
MeCP2 function by inducing its site-specific phosphorylation via CaMKII 
activity. Taken together, our results indicate that phosphorylation of 
MeCP2 at S438 is critical for MeCP2 to function as a reader and inter-
preter of the DNA methylation signal at the Avp enhancer.
That experience-dependent stimuli dynamically control the 
methylation of CGI3 is supported by the observation that ELS 
induced contemporaneous increases in CaMKII activation, MeCP2-
S438 phosphorylation and Avp expression in 10-d-old mice. On 
the other hand, MeCP2-S438 and CaMKII were phosphorylated 
to similar extents in adult control and ELS mice, indicating that 
ELS-induced MeCP2 phosphorylation is important for the estab-
lishment of epigenetic marks. Once established, the observed dif-
ferences in Avp enhancer methylation centered on MeCP2 binding 
sites, which appeared to be actively maintained in ELS and control 
mice. This interpretation is compatible with the view that MeCP2 
serves as an epigenetic integration platform on which synergistic 
cross-talk between histone deacetylation, H3K9 methylation and 
DNA methylation act to confer gene silencing22.
From a physiological perspective, it is conceivable that increased 
methylation of the Avp enhancer during early postnatal life serves to 
restrain the HPA axis in critical periods when homeostatic thresh-
olds are set; this would facilitate adaptation of the endocrine system 
to future environmental stimuli. Our data suggest that ELS tilts the 
balance toward persistent hypomethylation and Avp overexpression 
by inducing reductions in MeCP2 binding. Thus, phosphorylation of 
MeCP2 appears to be a conduit of experience-driven changes in gene 
expression, serving as an important mediator of the persistent effects 
of ELS. In this respect, certain parallels may be drawn between the 
mechanisms underlying ELS and Rett syndrome; the latter, caused by 
mutations in Mecp2, also presents with altered cognitive, mood and 
HPA axis function36.
Together with other recent work3,10, our results suggest that 
adverse events in early life can leave persistent epigenetic marks 
on specific genes that may prime susceptibility to neuroendocrine 
and behavioral dysfunction. Focusing on DNA methylation, our 
results provide evidence for postmitotic epigenetic modifications 
in neuronal function; such modifications can serve to facilitate (or 
disfavor) physiological and behavioral adaptations3,37. These marks 
and their initiators, mediators and readers (for example, MeCP2) 
provide new inroads for understanding the molecular basis of stress-
related disorders of the brain.
METhODS
Methods and any associated references are available in the online version 
of the paper at http://www.nature.com/natureneuroscience/.
Note: Supplementary information is available on the Nature Neuroscience website.
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ONLINE METhODS
elS. Maternal separation stress11,15 was used to induce ELS. Briefly, pups deliv-
ered (postnatal day 0 (P0) on day of birth) by timed-pregnant C57BL/6N mice 
(Charles River) were placed, as individual litters, in a clean cage (with heating 
pad) for 3 h each day on P1–10, having no physical contact with their mothers. 
Control (non-ELS) pups remained undisturbed in the maternal nest throughout. 
Pups remained with their mothers until weaning (P21), when they were housed 
in sex-matched groups (3–5 mice per cage); only males were used for analyses. 
Standard laboratory animal housing conditions were maintained throughout, 
with 12-h daily illumination (lights on at 06:00). All procedures were approved 
by the Regierung von Oberbayern and were in accordance with European Union 
Directive 86/609/EEC.
Behavioral phenotyping. At 3 months of age, control and ELS mice were housed 
singly and randomly assigned to the following long-term treatment groups: naive 
(no injections), vehicle (5% DMSO (vol/vol), 5% Chremophor EL (vol/vol), 
saline, intraperitoneal injection), and SSR149415 (20 mg per kg of body weight 
per d). Treatments started 4 weeks before behavioral phenotyping and continued 
for the duration of the experiments; injections were administered 1 h before 
behavioral testing. An investigator who was blind to the treatments carried out 
the behavioral analyses; an interval of 2 d was allowed between each test proce-
dure. Anxiety-like behavior was assessed in the elevated plus-maze38, light-dark 
avoidance39 and novelty-induced hypophagia40 tests.
The forced swim test was used to evaluate passive stress coping behavior and was 
performed essentially as described previously41. Briefly, each mouse was placed 
into a glass beaker (5 l × 23.5 × 16.5 cm) that was filled with water (25 ± 1 °C) 
up to a height of 15 cm, for 6 min. Floating (immobility) was scored during 
the last 4 min of the exposure. A mouse was considered to be immobile when it 
floated passively in an upright position, making only small movements to keep 
its head above water surface.
Memory was evaluated using the step-down avoidance learning test. Training 
sessions involved placing mice onto a platform (2.5 × 10 × 10 cm3) and admin-
istering a scrambled electric foot shock (0.7 mA) when they stepped off the 
platform onto a metal grid; mice were thereafter immediately returned to their 
home cages. Passive avoidance memory was tested by placing mice back onto the 
platform 24 h later and step-down latencies (four-paws criterion) were measured 
in three consecutive trials. Trials were terminated after 5 min in cases of failure 
to step down; a step-down latency of 301 s was ascribed to the trial. The mean of 
the three trials served as a measure of memory performance.
tissue preparation and hormone assays. Serum corticosterone was measured 
in adulthood by radioimmunoassay in blood samples. Samples were collected at 
6 p.m. (peak) and 30 min following application of a previously described acute 
psychological stressor (9–11 a.m.)42. At the age of 3 months, mice received an 
intraperitoneal injection of dexamethasone (10 µg per 100 g) at 12 a.m. noon and 
blood was collected at 6 p.m. for determination of corticosterone; the latter mea-
surements were compared to values obtained at the nocturnal sampling on the 
previous day. At various ages, mice were killed by cervical dislocation and tissues 
(brain, pituitary, thymus and adrenal) were collected. Brains for ISH and micro-
punching were cryosectioned (10 µm) at the level of the rostral PVN (bregma 
−0.75 to −0.85) and the hippocampus (bregma −1.70 to −1.90). Punches of the 
PVN were obtained by in loco microdissection under histological control.
ISH. Avp and Crh transcripts were detected with 48/50-mer 35S-labeled anti-
sense probes, complementary to the murine Avp (bases 1,493–1,540, accession 
number M88354) and Crh (bases 1,685–1,732¸ accession number AY128673) 
genes, respectively. Nr3c1 and Mecp2 transcripts were measured using ribonu-
cleotide probes (Nr3c1, bases 81–528, accession number M14053; Mecp2, bases 
612–1,604, accession number NM010788) and previously published protocols42. 
Avp, Crh and Mecp2 transcript signal intensities were measured in the ventro-
medial compartment of the PVN, representing the parvocellular division. Nr3c1 
hybridization signals were measured in the PVN and hippocampal subfields 
CA1–3 and dentate gyrus.
Bisulfite sequencing. Genomic DNA (200–400 ng) isolated from PVN tissue 
punches was digested with EcoRI, sodium bisulfite converted (Qiagen DNA 
methylation kit), aliquoted and used for PCR reactions. Primers used are listed in 
Supplementary table 1. Products were cloned into pGEM-T vector; at least 20 
independent recombinant clones per PCR and mouse were analyzed on an ABI 
Prism 3700 capillary sequencer. Overall methylation levels (Fig. 3d) were calculated 
for the entire enhancer region from mean levels of individual CpG residues.
Rt-PcR and RnA extractions. Primer sequences are listed in Supplementary 
table 2. The expression levels of the housekeeping genes Hprt and Gapdh were 
used for normalization. Total RNA was extracted with Trizol (Invitrogen) and 
reverse-transcription reactions were performed on 1 µg of total cell culture–
extracted RNA or 100 ng of tissue-derived RNA with SuperscriptII (Invitrogen) 
and poly-dT primer. qPCR was carried out on a LightCycler (Roche) using 
LightCycler FastStart DNA Master Plus SYBR Green (Roche).
In vitro methylation. Vectors were methylated with SssI and S-adenosylmethionine 
(New England Biolabs). For site-specific methylation, an 888-bp fragment contain-
ing CpGs 10–25 in the Avp enhancer was excised by digestion with Eco81I; the vec-
tor was further digested with XbaI and BamHI to prevent re-ligation. Methylated 
or control unmethylated digests were ligated into the dephosphorylated reporter 
construct, cleaved with Eco81I. Completeness of in vitro methylation and mainte-
nance (until cell harvesting) was confirmed by bisulfite sequencing.
Recombinant proteins and emSA. GST- or His-MeCP2 fusion proteins were 
grown in DH5α, purified and quantified as described previously43. For in vitro 
DNA-binding assays (Fig. 4j and Supplementary Fig. 8), recombinant MeCP2 
(0.5 µg) was incubated with 20,000 cpm of double-stranded 32P end-labeled 
naive or in vitro methylated oligonucleotides27. Reactions were fractionated on 
8% polyacrylamide gels. Although GST protein itself does not recognize methyl-
ated CpG10, inclusion of a GST antibody abolished MeCP2 binding, verifying 
the identity of the shifted complex (Fig. 4j). Dissociation constants (KD) were 
deduced by Scatchard analysis of saturation binding isotherms43.
Plasmids. The AVP expression vectors (kindly gifted by H. Gainer and R.L. Fields, 
US National Institutes of Health) were modified by exchanging the egfp reporter 
gene in the third exon of the Avp gene44, with a cDNA for Gaussia luciferase KDEL 
encoding intracellular Gaussia luciferase (Targeting Systems) (see Fig. 4c). The 
parent Avp-Gaussia construct contained 288 bp of the promoter region, all exons 
(numbered) and introns, and the entire 2.1-kb enhancer. The Avp∆enhancer 
construct has the entire enhancer sequence removed, whereas the Avp∆10–25 
was generated by deletion of an 888-bp fragment of the enhancer containing 
CpGs1–25 by digestion with Eco81I and subsequent vector religation.
The Mecp2 expression vector and His-tagged MeCP2 1–205 (kindly provided 
by A. Bird, University of Edinburgh) consisted of the mouse MeCP2α variant45 
in pRL-SV40 (Promega) and of a cDNA for the first 205 amino acids of human 
MeCP2 with a C-terminal His-tag46 in a pet30b vector (Novagen), respectively. 
For prokaryotic expression (pGEx2tk-Mecp2), the MeCP2α cDNA was PCR 
amplified (forward primer, AAG GGA TCC GTA GCT GGG ATG TTA GG; 
reverse primer, TCT GAT ATC CTC AGT GGT GGA GGA GGA G) and inserted 
into the BamHI and SmaI sites of pGEx2tk (Pharmacia).
N-terminal Flag-tagged forms of different Mecp2 constructs were obtained 
by PCR cloning of wild type (forward primer, AAG GGA TCC GCC GCC GCT 
GCC GCC ACC GC; reverse primer, TCT GAT ATC CTC AGC TAA CTC TCT 
CGG TC) or of a form lacking the 45 C-terminal amino acids of MeCP2 (forward 
primer, AAG GGA TCC GCC GCC GCT GCC GCC ACC GC; reverse primer, 
TCT GAT ATC CTC AGC TAA CTC TCT CGG TC) into the BamHI and EcoRI 
sites of pRK7-Flag43. The phosphor-acceptor residue Ser 438 was replaced by 
Ala in MeCP2 (S438A) by site-directed mutagenesis (forward primer, CCC GAG 
GAG GCC GAC TGG AAA GCG ATG GC; reverse primer, GCC ATC GCT TTC 
CAG TCG GCC TCC TCG GG).
The MeCP2 riboprobe (nucleotides 612–1,604, accession number NM_
010788) contains the conserved sequence in exons 3 and 4 of the mouse Mecp2 
gene. A corresponding PCR product (forward primer, AAA GGT GGG AGA CAC 
CTC CT; reverse primer, TCC ACA GGC TCC TCT CTG TT) was cloned in the 
pGEM-T vector (Promega) for generation of riboprobes.
Expression vectors for MBD2 and MBD3 (kindly provided by S.T. Jacob, Ohio 
State University) contain the mouse MBD2 or MBD3 cDNAs47 in the pcDNA3.1 
vector (Invitrogen). The MBD1 expression vector contains the full-length cDNA 
for mouse MBD1 (accession number NM_013594; forward primer, TAC CTC TAG 
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AAT GGC TGA GGA CTG GCT GGA CTG; reverse primer, TTT CTA GAA ACA 
ATT TGC AAA GAA TTT TCA GG) inserted in the pRK7 expression vector.
CaMKII expression vectors contained either full-length CaMKII (1–317) or 
CaMKII (1–290), a constitutively active form resulting from the absence of the 
calmodulin-binding domain (kindly provided by A.R. Means, Duke University 
Medical Center). The constitutively active CaMKII(T286D) contains a replace-
ment of Thr286, which is located in the autoinhibitory domain48, by Asp (kindly 
provided G. Turrigiano, Brandeis University). All constructs used in this study 
were entirely sequence verified.
cell culture and transfection experiments. Mouse hypothalamic cells (N6 line)26 
were grown using standard conditions (DMEM supplemented with 10% fetal calf 
serum, vol/vol). Cells (105) were treated for 5 consecutive days with different con-
centrations of 5-azacytidine (Calbiochem), which was replenished in fresh grow-
ing medium every other day. N6 cells were transfected using Lipofectamine 2000 
(Invitrogen). Briefly, 8 × 105 cells were seeded 24 h earlier in 6-well plates. DNA 
was mixed with 4 µl of Lipofectamine, incubated at 25 °C for 20 min and then 
added to the cells, which were grown for 18 h. Epithelial kidney cells (LLC-PK1, 
ATTC CL-101) were transfected by electroporation as described previously49. For 
cotransfection, we used 0.1 µg of the Camk2a expression constructs, 1 µg of the 
pRK7-Flag Mecp2 constructs and 1 µg of the Mbd1, Mbd2 and Mbd3 expression 
vectors. Luciferase values were normalized against β-galactosidase values42.
Immunohistochemistry, immunoblots and chIP experiments. Brains were 
extracted from microwave-fixed heads, placed overnight in 4% paraformaldehyde 
(wt/vol), cryo-preserved and sectioned (20 µm) at the level of the PVN before 
immunostaining. Immunoblot analysis was carried out on whole-cell extracts 
(50 µg) after fractionation by PAGE gel electrophoresis43. For ChIP experiments, 
chromatin from N6 cells or mouse PVN punches (individual pools formed from 
groups of three or five mice for 6-week-old and 10-d-old mice, respectively) was 
cross-linked50, disrupted by sonification (Diagenode Bioruptor, and purified with 
the Magna ChIP G kit (Millipore). The ChIP primers that we used for qPCR are 
listed in Supplementary table 3.
Antibodies. The antibodies that we used are listed in Supplementary table 4. 
The polyclonal antibody to MeCP2, which recognizes MeCP2 (accession number 
GI:123122664) irrespective of its phosphorylation status, was generated by 
injecting New Zealand White rabbits with the KLH-conjugated peptide NH2-
CSMPRPNREEPVDSRTPV-CONH2, corresponding to amino acids 480–496. The 
antiserum was purified by affinity chromatography on a column containing coupled 
MeCP2 480–496 peptide and the affinity-purified antibody to MeCP2 was eluted.
The polyclonal antibody to phosphor–S438-MeCP2 (MeCP2-pS438) was 
generated by injecting New Zealand White rabbits with the KLH-conjugated 
peptide NH2-CMPRGGpSLES-CONH2. The antiserum was purified by affinity 
chromatography on a column containing coupled nonphosphorylated MeCP2-
S438 peptide. The flow through was then passed over a second column containing 
coupled phosphorylated MeCP2-S438 peptide and the affinity-purified antibody 
to MeCP2-pS438 was eluted.
Characterization of the MeCP2 antibodies was performed by transfection of 
pRK7-FLAG MeCP2 and pRK7-FLAG MeCP2 (S438A) (0.1 µg each), singly or 
together, with the different CaMKII expression vectors (0.5 µg each) into LLC-
PK1cells. Mock transfections were performed using an equal amount of filling 
plasmid. Whole-cell extracts (20 µg) were fractionated on 8% SDS-PAGE gels, 
immunoblotted and tested with either antibody to MeCP2 (1:1,000), the UP-
MeCP2 (Upstate, 07013, 1:1,000), antibody to MeCP2-pS438 (1:1,000) or anti-
body to Flag (1:1,000). In a parallel set of experiments, the same cellular lysates 
were treated for 1 h at 37C° with calf intestine phosphatase (10 units) or assay 
buffer alone followed by PAGE gel electrophoresis.
Antibody to MeCP2-pS438 and antibody to MeCP2-pS421 (kindly provided 
by Z. Zhou and M.E. Greenberg30, Harvard Medical School) produced similar 
results when tested on PVN sections (Supplementary Fig. 8).
Statistical analysis. Numerical data were analyzed by t tests or ANOVA, followed 
by Newman-Keuls post hoc test. In all cases, the nominal level of significance was 
P ≤ 0.05. Correlations between AVP expression and CpG methylation were tested 
by Pearson’s correlation coefficient.
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2.2 Chapter 2: Depletion of the Neural Precursor Cell Pool by 
Glucocorticoids 
Yu S, Patchev AV et al., Annals of Neurology, 2010 
2.2.1 Rationale 
Glucocorticoids are well known to affect neuronal cell death and neurogenesis (Yu et al., 2008; 
Sousa et al., 2008). Previous work has shown that neuronal plasticity depends strongly 
(although not solely) on neuronal proliferation and differentiation from the neural precursor cell 
pool (Pittenger and Duman, 2008). The dentate gyrus within the hippocampal formation, is a 
brain area with a high degree of neuronal proliferation from multipotent precursors, especially 
during early ontogeny, but also in later life (Cameron and McKay, 1999). Albeit disputed, adult 
neurogenesis from the neuronal precursor cell pool has been ascribed a role in mediating the 
effects of (at least) some antidepressants (Hanson et al., 2011b; Pittenger and Duman, 2008). 
With regard to the use of glucocorticoids in obstetrics and perinatology, we examined the 
targeting of neuronal precursors for apoptosis by glucocorticoids and individual aspects of this 
process in vitro. We scrutinized whether neonatal application of corticosteroids to rat pups 
would affect the amount of neuronal precursor cells, and thus, hippocampal volume and 
function in later life. 
2.2.2 Major findings 
- in vitro 
o neural precursors, as well as immature neurons, express functional GR 
o GC induce apoptosis of neuronal cells in a dose-dependent manner 
o GC target proliferating, but also resting precursors for apoptosis 
o GC-induced apoptosis of neuronal precursors is mediated via caspase 3 and 
caspase 9, and mitochondrial reactive oxygen species (ROS) generation  
 
  28 
- in vivo 
o neonatal GC administration leads to increased apoptosis in the subgranular 
zone (SGZ), where most NPCs are located  
o both quiescent and amplifying neuronal precursors in the SGZ express GR 
o neonatal GC treatment reduces the neurogenic capacity in  later life by 
reducing the number of cells available for mitosis and proliferation 
o these changes are mirrored by corresponding growth retardation of the SGZ, as 
well as the granule cell layer, where more mature neurons are located 
2.2.3 Conclusions 
GC exposure during early ontogeny can affect brain plasticity in later life. Here we show that 
these effects also comprise apoptosis of the neural precursor and progenitor pool, thus reducing 
the cells available for neurogenesis in later life. These findings suggest the possibility that 
animals exposed to GC in early life might respond differently to stress and/or antidepressants in 
adulthood. The medical relevance of this work is epitomized by the fact that both, stress and 
antidepressants have been shown to affect hippocampal neurogenesis, while GC appear to be a 
key permissive component in this latter process. 
2.2.4 Outlook / ongoing studies 
To prove the hypothesis, that neonatal GC exposure selectively reduces the NPC pool and, thus, 
could lead to differential responses to stress and/or antidepressant medication, we carried out 
additional studies where animals treated neonatally with GC were followed up until 5-6 months 
of age and then subjected to either chronic unpredictable stress (known to reduce neurogenesis 
and increase apoptosis in the hippocampus (Sousa et al., 2008; Yu et al., 2008)) and/or daily 
Fluoxetine treatment (known to increase neurogenesis (Hanson et al., 2011b)). First results 
indicate that neonatally GC treated animals display differential HPA axis responses under basal 
circadian, as well as acute stress conditions. Currently, stereological evaluation of hippocampal 
cell numbers (including apoptotic and recently proliferated cells) and volumes is in progress. In 
addition to alteration of cell numbers, the observed volumetric changes indicate that neonatal 
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GC treatment also has long term (programming) effects on dendritic arborization and synaptic 
plasticity (Sousa et al., 2008). Further intriguing questions are exemplified by i) the 
neurochemical characteristics of the surviving proliferating cells; ii) their capacity to become 
integrated in functional networks derived from NPC pools that have not experienced neonatal 
GC impact, and iii) their resistance to noxious stimuli.  
2.2.5 Contributions 
- planning and performing of in vivo studies, including neonatal treatment, behavioral and 
endocrine analysis  
- involvement in histological analysis and preparation of the manuscript.  
Figure 2  Model of long-term effects of glucocorticoid-induced apoptosis of NPC 
during early ontogeny 
Supraphysiological doses of GC during early ontogeny (here neonatal period) induce apoptosis of NPC, thus reducing the 
number of NPC in the pool available for adult neurogenesis in the hippocampus. In addition, recent observations indicate that 
not only hippocampal neuronal numbers, but also dendritic arborization are reduced in animals with a history of neonatal GC 
exposure. 
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Objective: Glucocorticoids (GCs) are indicated for a number of conditions in obstetrics and perinatal medicine;
however, the neurodevelopmental and long-term neurological consequences of early-life GC exposure are still
largely unknown. Preclinical studies have demonstrated that GCs have a major inﬂuence on hippocampal cell
turnover by inhibiting neurogenesis and stimulating apoptosis of mature neurons. Here we examined the fate of
the limited pool of neural progenitor cells (NPCs) after GC administration during neonatal development; the
impact of this treatment on hippocampal structure was also studied.
Methods: Phenotype-speciﬁc genetic and antigenic markers were used to identify cultured NPCs at various
developmental stages; the survival of these cells was monitored after exposure to the synthetic glucocorticoid
dexamethasone (DEX). In addition, the effects of neonatal DEX treatment on the neurogenic potential of the rat
hippocampus were examined by monitoring the incorporation of bromodeoxyuridine and expression of Ki67 an-
tigen at various postnatal ages.
Results: Multipotent nestin-expressing NPCs and T1-tubulin–expressing immature neurons succumb to GC-
induced apoptosis in primary hippocampal cultures. Neonatal GC treatment results in marked apoptosis among the
proliferating population of cells in the dentate gyrus, depletes the NPC pool, and leads to signiﬁcant and sus-
tained reductions in the volume of the dentate gyrus.
Interpretation: Both NPCs and immature neurons in the hippocampus are sensitive to the proapoptotic actions
of GCs. Depletion of the limited NPC pool during early life retards hippocampal growth, thus allowing predictions
about the potential neurological and psychiatric consequences of neonatal GC exposure.
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Acquisition and loss of hippocampal neurons are im-plicated in the regulation of cognition, mood, and
neuroendocrine function.1–4 Most likely, the availability
of hippocampal neurons determines neuroplastic changes
in the intrahippocampal circuitry as well as connectivity
between the hippocampus and other cortical and subcor-
tical areas.5 The subgranular zone (SGZ) of the hip-
pocampal dentate gyrus is endowed with a pool of neural
precursor cells (NPCs) that can divide and differentiate
into either neurons or glial cells.2,6 Newly generated neu-
rons integrate into existing hippocampal circuits6 and fa-
cilitate learning and memory.2–4 Neurogenesis tapers off
over a lifetime and is regulated by intrinsic (eg, age7–9)
and extrinsic signals (eg, stress10,11), whose actions are
mainly mediated by glucocorticoids (GCs). Because the
size of the NPC pool is a potentially important determi-
nant of lifelong hippocampal function, there is consider-
able interest in the link between lifetime neurogenesis and
cognitive deficits that result from exposure to high GC
levels.12,13
The synthetic glucocorticoid receptor (GR) agonist
dexamethasone (DEX) is commonly used in obstetrics
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and neonatal medicine. Previously, we demonstrated that
DEX induces cell cycle arrest14and apoptosis15–17 in ma-
ture neurons of the dentate gyrus. In this study, we ad-
dressed the question of whether DEX can directly influ-
ence the survival of NPCs. In addition, we tested the
hypothesis that neonatal DEX administration perma-
nently depletes the neurogenic pool. Our results show
that GCs target NPCs for apoptosis and that neonatal
GCs markedly reduce the number of NPCs available for
the generation of new neurons.
Materials and Methods
Drugs and Plasmid
DEX (Fortecortin, Merck, Darmstadt, Germany), was added to
cultures for 48 hours (24 hours after transfection). The GR an-
tagonist RU38486 (10M; NHPP, Torrance, CA) was added 1
hour before DEX application. Mitotic cells were labeled (24
hours) with 5-bromo-2-deoxyuridine (BrdU) (20M; Sigma,
St. Louis, MO). The specific caspase 3 and 9 inhibitors Ac-
DEVD-cmk (1M) and Ac-LEHD-cmk (30M) were obtained
from Calbiochem (Schwalbach, Germany) and applied 30 min-
utes before addition of DEX.
NPCs, neural progenitors, and astrocytes were labeled
with pBSIISK-E/nestin–enhanced green fluorescent protein
(EGFP),18 pBSII SK-T1–green fluorescent protein (GFP),19
and phosphorylated glial fibrillary acidic protein (pGFAP)-
GFP20 (courtesy of Drs. Hideyuki Okano, Freda Miller, and
Helmut Kettenmann, respectively).
Primary Hippocampal Cultures and
Transfection
Hippocampal cultures were prepared from Wistar rats (Charles
River, Sulzfeld, Germany) on postnatal day (PND) 4, and trans-
fected (10% efficiency) 5 days after plating.16
Animals and Tissues
European Union and National Institutes of Health guidelines
on animal care and experimentation were observed. Forty-eight
male Wistar rats were housed under standard laboratory condi-
tions. Rats received subcutaneous injections of either vehicle (sa-
line) or DEX on PND 1–7 (DEX 200g/kg/d on PND 1–3;
100g/kg/d on PND 4–7). All animals received a single intra-
peritoneal injection of BrdU (50mg/kg) 24 hours before killing
on PND 10, 18, or 28. Serial coronal cryosections (20m), ex-
tending over the entire length of the hippocampal formation,
were cut and mounted before sequential double-staining of every
8th section with antibodies against BrdU (1:200; DAKO, Ham-
burg, Germany) and Ki67 (1:500, Biotrend, Cologne, Germa-
ny); cell nuclei were counterstained with Hoechst 33342 (1g/
ml, 10 minutes).
Immunocyto- and Histochemistry
Cells or sections were fixed (4% paraformaldehyde), perme-
abilized (0.3% Triton-X100/phosphate-buffered saline),
blocked, and incubated (4°C) with anti-BrdU (after treatment
with 2 N HCl), nestin (1:1,000; Millipore, Goettingen, Ger-
many), anti-TuJ1 (1:500; Babco, Richmond, CA), anti-MAP2
(1:500; Sigma), anti-doublecortin (DCX) (1:500; Santa Cruz,
Heidelberg, Germany), anti-GFAP (1:1,500; DAKO or
1:4,000, Sigma), anti-NeuN (1:500; Millipore), O4 antibody
(1:500; Millipore), anti-GR (1:300; M20, Santa Cruz), anti-
Sox2 (1:300, Santa Cruz), cleaved caspase 3 (1:200; Cell Sig-
naling/NEB, Frankfurt, Germany), and p47-phox (1:200, Mil-
lipore). Immunoreactivity was visualized using appropriate
Alexa Fluor-conjugated secondary antibodies (1:500; Invitro-
gen). Cells were analyzed (ImagePro software, Media Cyber-
netics, Bethesda, MD) on an Olympus BX-60 microscope.
Cell counts were performed on 10 individual microscopic
fields (0.072mm2), randomly chosen across 2 diameters of
each coverslip (400 magnification). An average of 1,000 cells
or 100 transfected cells was sampled on each coverslip; results
shown represent values from 6–9 coverslips/treatment.
Apoptotic cells were identified by terminal deoxynucleoti-
dyl transferase-mediated dUTP nick-end labeling (TUNEL) his-
tochemistry (with fluorescein isothiocyanate- or Texas Red-
conjugated avidin; Vector, Burlingame, CA), immunostaining
for cleaved (active) caspase 3, or Hoechst 33342 staining. Those
cells showing morphological signs of DNA fragmentation17,21
were considered to be apoptotic.
Stereology
StereoInvestigator (MicroBrightField, Williston, VT) was used
to estimate the volumes of different subdivisions of the dentate
gyrus and cell densities (NV) in the SGZ of the dentate gyrus.
The total number of BrdU or Ki67 NPCs in the SGZ was
derived from the product of Nv and total SGZ volume. To
identify BrdU and Ki67 double-stained cells, sections were ex-
amined (XY, YZ, and XZ views) by confocal microscopy (Olym-
pus IX81 LSM, Hamburg, Germany).
Statistics
Numerical data (shown as mean  standard error of the mean)
were subjected to 2-tailed Student t tests or analysis of variance
and appropriate post hoc analysis (SPSS Inc, Chicago, IL). The
level of significance was preset at p  0.05.
Results
Phenotypic Identity and GR Expression in
Hippocampal Cultures
After 6 days in vitro (DIV), hippocampal cultures ex-
pressed markers specific to NPCs (40% nestin) and
immature neurons (35% TuJ1and DCX); approxi-
mately 10% of the cells were young neurons (NeuN),
and 15% were astrocytes (GFAP) or oligodendrocytes
(O4) (Fig 1A). Immunoreactive GR was detectable in
NPCs and immature/young neurons (Fig 1B and C). GR
expression was observed in 45% of nestin-GFP–trans-
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fected NPC and 65% of T-tubulin-GFP–labeled im-
mature neurons (Fig 1B); stimulation with DEX resulted
in translocation of immunoreactive GR to the nucleus,
suggestive of its transcriptional potential (Fig 1B, inset).
Treatment of cultures with DEX resulted in a dose-
dependent induction of apoptosis that was preventable by
pretreatment with the GR antagonist RU38486 (Fig 1D);
because consistently robust effects were observed at a dose
of 10	5M, this dose was chosen for all subsequent in
vitro experiments.
Regulation of NPC and Postmitotic
Hippocampal Cell Fate by GCs
Neuroplasticity depends on the availability of NPC.6
Whereas neurogenesis is implicated in recovery from
stroke,22 reduced proliferative capacity of hippocampal
cells is associated with epilepsy,23 impaired cognition,2
and depression.24,25 We show here that DEX reduces the
number of immunocytochemically identified NPC (by
39%), neuroblasts (39%), and immature neurons
(54%) (p  0.05, in all cases; Fig 2A).
We previously demonstrated that GCs induce apo-
ptosis in hippocampal cells in culture16,17 and that GC-
induced apoptosis in situ is prominent in the SGZ, where
NPC reside and proliferate.21,26 To examine the hypoth-
esis that apoptosis leads to a reduction in NPC and im-
mature neuron numbers, we next treated hippocampal
Š FIGURE 1: Immature hippocampal cells are sensitive to glu-
cocorticoids. (A) After 7 days in vitro (DIV), primary hip-
pocampal cultures, derived from postnatal rats aged 4
days, were comprised of 40% neural precursor cells
(NPCs, labeled with antinestin) and 35% immature neu-
rons (stained with anti-TuJ1 or anti-doublecortin [DCX]);
<10% of the cells stained with anti-NeuN, a marker of
young neurons (NeuN), and <20% of the cells were astro-
cytes and oligodendrocytes (stained with antibody O4). (B)
Immunoreactive glucocorticoid receptor (GR) was localized
in both NPCs and neuronal progenitors; shown are the
percentage of GR-expressing cells in the different cell pop-
ulations, including NPCs (nestin-positive cells identiﬁed by
immunocytochemistry or cells transfected with nestin-green
ﬂuorescent protein [GFP]) and immature neurons (stained
with anti-DCX or anti-TuJ1, or transfected with T-tubulin-
GFP), as well as neurons (stained with anti-NeuN). The in-
set is an example of an immunoblot (IB) of cytoplasmic and
nuclear fractions probed with GR antibody; note the in-
creased GR signal in the nucleus (vs cytoplasm) in lysates
from cells that had been treated with glucocorticoid (dexa-
methasone [DEX], 105M). (C) Representative images of
nestin-GFP–transfected and anti-nestin–stained cells coex-
pressing GR are shown; also shown are images from the
same sets of cells after staining of the cell nuclei with
Hoechst dye 33342; arrowheads point to identical cells in
each row. (D) The dose-dependent induction of apoptosis
by DEX is shown in the left-hand panel; these results are
based on terminal deoxynucleotidyl transferase-mediated
dUTP nick-end labeling (TUNEL) of apoptotic cells. Consis-
tently robust responses are obtained at a dose of 105M
(used in all subsequent experiments). The right-hand panel
shows that similar results are obtained when apoptosis is
evaluated by either TUNEL histochemistry or immunocyto-
chemistry for the active (cleaved) form of the executioner
caspase, capsase 3. Note that the apoptotic actions of
DEX can be signiﬁcantly attenuated by pretreatment (30
minutes) of cells with the GR antagonist RU38486 (105M),
indicating mediation by GR. All numerical data are de-
picted as mean  standard deviation. *p < 0.05 vs control
(CON), #p < 0.05 vs DEX. Scale bar  50m in (A), 20m
in (C). GFAP  glial ﬁbrillary acidic protein. [Color ﬁgure
can be viewed in the online issue, which is available at
www.interscience.wiley.com.]
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cultures with the cytosine analog BrdU (to reveal recently
proliferated cells27) and DEX for 24 hours before quan-
tifying apoptosis (identified by TUNEL or activated
caspase 3 immunoreactivity) in recently proliferated
(BrdU-labeled27) cells. As compared with untreated cells
(Fig 2B1–B5), DEX-treated cells showed greater colocal-
ization of BrdU and TUNEL signals (Fig 2C1–C5). Eval-
uation of individual merged images revealed significantly
increased apoptosis among both mitotic (BrdU, control
[CON], 8.4  3.4%; DEX: 17.8  5.0%; p  0.05) and
resting (BrdU	, CON: 27.6  3.0%; DEX: 41.0 
4.1%; p  0.05) cell populations after GC treatment (Fig
2D). The results obtained with TUNEL histochemistry
were corroborated by cleaved (activated) caspase 3 immu-
nocytochemistry (Fig 2E).
Phenotype-Speciﬁcity of the Apoptotic
Actions of GCs
NPC proliferate and differentiate along either neuronal or
glial lineages.6 Given the intrinsic characteristics of NPC
and the heterogeneous nature of primary hippocampal
cultures (Fig 1), we here analyzed the cell phenotypes tar-
geted for GC-induced apoptosis in mixed hippocampal
cultures transfected with specific plasmids that would fa-
cilitate distinction between NPC (nestin-EGFP) and neu-
ronal progenitors (T1-GFP). Exposure of cells to DEX
produced a significant increase in TUNEL-labeled apo-
ptotic cells among the NPC (Fig 3A–C, G–I, and U; p 
0.05) and neuronal progenitor (Fig 3D–F, J–L, and U;
p  0.05) cell populations; the TUNEL results were con-
firmed by staining for cleaved (activated) caspase 3 immu-
noreactivity (Fig 3M–P, Q–T, and V; p  0.05). In all
cases, the apoptotic actions of DEX were attenuated when
cells were pretreated with the GR antagonist RU 38486,
indicating their mediation by GR (Fig 3U, V). Interest-
ingly, astrocytes marked with GFAP-GFP did not suc-
cumb to the apoptotic effects of DEX (Fig 3U).
Mitochondrial Mechanisms Mediate GC-
Induced Apoptosis in NPC
The data showing that DEX treatment leads to an acti-
vation of caspase 3 (Fig 2E, Fig 3M–T, and V, and Fig
5B–D) in NPC hinted at involvement of the mitochon-
drial or “intrinsic” pathway of apoptosis.15 These findings
were confirmed in hippocampal cultures using pharmaco-
logical inhibitors of caspase 3 and its upstream caspase,
caspase 9 (Fig 4A). Examining events upstream of the
caspases, we observed that DEX treatment dose-
dependently increases the ratio of proapoptotic bax to an-
tiapoptotic bcl-2 mRNA expression, without influencing
the bax:bclXL mRNA expression ratio (Fig 4B); the latter
findings are consistent with the fact that the predominant
antiapoptotic protein in developing neurons is Bcl-2
rather than BclXL.
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The mitochondrial proteins Bax and Bcl-2 act in a
rheostatic manner to regulate the integrity of the mito-
chondrial permeability transition which is particularly
sensitive to perturbation by reactive oxygen species
(ROS). Measurement of ethidium intercalation into DNA
FIGURE 2: Proliferating and resting cells are targets of
glucocorticoid-induced apoptosis. (A) Exposure of DIV 7 hip-
pocampal cultures to dexamethasone (DEX) (105M) leads to
a signiﬁcant loss of neural precursor cells (nestin-positive) and
immature neurons (doublecortin [DCX]/TuJ1-positive). (B–C)
Representative images of cells that were treated simulta-
neously with 5-bromo-2-deoxyuridine (BrdU) (20M) and
DEX (105M) before staining 24 hours later for BrdU (to
mark cells born in the preceding 24 hours) and terminal de-
oxynucleotidyl transferase-mediated dUTP nick-end labeling
(TUNEL). TUNEL are shown in control (CON) (B1) and DEX-
treated cells (C1), respectively; panels B2–B5 and C2–C5 are
higher magniﬁcations of the areas marked by the dotted
boxes in B1 and C1, respectively; B2 and C2 show apoptotic
cells, B3 and C3 show BrdU-incorporating cells, and B4 and
C4 show nuclear staining with Hoechst dye, in CON and
DEX-treated cells, respectively; panels B5 and C5 show
merged images of B2–B4 and C2–C4, respectively. Arrow-
heads point to identical cells in each column and exemplify
apoptosis (TUNEL-stained) in recently-proliferated cells (BrdU-
stained). (D) Quantitative analysis of TUNEL staining in pro-
liferative (BrdU) and resting (BrdU) cells. (E) Comparable
data to those shown in (D) were obtained when cells were
double-labeled for BrdU and cleaved (active) caspase 3. All
numerical data are shown as mean  standard deviation. As-
terisks indicate signiﬁcant differences vs CON (untreated)
cells (p < 0.05). Scale bars: 20m. [Color ﬁgure can be
viewed in the online issue, which is available at www.
interscience.wiley.com.]
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showed that ROS generation represents a mechanism
through which DEX induces apoptosis (Fig 4C). Addi-
tionally, DEX stimulates ROS production in NPC (Fig
4D and E); this effect is accompanied by a translocation
of membrane-associated p47phox (an essential component
of the nicotinamide adenine dinucleotide phosphate oxi-
dase complex required for the production of superoxide
anions) (Fig 4F) and reductions in the activities of Cu/
Zn superoxide dismutase and glutathione, 2 key anti-
oxidant enzymes (Fig 4G).
Depletion of the NPC Pool by GC Treatment
During Peak Neurogenesis In Vivo
Hippocampal neurogenesis occurs at a high frequency dur-
ing early postnatal life.28 However, NPC have limited self-
renewal capacity,29 and the NPC pool from which new
neurons are generated diminishes exponentially with age7,9;
GCs are thought to at least partially contribute to the latter
phenomenon.28 On the other hand, proliferating hip-
pocampal cells were previously reported to express GR only
sparsely.30 As shown in Figure 5A, numerous cells in the
neonatal dentate gyrus express GR along a gradient that
increases from the SGZ to the inner layers of the granule
cell layer (GCL), where more mature granule neurons are
localized. Importantly, DEX treatment provoked a 60% in-
crease in apoptosis (increase in active caspase 3 immunore-
activity) in the SGZ (Fig 5B–D; p  0.05). Two types of
NPC are found in the SGZ: quiescent neural precursors
(QNP; GFAP-positive, proliferate relatively slowly) and
amplifying neural precursors (ANP; GFAP-negative, display
high proliferative activity).31 Accordingly, it was considered
important to investigate if QNP and ANP might be differ-
entially sensitive to glucocorticoids. Both QNP and ANP
express nestin and Sox2, but whereas nestin levels in ANP
diminish over time, Sox2 expression is maintained at rela-
tively steady levels in both NPC subtypes and serves as a
more reliable marker of NPC (QNP: GFAP/Sox2;
ANP: GFAP	/Sox2). Exploiting these characteristics,
colocalization studies showed that a similar proportion of
QNP and ANP express GR (Supplementary Fig S1A–C),
suggesting their similar vulnerability to DEX.
We subsequently assessed the impact of neonatal
GC administration on the proliferative capacity of the
dentate gyrus in later life by performing stereological
FIGURE 3: Neural precursors and neuronal progenitors are driven into apoptosis by dexamethasone (DEX). Cultures were
transfected with either nestin-green ﬂuorescent protein (GFP) or T-tubulin-GFP plasmids to label neural precursors or
neuronal progenitors, respectively. The percentage of cells staining positively for terminal deoxynucleotidyl transferase-
mediated dUTP nick-end labeling (TUNEL) or activated caspase 3 among the nestin- or T-tubulin–labeled populations were
counted to examine how each phenotype was inﬂuenced by DEX. Representative images are shown from TUNEL-stained
cells that had been previously transfected with nestin-GFP (A–C and G–I) or T-tubulin-GFP (E–F and J–L); control (CON)
cells are shown in A–C and D–F, and DEX-treated cells are shown in G–I and J–L, where solid arrowheads indicate apoptotic
GFP cells, detected by TUNEL and Hoechst staining. Examples of activated caspase 3 staining in speciﬁcally tagged neural
precursor cells (nestin-GFP) and neuronal progenitor (T-tubulin-GFP) subpopulations are shown in M–T; open arrowheads
indicate activated caspase 3/GFP cells, and solid arrowheads point to activated caspase 3/GFP cells. Numerical
analysis of these data is shown in U and V. Note that astrocytes labeled with glial ﬁbrillary acidic protein (GFAP)-GFP do
not undergo DEX-induced apoptosis (U). All numerical data are given as mean  standard deviation. *p < 0.05 vs CON,
#p < 0.05 vs DEX. Scale bars: 20m. [Color ﬁgure can be viewed in the online issue, which is available at www.
interscience.wiley.com.]
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counts of the number of BrdU- and Ki67-stained cells in
the SGZ at PND 10, 18, and 28 (Fig 6A–C). The results
of this analysis revealed that neonatal treatment with
DEX results in a significant reduction in the number of
cells available for mitosis at any given time (p  0.05; Fig
6D), suggesting a depletion of the NPC pool by neonatal
DEX. Interestingly, the absolute differences between the
number of proliferating cells in the SGZ of both control
and DEX-treated rats diminished over time (but remained
significantly different), probably reflecting age-related de-
creases in proliferative activity (Fig 6D) and the fact that
a subpopulation of NPC that do not express GR (see
Supplementary Fig S1) may escape the apoptotic actions
of neonatal GC treatment.
Because expansion of the GCL occurs primarily dur-
ing early postnatal life, we next carried out a stereological
assessment of the volumes of the SGZ and GCL. This
analysis revealed that SGZ volumes of DEX-treated ani-
mals were significantly smaller (p  0.05), despite similar
volumetric increments over time (14–20%) (Fig 6E); the
latter suggests proliferation by residual NPC that were
spared from the apoptotic effects of neonatal DEX. Al-
though both controls and DEX-treated animals showed
significant increases in the volumes of their GCL between
FIGURE 4: Dexamethasone (DEX) induces neural precursor cell (NPC) apoptosis by increasing reactive oxygen species (ROS)
production, perturbation of the mitochondrial membrane potential, and subsequently activation of the intrinsic apoptotic path-
way. (A) Pretreatment with either Ac-DEVD-cmk (caspase 3 inhibitor) or Ac-LEHD-cmk (caspase 9 inhibitor) rescues NPC from
DEX-induced apoptosis. (B) Expression levels of Bcl-2 family members were measured by quantitative polymerase chain reaction
after exposure of cultures to various doses of DEX; dose response curves, in terms of the ratio of proapoptotic bax to anti-
apoptotic bcl-2 or bcl-xl, reveal that DEX ﬁrst produces a signiﬁcant increase in the bax:bcl-2 ratio at a dose of 105M, and that
the ratio of bax:bcl-xl is not inﬂuenced by DEX treatment. (C) Treatment of NPC cultures with DEX (105M) stimulates ROS
production, indicated by the intercalation of ethidium into DNA (red ﬂuorescence). (D) Conﬁrmation of DEX-stimulated ROS
production in identiﬁed NPC that were labeled with nestin-GFP. (E) Treatment of primary cultures with DEX increases ROS
production, as measured by dihydroethidium (DHE) staining; note NPCs, marked with nestin-green ﬂuorescent protein, also show
signiﬁcantly increased levels of ROS in response to DEX. (F) Immunostaining for the p47-phox, a subunit of nicotinamide adenine
dinucleotide phosphate oxidase, showing localization of the signal from the cytoplasm to the plasma membrane (arrowheads) in
NPCs (identiﬁed by nestin immunostaining) after DEX treatment. (G) Treatment of cultures with DEX leads to signiﬁcant reduc-
tions in 2 key antioxidant enzymes, glutathione (GSH) and superoxide dismutases (SOD); enzyme activities were normalized to
protein concentrations of the cell extracts. All numerical data are depicted as mean  standard deviation. *p < 0.05 vs control
(CON), #p < 0.05 vs DEX. Scale bar  20m in C, 10m in D and F. [Color ﬁgure can be viewed in the online issue, which is
available at www.interscience.wiley.com.]
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the ages of 10 and 28 days (Fig 6E, p  0.05), GCL
volumes in the DEX-treated animals were significantly
smaller than in controls (Fig 6E, p  0.05). In sum, these
results suggest that reduced neurogenesis and subse-
quently, reduced cell acquisition in the GCL, result in a
marked retardation of GCL development in animals ex-
posed to neonatal DEX (Fig 6E).
Discussion
Several neurological and psychiatric disorders are hall-
marked by hippocampal dysfunction. The last decade has
witnessed compelling evidence for a link between hip-
pocampal function and cell turnover in the postnatal hip-
pocampus.6,13,24,25,32 Neuronal turnover in the hip-
pocampus is a dynamic process involving neurogenesis
and apoptosis in the germinative layer (SGZ) of the den-
tate gyrus3; stress and elevated GC levels inhibit neuro-
genesis and stimulate apoptosis in the hippocam-
pus.11,12,21,26 Although GCs are known to interfere with
the neural cell cycle,14 it is not known whether GCs tar-
get NPC for apoptosis. Accordingly, we here examined
the incidence of apoptosis in hippocampal cultures that
were genetically marked with developmental phase-
specific markers to identify proliferating multipotent
NPC and NPC destined to become neurons. In addition,
we studied the consequences of neonatal treatment with
DEX, a synthetic GC (when neurogenesis and apoptosis
occur at high frequency28) on dentate gyrus development
in situ.
The presented results demonstrate that both NPCs
and neuronal progenitors are subject to DEX-induced ap-
optosis. The actions of DEX were shown to be mediated
by GRs, which are expressed by NPCs, by neuronal pro-
genitors and mature neurons (in culture), and by QNP
and ANP cells residing in the SGZ; notably, the SGZ
displays a prominent apoptotic response to DEX. It is im-
portant to note, however, that because GR expression by
NPCs is not ubiquitous, a subpopulation of NPCs may
be (at least transiently) spared from the actions of DEX.
However, given the finite self-renewing properties of
NPCs,29 disruption of the lifelong cycle of neuronal birth
and therefore, sustained deleterious effects on hippocam-
pal growth and function, is a plausible scenario being in-
vestigated in a long-term study. Meanwhile, analysis of
the mechanisms through which DEX induces NPC apo-
ptosis revealed a role for the mitochondrial pathway.
Consistent with previous findings,33 our results indicate
that the proapoptotic actions of DEX are initiated by an
increase in ROS levels and concomitant decreases in the
cellular defenses against oxidative stress. Through their
disruption of the mitochondrial membrane potential,
these events subsequently lead to activation of caspase 9
and caspase 3. Notably, we show that DEX treatment re-
sults in increased activation of the “executor caspase,”
FIGURE 5: Neonatal glucocorticoid treatment induces apoptosis in the subgranular zone (SGZ) in situ. (A) Immunohisto-
chemistry for glucocorticoid receptor (GR) in the dentate gyrus of PND10 rats revealed a gradient of staining intensity, from
the germinative SGZ (high) to the granule cell layer (GCL) (low); the area enclosed by the white box is enlarged in the inset,
where the arrowheads mark examples of GR-positive neural precursor cells at the hilus-SGZ border. (B–C) Confocal images
of activated caspase 3 immunostaining in a section from the dorsal portion of the dentate gyrus of a control (CON) (B) and
a dexamethasone (DEX)-treated (C) rat (PND10); the arrowheads point to examples of cells showing immunoreactivity in the
SGZ. (D) Numerical analysis of sections from CON (n  7) and DEX-treated rats (n  8) stained for activated caspase 3
activity in SGZ; data shown are mean  standard error of the mean. *p < 0.05 vs CON. Scale bar: 1mm in (A) and 20m
in the inset of (A), and (B) and (C). [Color ﬁgure can be viewed in the online issue, which is available at www.interscience.
wiley.com.]
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caspase 3, in NPCs in culture and in the SGZ of the
intact hippocampus.
The capacity of the hippocampus to produce new
neurons declines markedly with age.7–9,34 Whereas previ-
ous work reported an 80% decrease in the neurogenic ca-
pacity of the hippocampus between 1 and 22 months of
age,7–9,34 our results show an even steeper decline
(92%) between PND10 and 28. Thus, the hippocam-
pus undergoes its most dynamic structural organization
during the early postnatal period, with a precipitous de-
pletion of the NPC pool9 that probably reflects changes
in the milieu that normally encourages NPC prolifera-
tion.35 Given that NPCs are vulnerable to the apoptotic
actions of DEX (this study), and have a limited capacity
for self-renewal,29 as well as the fact that the dentate gyrus
increases in neuronal number and volume for at least 1
year,36 it was considered important to examine whether
DEX influences the in vivo NPC pool in a transient or
sustained fashion. We observed that neonatal DEX treat-
ment induces a sustained reduction in the number of mi-
totic cells and, importantly, retards the volumetric growth
of the SGZ and GCL. This finding is consistent with pre-
vious reports in rats and rhesus monkeys.37–39 On the
other hand, postnatal neurogenesis and granule cell vol-
umes appear to be unaltered by prenatal exposure to
DEX,40 and neurogenesis is only transiently inhibited
when DEX is administered to adults.41 These observa-
tions suggest that early postnatal life may represent a win-
dow during which NPCs are particularly sensitive to
DEX, and that exposure to DEX during this period re-
sults in a protracted retardation of dentate gyrus develop-
ment.
The paradigm of chronic DEX administration dur-
ing perinatal life is clinically relevant; there is convincing
evidence that glucocorticoids during early childhood lead
to impairments of neuromotor functions and cognition,
as well as head and somatic growth.42,43 This study shows
that the hippocampus endures increased levels of neuronal
apoptosis, retarded growth, and sustained reductions in
the rate of neurogenesis when DEX is administered dur-
ing neonatal life; moreover, an earlier study associated
such treatment with reduced forebrain expression of syn-
aptic proteins and disruption of the ontogeny of neuro-
transmitter systems.37 Since lifetime cognitive perfor-
mance relies on plasticity (including neurogenesis) in the
hippocampus,2,4,6,34 the sustained depletion of the NPC
pool by neonatal DEX is likely to have a major impact on
lifetime learning and memory. Lastly, early life experi-
ences that stimulate endogenous glucocorticoid secretion
and interfere with neuroplasticity are established etio-
FIGURE 6: Glucocorticoid treatment in neonatal life results
in a sustained reduction of neurogenic capacity. (A–C) Con-
focal images showing double staining with anti–5-bromo-
2-deoxyuridine (BrdU) (A) and anti-Ki67 (B). Arrowheads
indicate cells colabeled with the BrdU and Ki67 antibodies.
Hoechst 33342 staining (C) was used to identify cell nuclei
and to help delineate the subgranular zone (SGZ) and
granule cell layer (GCL). (D) Dexamethasone (DEX) treat-
ment (200g/kg/d on postnatal day [PND] 1–3, tapering to
100g/kg/d) on PND 1–7 results in a signiﬁcant reduction
in the number of proliferating cells, as judged by immuno-
staining of BrdU-incorporating cells and Ki67-immuno-
reactive cells on PND 10, 18, and 28; note the progressive
decline in proliferating cells in controls over the time pe-
riod examined. (E) The volume of the SGZ and GCL of rats
exposed to DEX on PND 1–7 is signiﬁcantly smaller when
estimated on PND 10 and 28. Note that the increase in
GCL volume between PND 10 and PND 28 was greater in
controls (CON) than in neonatally DEX-treated rats. All nu-
merical values are mean  standard error of the mean.
*p < 0.05, **p < 0.01, as compared with age-matched
controls; ## indicates signiﬁcant difference between PND
10 and PND 28 (p < 0.01). PND 10: CON, n  7; DEX,
n  8. PND 18: CON, n  8,; DEX, n  8. PND 28: CON,
n  8; DEX, n  9. Scale bar: 20m. [Color ﬁgure can be
viewed in the online issue, which is available at www.
interscience.wiley.com.]
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pathogenic factors in a number of psychiatric conditions,
best exemplified by major depression.1,13
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2.3 Chapter 3: Probing the role of estrogen receptor isoforms in neonatal 
programming of neuroendocrine and behavioral functions 
Patchev AV et al., Endocrinology Studies, 2011 
2.3.1 Rationale 
The HPA axis in rodents displays strong sexual dichotomy, with females showing higher basal 
and stress induced corticosteroid secretions, but also a more effective GC negative feedback. 
Previous work from our lab has shown that the neonatal sex-steroid milieu in the rat is crucially 
involved in the sex-specific organization of the HPA axis (Patchev et al., 1995). The discovery of 
the estrogen receptor  (ER) (Kuiper and Gustafsson, 1997), as well as the capacity of both 
ER isoforms to induce differential transcriptional programs depending on the cell phenotype and 
mutually curb their transcriptional effects when co-expressed (Matthews and Gustafsson, 2003) 
prompted us to ask, whether isoform-selective ER activation might have differential 
consequences for sex-specific HPA axis organization and function. In earlier studies we have 
shown that selective neonatal ER or ER activation in female rats leads to distinct 
neuroendocrine and behavioral effects relevant to reproduction (Patchev et al., 2004).  Neonatal 
ER activation lead to defeminization of several aspects of gonadal function, sexual behavior 
and morphological features of sensitive brain areas, while ER effects were confined to 
abrogation of the ovarian cycle and changes in neuronal populations which control gonadotropin 
secretion patterns. In this context, and in view of the finding that ER is predominantly 
expressed in brain areas involved in the neuroendocrine stress response (Laflamme et al., 
1998), we hypothesized that selective neonatal activation of ER isoforms might differentially 
affect sex-specific HPA axis organization and function in later life. 
2.3.2 Major findings 
- the validity of the experimental model was confirmed by demonstration of sex 
dichotomy in several aspects of HPA axis function and by their abrogation by neonatal 
administration of the non-selective ER agonist estradiol in female rats 
  41 
- neonatal isolated activation of any of the ER isoforms could not emulate the effects of 
estradiol  
- selective ER-activation was associated with impaired GC negative feedback and signs 
of increased behavioral anxiety in adulthood  
- selective ER-activation led to increased basal GC secretion and blunted circadian 
oscillations, as well as a hypoanxious phenotype 
- selective neonatal ER activation lead to stronger gonadal axis impairments, while ER 
activation was associated with a preservation of residual ovarian sex hormone 
secretions.  
- Homologous down-regulation of the corresponding ER isoform (and, thus, subsequent 
male-like insensitivity) by neonatal ligand exposure was manifest only in animals treated 
with ER agonist and the non-selective agonist estradiol   
2.3.3 Conclusions 
Defeminization of HPA axis function is a result of an orchestrated interplay between both ER 
isoforms. In contrast to the sex-specific organization of reproductive behaviors and 
neuroendocrine functions, the sex dichotomy of HPA axis function appears to depend also on 
superimposed effects of gonadal secretions in adulthood. Our data strongly indicate that the 
degree of preservation of female gonadal secretions and, corollary, activational effects of 
estrogens, in animals with a history of neonatal ER activation accounts for the manifestation or 
abrogation of sex differences in HPA axis function.  
2.3.4 Outlook / ongoing studies 
In future studies we plan to explore the hypothesis that sex dimorphisms in emotional and 
cognitive behaviors, like those in HPA axis function, are secondary to activational effects of sex-
steroids, rather than products of their organizational action. To this end, females will be 
neonatally exposed to estradiol or isoform-selective ER agonists; in adulthood the animals will be 
ovariectomized and supplemented with estradiol. We expect that only animals with a history of 
neonatal ER activation will display female-like HPA axis function. Furthermore, the importance 
  42 
of androgen receptor signaling as mediator of behavioral and neuroendocrine masculinization 
should be evaluated in greater detail.  
Remark: Unfortunately, due to changes in institute infrastructure in 2009 precluding the use of 
rats as experimental models, we could not complete these experiments. The alternative use of 
mice may become problematic, as sex-specific dimorphisms, which serve as validation criteria 
for the organizing efficacy of isoform-selective ER agonists are not reliably expressed in the 
murine brain (Bonthuis et al., 2010). 
2.3.5 Contributions 
- Performing of all in vivo studies (including day to day treatment, blood sampling and 
behavioral analysis)  
- Supervision of a master student (A. Wolff-Muscate) on a daily basis.  
- Molecular and histological analysis of brain specimens  
- Performing endocrine measurements 
- Writing the manuscript 
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Figure 3  Selective ER isoform activation leads to distinct disruption, rather than 
sex-specific organization, of HPA axis function 
Sex-specific HPA axis function seems to be strongly affected by activational sex-steroid effects, and thus depends on the 
organization and function of the gonadal (HPG) axis, although direct organizational effects of sex-steroids on discrete pathways 
within the HPA axis can not be excluded. Neonatal estrogenization of female rats with estradiol (a mixed ER agonist) leads to 
male-like gonadal function and activational effects (e.g. ER expression in the brain), thus leading to male-like HPA axis function. 
None of these effects could be reproduced by selective ER isoform activation, which resulted in distinct disruption profiles of 
HPA axis function.  
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Probing the role of estrogen receptor isoformsin neonatal programming of neuroendocrine and behavioral functions
Alexandre V. Patchev,1Annemarie Wolff-Muscate,1,2Dieter Fischer,1 Osborne F.X. Almeida11Max Planck Institute of Psychiatry;2Institute of Developmental Genetics,Helmholtz Center, Munich, Germany
Abstract 
Sex differences in the activity of the hypo-
thalamus-pituitary-adrenal (HPA) axis in rats
are programmed by neonatal estrogens; expo-
sure of female neonates to estradiol (E2) leads
to overt defeminization of endocrine and
behavioral functions in adulthood. E2 activates
both estrogen receptor isoforms (ERα and
ERβ); these are widely expressed in the brain,
and differentially regulate HPA axis activity in
adulthood. However, the contributions of each
ER isoform to the sex-specific organization of
the neural mechanisms governing HPA axis
function remain unknown. ERα, ERβ agonists
(PPT and DPN, respectively) or E2 were admin-
istered to female rats on days 1-10 of life.
Animals subsequently underwent endocrine
(HPA axis and reproductive) and behavioral
profiling (anxiety-related and reproductive) in
adulthood, and patterns of expression of rele-
vant genes were monitored in limbic struc-
tures post mortem. Exposure of neonatal
females to PPT or DPN led to distinctly differ-
ent HPA secretory profiles, neither of which
completely recapitulated the effects of E2.
Thus, whereas impaired glucocorticoid nega-
tive feedback was the most prominent effect of
PPT treatment, increased basal corticosterone
secretion was the most obvious characteristic
of DPN-treated animals. Behavioral analysis
revealed higher anxiety levels in PPT-treated
animals, similar to those observed in E2-treat-
ed female neonates and control males; in con-
trast, DPN treatment was associated with
reduced anxiety-like behavior. Parallel treat-
ment-specific alterations in the expression of
the genes encoding mineralocorticoid (MR)
and glucocorticoid (GR) receptors in the hip-
pocampus and amygdala and altered expres-
sion of ERβmRNA in discrete brain regions, as
well as disturbed ovarian activity, were also
found; together, they suggest potential mecha-
nisms that could account for the different
endocrine and behavioral phenotypes
observed. 
Defeminization of HPA axis activity and
associated anxiety-related behavior depends
on balanced activation of ERα and ERβ during
early postnatal life, rather than on the activa-
tion of a specific ER isoform. Long-term E2-,
PPT- and DPN-induced alterations in the
expression levels of GR and MR in the hip-
pocampus and amygdala, as well as disrupted
ovarian activity appear to be largely responsi-
ble for eliciting and maintaining the aberrant
endocrine and behavioral phenotypes induced
by estrogenization of neonatal females.
Introduction 
Understanding the neurobiological basis of
sex differences in the activity of the hypothal-
amus-pituitary-adrenal (HPA) axis is of med-
ical relevance given the association between
excessive glucocorticoid (GC) secretion and
mood and anxiety disorders, conditions that
occur more frequently in women.1 Women and
female rodents secrete higher GC levels under
both basal and stressful conditions; however,
in contrast to males, healthy females show
more efficient GC negative feedback regula-
tion of adrenocorticotropin (ACTH) and gluco-
corticoid receptors (GR) in the pituitary, corti-
cotrophin-releasing hormone (CRH), arginine
vasopressin (AVP) and GR in the hypothala-
mus, and GR in the hippocampus.2-4 In adults
of both sexes, these molecules are subject to
dynamic regulation by gonadal steroids such
as estradiol (E2). In females, cyclical fluctua-
tions in the secretion of sex steroids con-
tribute to the regulation of glucocorticoid
secretion5-6 and a variety of behaviors in
rodents7 and primates, including humans;  the
influence of estradiol (E2) on these functions
is well known.8 On the other hand, neonatal
exposure of female rats to E2 results in the
expression of a male-like HPA axis function.3
Since neonatal rats are considered to have a
default female status, it is thought that the
male phenotype results from the so-called
organizing actions of neonatal estrogen,9 a
view supported by the observation that neona-
tal castration of males prevents manifestation
of masculine endocrine and behavioral fea-
tures.10 Adult female gonadal secretions have
been shown to affect HPA axis function
through so called activational effects, whose
magnitude and quality strongly depend on the
organizing effects during early ontogeny.2
Estrogen actions are mediated by estrogen
receptors (ER), of which there are two major
isoforms (ERα and ERβ). While ERα are pre-
dominantly expressed in brain nuclei implicat-
ed in the control of reproductive hormone
secretion and behavior, ERβ are found in
regions that are responsible for the regulation
of non-reproductive functions, including HPA
axis activity.11-12 Since E2 activates both ERα
and ERβ in a relatively non-selective manner
(EC50 values: 50 pM and 200 pM for ERα and
ERβ respectively),13 questions regarding the
individual contributions of each ER isoform to
the organization of sex differences in HPA axis
function remain open. This study addressed
this issue by selectively activating ERα and
ERβ with 4,4',4''-(4-Propyl-[1H]-pyrazole-
1,3,5-triyl)trisphenol (PPT; EC50 of 200 pM at
ERα 410-fold higher affinity for ERα than
ERβ)14 and 2,3-bis(4-Hydroxyphenyl)-propi-
onitrile (diarylpropionitrile; DPN; EC50 of 0.85
nM at ERβ; 170-fold higher affinity for ERβ
than ERα),15 respectively. In addition to moni-
toring GC secretion under differing conditions,
we also monitored a number of pathways
involved in the regulation of the HPA axis and
of anxiety-related behavior; the latter is influ-
enced by adrenal and gonadal steroids.16-17 Our
results highlight the importance of co-activa-
tion of both ER isoforms during sex-specific
organization of the brain since activation of
just one isoform results in erroneous program-
ming of both neuroendocrine and behavioral
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functions. These findings are interesting from
an environmental health perspective, as many
environmental pollutants and endocrine dis-
rupting compounds show differential affinities
for the two ER isoforms.18-19 Further, our exper-
iments draw attention to the fact that the dis-
ruptive effects of neonatal estrogenization par-
adigms on ovarian secretions and their recep-
tive targets must be considered when inter-
preting the results from such experiments.
Specifically, our results hint that sex differ-
ences of HPA axis function arise from impair-
ment of activational estrogenic effects due to
impairment of sex-steroid secretion and ER
expression patterns in the brain, which are the
consequence of the neonatal sex-steroid
milieu.
Materials and Methods
Animals and treatment paradigms
All experiments were conducted in compli-
ance with the Code of Ethics of The Endocrine
Society and European Union Directive on
Animal Experiments (Directive 2010/63/EU);
specific procedures were approved by the
ethics committee of the Government of Upper
Bavaria, Germany (Permit 2531-22-07). Timed
pregnant Wistar rats were purchased from
Charles River Laboratories (Sulzfeld,
Germany) on gestation day 15 and were
housed individually under standard conditions
(lights on: 18.00, lights off: 6.00). On the day of
birth, litters were culled (8-10 pups), with
equal distribution of males and females across
litters. On postnatal days 1-14 (PND 1-14), lit-
ters were assigned to one of four treatment
groups: vehicle (peanut oil), estradiol ben-
zoate (EB, 7.5 µg; n = 13), 4,4',4''-(4-Propyl-
[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT, ERα
agonist, 50 µg; n = 10), or 2,3-bis(4-
Hydroxyphenyl)-propionitrile (DPN, ERβ ago-
nist, 50 µg; n=14). Estradiol benzoate (Sigma
Aldrich, Deisenhofen, Germany), PPT and DPN
(both from Tocris, Bristol, UK) were initially
dissolved in absolute ethanol and peanut oil
(final ethanol: 0.001%) and injected subcuta-
neously in a volume of 0.1 mL on every second
day. Choice of doses was based on the relative
binding affinities of PPT and DPN to ERα and
ERβ respectively14-15 and the relative transcrip-
tional efficacies of these compounds compared
to previously used compounds.20 Upon weaning
on PND 21, animals were ear-marked and
housed in groups of 4 under an inversed light
rhythm. Ovarian cyclicity was monitored (vagi-
nal smear cytology) from post natal days 80 to
121 and female sexual behavior was assessed
between days 114 to 121. Animals were tested
for locomotor and anxiety-related behaviors in
the open field21 and elevated plus maze22 start-
ing at ca. 130 days of age, with an interval of at
least 1 week between each test. All methods of
behavioral analysis are described below. Blood
samples (tail vein) were collected for evalua-
tion of HPA axis activity and glucocorticoid
negative feedback (PND 130); serum was
stored at -20°C until assayed for hormones.
Animals were killed on PND 150.Assessment of female sexualbehavior 
Female sexual behavior was evaluated
according to established protocols.20 In brief,
vasectomized, sexually experienced male
Wistar rats were placed in the testing cage and
allowed to habituate for 5 min before being
presented with estrous females. The number
of mounts, lordosis responses and ejaculations
were used to compute the lordosis quotient
over an observation period of 5 min.Assessment of anxiety-relatedbehavior
Thigmotaxis was evaluated (5 min) in an
open field arena (LxBxH: 70¥70¥50 cm; non-
reflecting white PVC) according to established
protocols.21 Randomly-cycling non-treated
females were used as controls (to ensure a
normal distribution of the phases of the
oestrous cycle throughout the experiment)
and both tests were performed under 100 lux
illumination. Central and peripheral line
crossings as well as time spent in the central
area of the arena were scored. Anxiety-related
behavior was evaluated in the elevated plus
maze test22 (LxBxH: 50¥10¥40 cm, with open-
arm edges 0.5 cm high; placed 70 cm above the
floor). The number of entries into, and the
time spent in the open compartments of the
maze were evaluated over a period of 5 min.
Events in the open field apparatus and elevat-
ed plus maze were video-recorded and subse-
quently scored by an investigator blind to the
treatments.Characterization of HPA axis activity 
Basal and stress-induced corticosterone
secretion was monitored in serial blood sam-
ples as reported elsewher.23 Serial blood sam-
ples (ca. 20 µL) were obtained while animals
were in their home cages over approximately
20 s. 
Samples for estimation of diurnal fluctua-
tions in corticosterone were collected at the
circadian zenith (06:00) and nadir (18:00).
Immediately thereafter, animals were exposed
to an emotional stressor for 2 min; to this end,
animals were placed in an empty cage and
exposed to an air puff delivered with a hair
dryer. Blood samples were obtained 30 and 180
min later, to determine maximal corticos-
terone responses and shut-off of the endocrine
response to stress. After a resting period of 3
days, animals were subjected to a dexametha-
sone suppression test (DST). For this, animals
were given a bolus intraperitoneal (i.p.) injec-
tion of dexamethasone (Fortecortin®, Merck,
Darmstadt, Germany; 10 µg/kg BW in a volume
of 0.2 mL) at 24:00. Animals were blood sam-
pled at 06:00 (the expected time of the circadi-
an peak of corticosterone secretion). Serum
samples were stored at -20°C until hormone
assay.Tissue processing 
Animals were sacrificed at the circadian
zenith of HPA axis activity (06:00) by rapid
decapitation. Brains were rapidly removed
from the skull, snap-frozen in pre-chilled
isopentane and kept at -80°C until further pro-
cessing. Six serial coronal (10 µm) cryosec-
tions were prepared from the PVN (bregma -
1.53 to -1.78) amygdala (bregma -1.78 to -2.0)
and dorsal hippocampus (bregma -2.45 to -
4.60) and micropunches from the remaining
parts of these areas of interest were obtained
as previously described.24 Sections and microp-
unches were stored at -80°C until further pro-
cessing. RNA isolation and qPCR 
RNA was isolated from micro-dissected
brain areas using RNAeasy® kits (Qiagen,
Hilden, Germany), and 100 ng RNA were used
for cDNA synthesis (RevertAid® kit;
Fermentas, St. Leon-Rot, Germany).
Quantitative polymerase chain reaction
(qPCR) was performed using SYBR Green I
Master mix on a LightCycler 480 (Roche
Applied Science, Mannheim, Germany).
Expression levels of mRNAs of interest were
normalized against levels of Mas mRNA since
preliminary studies showed that Mas per se is
not regulated by sex or hormonal status (data
not shown). Primer sequences are listed in
Table 1 (5’-3’). GR and MR mRNA expression inhippocampus and amygdala 
Labeled ribonucleotide probes for the detec-
tion of GR and MR protein-encoding tran-
scripts were produced from linearized plas-
mids using in vitro transcription kits with T7,
T3 and Sp6 RNA polymerases (Promega,
Madison, WI) and [35S]-dUTP (Perkin Elmer,
Rodgau, Germany). The GR and MR expression
plasmids were a generous gift from Dr. J. L.
Arriza.25-26 Cryosections were permeabilized
and hybridized according to published proto-
cols.27 Autoradiograms (BioMax MR; Kodak,
Rochester, NY) were analyzed by densitometry
on two sections per animal, using the NIH soft-
ware Scion Image Beta 4.2.0. Individual aver-
aged transmittance levels were converted to
specific radioactivity by third-order polynomial
equations generated from co-exposed 14C
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standards (ARC, St. Louis, MO, USA).Hormone measurements
Serum corticosterone levels in serial blood
samples, and estradiol, progesterone and
luteinizing hormone (LH) concentrations in
probes derived from trunk blood, were deter-
mined using commercially available radioim-
munoassay (corticosterone: DRG Instruments,
Marburg, Germany) or enzyme immunoassay
(estradiol and progesterone: Beckman Coulter,
Krefeld, Germany; LH: Millipore, Schwalbach,
Germany) kits.Statistics 
Data are presented as either group means ±
SEM or scatter plots with medians. Group
means were compared by either parametric or
non-parametric 1-way ANOVA and appropriate
post-hoc tests (Tukey-Kramer or Kruskal-
Wallis, respectively). The threshold of signifi-
cance was defined as P<0.05. 
ResultsProgramming versus disorganiza-tion of HPA axis activity 
Several aspects of HPA axis function differ
markedly in the two sexes. For example, previ-
ous studies showed that females secrete high-
er levels of corticosterone under both baseline
and stressful conditions.2-3 Further, those stud-
ies demonstrated that these endocrine profiles
are subject to defeminization by neonatal
exposure of female rats to estradiol benzoate
(EB).3,4 As shown in Figure 1, those earlier
findings with EB were reproduced in the pres-
ent work, in which neonatal estrogenization
resulted in attenuated corticosterone secretory
responses to stress (Figure 1A, P<0.0001,
F=26.4) as well as reduced night time (zenith)
baseline levels of corticosterone (Figure 1B,
P<0.0001, F=45.5). Together, these results
attest to the ability of neonatal EB to program
the neuroendocrine system to elicit phenotypi-
cally male HPA axis responses in rats with a
female genotype.  
Since EB non-selectively activates both ERα
and ERβ, HPA axis activity in adulthood was
next assessed in females that had been
exposed to selective agonists of either ERα
(PPT) or ERβ (DPN) during neonatal life. As
compared to normal female rats, PPT-treated
animals had significantly lower daytime base-
line corticosterone levels (P < 0.01, F = 62.2)
although night time levels did not differ
between the two groups (Figure 1B). Notably,
neither PPT nor DPN treatments reproduced
the effects of EB (daytime corticosterone: DPN
> EB > PPT; night-time corticosterone: DPN >
PPT > EB; Figure 1B). Interestingly, vehicle-,
PPT- and DPN-treated rats all responded to an
acute stressor with significant increases in
corticosterone secretion. However, the
between-group magnitudes of response dif-
fered remarkably (approximately 5-fold, 8-fold
and 2-fold in the vehicle-, PPT- and DPN-treat-
ed groups, respectively; Figure 1A). In terms of
relative magnitude of response to stress, the
DPN-treated animals showed closest resem-
blance to the EB-treated group; however, it
should be noted that the DPN group displayed
high basal corticosterone levels, and that the
attenuated corticosterone response to stress in
DPN-treated rats is unlikely to be the result of
reduced steroidogenic capacity since the levels
of the mRNAs encoding for critical regulators
of adrenocortical steroidogenesis (StAR pro-
tein, P450scc, 3β-hydroxysteroid dehydroge-
nase, and the ACTH receptor) were unchanged
(data not shown). Considered together with
the results obtained with EB, it is concluded
that whereas dual occupation of ER during
neonatal life programs the female HPA axis to
express a male-like phenotype, selective acti-
vation of either ERα or ERβ results in malpro-
gramming of the central mechanisms that reg-
ulate HPA axis function. Disruption of central mechanismsregulating HPA axis function
Homeostatic control of corticosterone secre-
tion is maintained through a series of regula-
tory loops that are sensitive to the negative
feedback actions of corticosterone. The dex-
amethasone suppression test (DST) serves as
a powerful tool to assess the efficacy of corti-
costeroid negative feedback at both brain and
pituitary levels.28 Here, administration of the
DST revealed that, as compared to vehicle- EB-
and DPN-treated females, PPT-treated females
display impaired corticosteroid-mediated neg-
ative feedback (Figure 2A, P<0.0001, F=10.1).
Since males are known to be less sensitive to
glucocorticoid negative feedback in the DST,28
it is interesting to note that neonatal PPT
treatment of females resulted in even greater
insensitivity to dexamethasone (P<0.001).
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Table 1. Primer sequences (5’-3’) used for quantitative polymerase chain reaction.
Gene Forward primer sequence Reverse primer sequence
Mas AGTACCGTCGTGGCTGCTGAGAA GGCGTTGTCCATGGCGGTCAT
SCC TGCAGCTGCCTGGGATGTGATT ATGGAGGTCGTGTCCACCCCTCC
StAR GGCGTCGGAGCTCTCTACTTGGTTC ACCTTGCCCACACCTGGCAC
3β-HSD TTGTGGTGAGTCAGAAGACCAGGG TGCTCCTGTCACCAGGCAGC
ACTHR TTGTGACCATGCGACGCACC CATGGTGATGCCGCTCCCTGT
ERα GGCTGCGCAAGTGTTACGAA CATTTCGGCCTTCCAAGTCAT
ERα TTCCCGGCAGCACCAGTAACC TCCCTCTTTGCGTTTGGACTA
GR ACCTCGATGACCAAATGACC AGCAAAGCAGAGCAGGTTTC
MR CGTACAAACATACGAACAGCCA TAGAACCTCTGCCAACTCTGTC
Mas, NM_053825; SCC, steroid side-chain cleavage; StAR, Steroid acute regulatory protein; 3-HSD, 3β-hydroxysteroid dehydrogenase;
ACTHR, Adrenocorticotropin (ACTH) receptor; ERα, Estrogen receptorα; ERβ, Estrogen receptorβ ; GR, glucocorticoid receptor; MR, min-
eralocorticoid receptor.
Figure 1. Corticosterone secretory profiles.
Neonatal female rats were exposed to estra-
diol benzoate (EB), PPT (selective ER
agonist) or DPN (selective ER  agonist)
and their basal and stress-induced corti-
costerone levels assessed during adulthood
(PND 100). Comparisons were made with
vehicle-treated female and male rats: A)
depicts corticosterone levels at the circadi-
an nadir, and 30 and 180 min after expo-
sure to a brief emotional stressor; B) diur-
nal trough and peak levels of corticos-
terone secretion under quiescent condi-
tions. One-Way-ANOVA were performed
for each sampling time point: basal
(nadir): F=62.2; 30 min: F=26.4; 180 min
(Kruskal-Wallis ANOVA) H=26.3; zenith:
F=45.5. Bars represent mean ± SEM of 9-
14 animals/group. Asterisks indicate sig-
nificant (P<0.05) differences as compared
to control vehicle-treated females, crosses
indicate significant (P<0.05) differences
vs. control males. 
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While this impaired response to the negative
feedback actions would be expected to result in
increased basal corticosterone levels, PPT-
treated females displayed significantly reduced
levels of this hormone under basal conditions,
as compared to control females (Figure 1B). In
marked contrast to the PPT group, DPN-treat-
ed females showed high basal levels of corti-
costerone (Figure 1B) and were unimpaired in
the DST (Figure 2A). These differences in
feedback efficacy imply differential roles of
ERα and ERβ in the programming and, possi-
bly, regulation of corticosteroid feedback
mechanisms. 
The hippocampus is implicated as a major
site of corticosteroid negative feedback.29 It is
richly endowed with the two types of corticos-
teroid receptors, mineralocorticoid (MR) and
glucocorticoid (GR) receptors. MR and GR dif-
fer in their affinities for corticosterone and
together contribute to the maintenance of
homeostasis in the HPA axis under basal and
stressful conditions.30 Analysis of GR and MR
mRNA transcripts in the hippocampi of PPT-
and DPN-treated animals indicated differential
regulation of the two receptors by the ERα-
and ERβ-selective ligands: as compared to
vehicle-treated females, PPT- and DPN-treated
females showed reduced levels of GR and MR
expression, respectively (Figure 2B and 2C,
P<0.0001, F=16.6 and P<0.0001, F=11.3
respectively). Together with the above-report-
ed differences in baseline corticosterone
secretion and sensitivity to corticosteroid feed-
back in the PPT- and DPN-treated groups,
these observations are consistent with the
suggestion that MR are responsible for main-
taining HPA axis activity under resting condi-
tions whereas GR are responsible for mediat-
ing corticosteroid negative feedback when cor-
ticosterone levels exceed a certain threshold.30Opposing behavioral effects of iso-form-selective neonatal ER activation
The amygdala is another important site of
corticosteroid actions. This brain region is not
only implicated in the control of emotional
behaviors such as anxiety but also of HPA axis
activity. However, in contrast to the hippocam-
pus, the amygdala exerts a positive drive on
the HPA axis.31 Chronically increased levels of
corticosterone are closely linked to the expres-
sion of anxiety-related behaviors32 and, given
the results described in the previous section, it
was predicted that rats neonatally exposed to
DPN would show the highest levels of anxiety.
In this study, neonatal administration of PPT
and DPN did not significantly influence amyg-
daloid GR mRNA transcript levels (as com-
pared to vehicle-treated females; Figure 2E). In
contrast, amygdaloid MR expression was sig-
nificantly down- and upregulated after neona-
tal exposure to PPT and DPN, respectively
(Figure 2D, P<0.01 and P<0.0001 respectively,
F=22.2). In the present study, anxiety-related
behavior was evaluated in the open field (OF)
arena and elevated plus-maze (EPM) by moni-
toring the following standard parameters, vali-
dated to reflect anxiety-related behavior in
rodents:21,22 time spent by animal exploring the
center area of the unfamiliar OF and in the
open arms of the EPM as well as frequency of
these events. When compared to untreated
males and PPT-treated females, random-
cycling control females showed less anxious-
ness in terms of the number of entries into
(P<0.01, H=33.4) and time spent in the open
arms (P<0.01, F=29.9) of the EPM (Figure 3A,
3B and 3C). However, DPN-treated animals
displayed significantly less anxiousness than
Article
Figure 2. Glucocorticoid negative feedback and its molecular correlates. A) Efficacy of
glucocorticoid negative feedback was evaluated by the dexamethasone suppression test
(DST). Animals were given 10µg/kg BW dexamethasone 6 h before blood samples were
collected at the time of the daily peak in corticosterone secretion. Data are presented as
a percentage of each individual’s peak level of corticosterone secretion on the previous
(dexamethasone-free) day. One-Way-ANOVA: F = 10.1; asterisks indicate P<0.05 vs. con-
trol females, crosses indicate significant difference vs. control males (n=9-14
animals/group); mRNA expression levels of mineralocorticoid (B, D) and glucocorticoid
(C, E) in the hippocampus and amygdala, respectively. mRNA transcripts in the hip-
pocampus were assessed using semi-quantitative in situ hybridization histochemistry.
Tissue punches from the amygdala were used to quantify mRNA levels by qPCR; values
were normalized against those obtained in control females to yield fold-differences. One-
Way-ANOVA: B) F = 11.3; C) F = 16.6; D) F = 22.2; E) F=6.5. All data are shown as mean
± SEM of 5-6 animals/group; asterisks indicate significant differences from control
females (P<0.05), crosses indicate significant (P<0.05) difference vs. control males.
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the vehicle-treated controls on these measures
(Figure 3A, 3B and 3C, P<0.001 respectively).
These results show that activation of ERβ in
neonatal females results in a hypo-anxious
phenotype despite overt hypercorticism. The
analysis of the data from the OF test yielded a
similar picture: DPN- and vehicle-treated
females spent more time exploring the central
area of the arena (a sign of reduced anxiety-
related behavior) than males, EB- and PPT-
treated animals (Figure 3D, P<0.001, F=6.22). Modulatory influence of ovariansteroids
Neonatal estrogenization is known to abol-
ish ovarian cyclicity by inducing the so-called
interrupted persistent estrus syndrome33 and we
previously showed that activation of either ER
isoform results in persistent estrus in adult-
hood.20 The above-described mismatches
between behavior and endocrine phenotype in
the PPT- vs DPN-treated animals led us to con-
sider the potential importance of differential
alterations in gonadal status, resulting from
isoform-selective neonatal estrogenization, in
the observed behavioral phenotypes. The iso-
form-selectivity of the different neonatal treat-
ments was verified by assessing female sexual
behavior. We found that, whereas neonatal
treatment with either EB or PPT results in a
loss of female sexual behavior, neonatal expo-
sure to DPN does not influence this parameter
(data not shown); these results are consistent
with our previous findings using other ERα
and ERβ agonists.20 As shown in Figure 4A,
estradiol levels in adult females that had been
exposed to PPT or DPN during neonatal life
were not markedly different from those found
in random cycling control females; on the other
hand, neonatal EB treatment resulted in sig-
nificantly reduced levels of estradiol secretion
(P<0.001, H=13.13). Interestingly, serum
progesterone levels were significantly reduced
only in the EB and PPT-treated animals
(P<0.001 and P<0.0001 respectively, H=22.8),
but not in the DPN-treated group; these find-
ings support the view that neonatal exposure
to the ERβ-selective agonist does not abolish
the steroid secretory activity of the adult
gonad. While ovarian cyclicity (as judged by
vaginal epithelial cornification) was abolished
by all of the neonatal estrogenization para-
digms (data not shown), the degree of ovarian
dysfunction, as judged by gonadotropin (LH)
secretion (Figure 4C, P<0.001, F = 10.4), ovar-
ian histology (not shown) and ovarian and
uterine weights (Figure 4D, P<0.0001, F=48.6
and P<0.0001, F=30.2 respectively) was grad-
ed: EB > PPT > DPN. It is interesting to note
that, although elevated HPA axis activity is fre-
quently associated with impaired reproductive
function, the DPN-treated animals showed the
least degree of ovarian disruption despite their
high levels of corticosterone secretion (Figure
1B). Sex differences in basal and stress-
induced anxiety are well-known and estrogens
have been implicated in the regulation of anx-
iety in humans and rodents.34 Experiments
using either pharmacological or genetic
approaches have suggested that ERβ mediate
the anxiolytic effects of estrogens.17,35-37 The
latter, together with the above-reported hypo-
anxious state of DPN-treated animals prompt-
ed us to examine ERβ expression in the amyg-
dala. As shown in Figure 4E, amygdaloid levels
of ERβ mRNA are sexually differentiated, with
females displaying higher ERβ expression as
compared to males (P<0.01, F=17.3).
Generally, exposure of neonatal females to EB,
PPT or DPN resulted in a significant reduction
of ERβ mRNA levels in the amygdala (Figure
4E, P<0.0001, P<0.001 and P<0.001 respec-
tively), but the degree of down-regulation was
significantly less in the DPN-treated animals
as compared to the EB- and PPT-treated groups
(P<0.01). The latter suggests that neonatally
DPN-treated animals are more responsive to
estrogens, thus providing an explanation for
their lower levels of anxiety. Further, since
ERβ are implicated in mediating the ability of
estrogens to drive the HPA axis at the level of
the hypothalamic PVN,17 it is interesting to
note that ERβ mRNA levels in the PVN were
least downregulated by DPN vs EB and PPT
(Figure 4F, P<0.01, F=9.28). Together, the ERβ
expression data in the amygdala and PVN offer
a plausible mechanistic basis for the mismatch
between the behavioral and endocrine pheno-
types of the DPN-treated animals. 
Discussion
Sexual differentiation of the mammalian
brain results from activation of estrogen recep-
tors (ER) by estradiol (E2) during perinatal
life.9 Estradiol binds to both ER isoforms and is
crucial for their transcriptional activity.13 ERα
and ERβ are expressed in a tissue-specific
manner in peripheral tissues; in the brain,
ERα and ERβ show discrete patterns of distri-
Article
Figure 3. Differential effects on anxiety-related behavior. Measures of anxiety-related
behavior were obtained in an open field arena and the elevated plus maze (EPM); ani-
mals were monitored in each test over a total of 300 s and behaviors were scored by an
observer who was blind to the treatments. A) Percentage of time spent in the open arms
of the EPM (Kruskal-Wallis-ANOVA H = 29.9); B) Number of entries into the open com-
partments of the EPM (Kruskal-Wallis-ANOVA H=33.4); C) Total number of entries into
either open or closed arms of the EPM, serving as an index of locomotor activity
(Kruskal-Wallis-ANOVA H = 31.9); D) Percentage of time spent in the center of an unfa-
miliar OF (One-Way-ANOVA F = 6.22). The results of each individual are plotted (hor-
izontal lines show group median values), asterisks indicate P<0.05 vs. control females,
crosses indicate significant (P<0.05) difference vs. control males. 
N
on
-c
om
m
er
ci
al
 u
se
 o
nl
y
[Endocrinology Studies 2011; 1:e12] [page 55]
bution.11,12 While ERα are predominantly
involved in the regulation of reproductive
behavior and hormone secretion as well as
growth and maintenance of peripheral repro-
ductive tissues, ERβ are implicated in the con-
trol of a variety of non-reproductive functions,
including the regulation of emotion and cogni-
tion.17
Estradiol can activate both ERα and ERβ13
and current evidence suggests that estrogen
actions are determined by cooperative as well
as antagonistic actions of the two receptor
types.38 Previous studies in animals with tar-
geted deletions of ERβ indicated that this ER
isofrom is a crucial mediator of the anxiolytic
effects of estrogens.17,35,39 In addition, genetic
and pharmacological approaches have demon-
strated a role for ERβ in the regulation of cor-
ticosterone secretion. On the other hand, mice
with ERα or ERβ null mutations do not display
clear sexually differentiated HPA axis pheno-
types. Accordingly, the goal of this study was to
attempt to understand the relative contribu-
tions of each ER isoform to the sexual differen-
tiation of the neural substrates responsible for
regulation of HPA axis activity and anxiety.
Based on the well-established paradigm of
neonatal estrogenization of the female rat with
E2 – which results in the expression of clear
male-like behavioral and neuroendocrine pro-
files2,9 – we here treated neonatal female rats
with selective ERα (PPT) or ERβ (DPN) ago-
nists and analyzed their behavioral and
endocrine phenotypes during adulthood. The
specific features examined included activity of
the HPA axis and expression of anxiety-related
behavior. Sex differences have been described
in both of these functions2,40,41 and, in addition,
elevated HPA axis activity is positively correlat-
ed with increased emotionality and suscepti-
bility to depression and anxiety in humans and
animals.1,42
As compared to females, males secrete lower
amounts of corticosterone under basal condi-
tions and in response to stressful stimuli.2
Further, glucocorticoid negative feedback is
less efficient in males than in females and
thus, shut-off of the HPA axis response to
stress is more sluggish in males.2,4,28 We previ-
ously showed that neonatal administration of
E2 defeminizes these measures of HPA axis
function in female rats,4 a result reproduced in
the present work. Our results also show that
neonatal activation of either ERα or ERβ does
not defeminize, but clearly disrupts the mech-
anisms governing HPA axis activity.
Interestingly, the two agonists resulted in
opposing endocrine phenotypes: whereas ani-
mals exposed to neonatal PPT showed female-
like corticosterone secretory response to
stress, those exposed to DPN presented with
hypersecretion of corticosterone under resting
conditions and a relatively blunted endocrine
response to stress. Despite these anomalies,
the DPN-treated group did not show alter-
ations in their ability to respond to the nega-
tive feedback actions of glucocorticoids, as
judged by their normal post-stress shut-off of
corticosterone secretion and their responses
in the DST. In contrast, the animals that had
been exposed to neonatal PPT showed marked
impairment in terms of glucocorticoid nega-
tive feedback. 
The actions of corticosterone are mediated
by MR and GR; these nuclear receptors are
negatively regulated by corticosterone and play
a key role in maintaining homeostasis in the
HPA axis. Both MR and GR are strongly
expressed in limbic regions such as the hip-
pocampus and amygdala where they act to reg-
ulate emotional and cognitive behaviors.30 In
addition, MR and GR are expressed in the
Article
Figure 4. Descriptors of reproductive function and ERβ expression in the amygdala and
hypothalamus. Reproductive parameters evaluated included A) serum estradiol, B) prog-
esterone, C) luteinizing hormone (LH), and D) ovarian and uterine weights. The latter
were normalized to body weight (BW) at the time of sacrifice. Individual hormone val-
ues and group medians are depicted in A-C). Kruskal-Wallis-ANOVA: A) H = 13.1; B) H
= 22,8; C) (One-Way-ANOVA): F=111.4 (asterisks indicate P<0.05 vs. control). Data in
D) are means ± SEM (n = 9-14); significant differences from control females are denoted
by asterisks (P<0.05; One-Way-ANOVA ovaries: F=48.6; uteri: F=30.2).  Expression lev-
els of ERβ mRNA in tissue punches from the amygdala (E) and paraventricular nucleus
of the hypothalamus (PVN) (F) were obtained by qPCR and values (fold change) are
shown normalized against those obtained in control females. Bars represent group means
± SEM of 5-6 animals per group. One-Way-ANOVA E) F = 17.3; F) F = 9.3. Asterisks
indicate significant differences vs. control females, crosses indicate significant differences
vs. control males (P<0.05). 
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hypothalamus; within the hypothalamic par-
aventricular nucleus (PVN), MR and GR are
important for inhibiting the central neuropep-
tidergic (CRH, AVP) drive on the pituitary-
adrenal unit.43 While MR are suggested to be
responsible for maintaining corticosterone lev-
els under basal conditions, GR are implicated
in restoring physiological levels of corticos-
terone secretion following stress.30 Given the
above-mentioned disruption of HPA axis regu-
lation, it was considered important to gain
some insight into the contributory mecha-
nisms by analyzing MR and GR expression in
the hippocampus. Our finding that hippocam-
pal MR mRNA expression is reduced in ani-
mals given DPN during neonatal development
provides an explanation for the elevated basal
levels of corticosterone secretion in these ani-
mals. Neonatal exposure to PPT resulted in a
downregulation of GR expression in the hip-
pocampus, providing a potential mechanistic
explanation for the impaired negative feed-
back efficacy of corticosteroids in the PPT-
treated animals. 
As already alluded to, chronically elevated
levels of corticosterone are frequently associ-
ated with a hyperanxious state.32 Most studies
consider impaired glucocorticoid negative
feedback as a factor that contributes to this
correlation.44 Intriguingly, our assessment of
anxiety in animals that had undergone selec-
tive neonatal activation of ERα or ERβ does
not support the view that anxiety is a direct
correlate of HPA axis activity. On the one hand,
we found that neonatal activation of ERα with
PPT leads to increased anxiety, an effect that
could be explained by the fact that PPT-treated
animals are poor responders in the DST and
show exaggerated endocrine response to
stress; the latter is believed to be a precipitat-
ing factor in anxiety disorders.45 On the other,
we observed reduced anxiety in the DPN-treat-
ed rats; these animals showed chronically ele-
vated baseline corticosterone secretion but
normal endocrine responses to stress and the
DST. 
Several groups have suggested a role for GR
in the regulation of anxiety. For example, con-
ditional overexpression of GR in the dentate
gyrus of the mouse hippocampus reportedly
increases anxiety-related behavior as meas-
ured in the elevated plus maze,46 while GR
knockout mice display reduced anxiety-related
behaviors.47,48 In contrast, forebrain- or amyg-
dala-targeted overexpression of MR is reported
to reduce anxiety in rodents.49 In this respect,
it is notable that animals in which ERα were
activated by PPT during neonatal life display
significantly reduced levels of amygdaloid MR
mRNA as compared to vehicle-treated controls;
in contrast, neonatal PPT treatment did not
elicit any changes in GR expression in this
brain area. Interestingly, the hypo-anxious
state observed in DPN-treated rats was associ-
ated with a >2-fold upregulation of MR expres-
sion in the amygdala and we propose that
increased MR levels in the amygdala, resulting
from neonatal activation of ERβ, serve to
reduce anxiety. Amygdaloid MR may also act to
buffer against the high levels of corticosterone
experienced by animals exposed to the ERβ
agonist during neonatal development by reduc-
ing the availability of corticosterone at GR (cf.
the MR-GR balance hypothesis proposed by de
Kloet and colleagues30) or the efficacy of GR
activity.50,51 In addition the increased MR
expression in the amygdala of neonatally DPN-
treated animals might account for the sluggish
acute adrenocritical stress response in these
animals (Figure 1A); previous work described
a dampening of stress-induced corticosterone
secretion in rats overexpressing amygdaloid
MR.49
Although plausible explanations can be
found for the apparently dissociated endocrine
and behavioral profiles observed in adult rats
whose ERα or ERβ had been activated during
neonatal life, it is important to consider other
factors that could have contributed to the
development of the specific phenotypes. The
neonatal treatments in the present study were
used to study the so-called organizational
actions of early estrogens on HPA axis function
and expression of anxiety. However, results
from our previous studies showing that ERα or
ERβ also differentially organize reproductive
development cannot be ignored.20 Here, we
found that, whereas neonatal E2 treatment
results in hypogonadotropic hypogonadism,
anovulatory ovaries and persistent estrus as
expected,20,52,53 neonatal exposure to PPT and
DPN, while also causing persistent cornifica-
tion of vaginal epithelia, only partially disrupts
ovarian activity; in particular, the DPN-treated
animals did not differ markedly from vehicle-
controlled rats in this respect and continued to
secrete amounts of estrogen that would be suf-
ficient to exert so-called activational actions.
Numerous studies have shown that estrogens
sex-dependently stimulate the HPA axis in
adulthood and there is evidence that low estro-
gen levels are associated with increased anx-
iousness in humans and animals.7,34,54 In light
of previous studies that described the anxiolyt-
ic actions of ERβ agonists,36 the present find-
ing that ERβ are significantly less downregu-
lated in the amygdala of DPN- treated animals
indicates that preserved ERβ signaling in the
amygdala contributes to the anxiolytic pheno-
type in the DPN-treated animals. This assump-
tion is further supported by the finding that
gonadal secretory activity was not completely
abolished in this group, despite the cytological
observation of persistent estrus. While levels
of estradiol secretion were similar in PPT-
treated and control animals, it should be noted
that the PPT-treated group showed the highest
degree of ERβ downregulation and high levels
of anxiety-related behavior. Accordingly, the
distinct behavioral and endocrine phenotypes
expressed in adult females that had experi-
enced selective neonatal stimulation of either
ERα or ERβ likely result from the activational
effects of residual estrogen secretion.   
Taken together, the present results show
that isoform-selective ER activation during
neonatal life does not per se contribute to sex-
specific organization of the HPA axis, but
rather leads to dysregulation of the central
mechanisms governing corticosterone secre-
tion under basal and stressful conditions, and
dissociate the usual relationship between cor-
ticosterone levels and anxiety. In contrast to
individual activation of ERα and ERβ, dual
activation of both ER isoforms with E2 in
neonatal females produces a male-like pheno-
type in which low levels of corticosterone are
associated with reduced anxiety-related behav-
ior. Further, our results identify hippocampal
and amygdaloid MR and GR expression pat-
terns as correlates of the disrupted endocrine
and behavioral profiles. Nevertheless, the
molecular and cellular pathways and mecha-
nisms through which neonatal estrogenization
exerts its sustained effects on the expression
of MR and GR remain to be elucidated. While
epigenetic marking of ER-responsive gene loci
may account for the sustained effects of
neonatal estrogen exposure,55 the present
work indicates that both HPA axis activity and
anxiety in neonatally PPT- and DPN-treated
animals remain subject to regulation by resid-
ual ovarian secretions acting at central ERβ.
Since many environmental endocrine disrup-
tors activate ERα and ERβ18,19 these findings
may be of wider relevance, beyond the present
interest in sexual differentiation of the brain
and regulation of the endocrine response to
stress and stress-related behavior. 
Lastly, the present findings have implica-
tions for human health since dysregulation of
the HPA axis is associated with the pathogen-
esis of mood and anxiety disorders, both of
which show a higher prevalence in women.1
References
1. Young EA. Sex differences and the HPA
axis: implications for psychiatric disease.
J Gend Specif Med 1998;1:21-7.
2. Patchev VK, Almeida OF. Gender specifici-
ty in the neural regulation of the response
to stress: new leads from classical para-
digms. Mol Neurobiol 1998;16:63-77.
3. Patchev VK, Hayashi S, Orikasa C, Almeida
OF. Implications of estrogen-dependent
brain organization for gender differences
in hypothalamo-pituitary-adrenal regula-
tion. Faseb J 1995;9:419-23.
4. Patchev VK, Hayashi S, Orikasa C, Almeida
Article
N
on
-c
om
m
er
ci
al
us
 o
nl
y
[Endocrinology Studies 2011; 1:e12] [page 57]
OF. Ontogeny of gender-specific respon-
siveness to stress and glucocorticoids in
the rat and its determination by the
neonatal gonadal steroid environment.
Stress 1999;3;41-54.
5. Kirschbaum C, Kudielka BM, Gaab J et al.
Impact of gender, menstrual cycle phase,
and oral contraceptives on the activity of
the hypothalamus-pituitary-adrenal axis.
Psychosom Med 1999;61:154-62.
6. Atkinson HC, Waddell BJ. Circadian varia-
tion in basal plasma corticosterone and
adrenocorticotropin in the rat: sexual
dimorphism and changes across the
estrous cycle. Endocrinology
1997;138:3842-8.
7. Mora S, Dussaubat N, Diaz-Veliz G. Effects
of the estrous cycle and ovarian hormones
on behavioral indices of anxiety in female
rats. Psychoneuroendocrinology
1996;21:609-20.
8. De Nicola AF, Saravia FE, Beauquis J et al.
Estrogens and neuroendocrine hypothala-
mic-pituitary-adrenal axis function. Front
Horm Res 2006;35:157-68.
9. Arnold AP, Breedlove SM. Organizational
and activational effects of sex steroids on
brain and behavior: a reanalysis. Horm
Behav 1985;19:469-98.
10. McCormick CM, Furey BF, Child M et al.
Neonatal sex hormones have organiza-
tional' effects on the hypothalamic-pitu-
itary-adrenal axis of male rats. Brain Res
Dev Brain Res 1998;105:295-307.
11. Laflamme N, Nappi RE, Drolet G et al.
Expression and neuropeptidergic charac-
terization of estrogen receptors (ERalpha
and ERbeta) throughout the rat brain:
anatomical evidence of distinct roles of
each subtype. J Neurobiol 1998;36:357-78.
12. Shughrue PJ, Lane MV, Merchenthaler I.
Comparative distribution of estrogen
receptor-alpha and -beta mRNA in the rat
central nervous system. J Comp Neurol
1997;388:507-25.
13. Dahlman-Wright K, Cavailles V, Fuqua SA
et al. International Union of Pharma -
cology. LXIV. Estrogen receptors.
Pharmacol Rev 2006;58:773-81.
14. Stauffer SR, Coletta CJ, Tedesco R et al.
Pyrazole ligands: structure-affinity/activity
relationships and estrogen receptor-alpha-
selective agonists. J Med Chem 2000;43:
4934-47.
15. Meyers MJ, Sun J, Carlson KE, Marriner
GA, Katzenellenbogen BS, Katzenellen -
bogen JA. Estrogen receptor-beta potency-
selective ligands: structure-activity rela-
tionship studies of diarylpropionitriles and
their acetylene and polar analogues. J Med
Chem 2001;44:4230-51.
16. Landgraf R, Wigger A, Holsboer F,
Neumann ID. Hyper-reactive hypothala-
mo-pituitary-adrenocortical axis in rats
bred for high anxiety-related behaviour. J
Neuroendocrinol 1999;11:405-7.
17. Bodo C, Rissman EF. New roles for estro-
gen receptor beta in behavior and neu-
roendocrinology. Front Neuroendocrinol
2006;27:217-32.
18. Shanle EK, Xu W. Endocrine disrupting
chemicals targeting estrogen receptor sig-
naling: identification and mechanisms of
action. Chem Res Toxicol 2011;24:6-19.
19. Swedenborg E, Pongratz I, Gustafsson JA.
Endocrine disruptors targeting ERbeta
function. Int J Androl 2010;33:288-97.
20. Patchev AV, Gotz F, Rohde W. Differential
role of estrogen receptor isoforms in sex-
specific brain organization. Faseb J
2004;18:1568-70.
21. Walsh RN, Cummins RA. The Open-Field
Test: a critical review. Psychol Bull
1976;83:482-504.
22. File SE, Lippa AS, Beer B, Lippa MT.
Animal tests of anxiety. Curr Protoc
Neurosci 2004;Chapter 8:Unit 8.3.
23. Patchev VK, Patchev AV. Experimental
models of stress. Dialogues Clin Neurosci
2006;8:417-32.
24. Murgatroyd C, Patchev AV, Wu Y et al.
Dynamic DNA methylation programs per-
sistent adverse effects of early-life stress.
Nat Neurosci 2009;12:1559-66.
25. Miesfeld R, Rusconi S, Godowski PJ et al.
Genetic complementation of a glucocorti-
coid receptor deficiency by expression of
cloned receptor cDNA. Cell 1986;46:389-99.
26. Arriza JL, Weinberger C, Cerelli G et al.
Cloning of human mineralocorticoid
receptor complementary DNA: structural
and functional kinship with the glucocorti-
coid receptor. Science 1987;237:268-75.
27. Whitfield HJ Jr, Brady LS, Smith MA et al.
Optimization of cRNA probe in situ
hybridization methodology for localization
of glucocorticoid receptor mRNA in rat
brain: a detailed protocol. Cell Mol
Neurobiol 1990;10:145-57.
28. Almeida OF, Canoine V, Ali S et al.
Activational effects of gonadal steroids on
hypothalamo-pituitary-adrenal regulation
in the rat disclosed by response to dexam-
ethasone suppression. J Neuroendocrinol
1997;9:129-34.
29. van Haarst AD, Oitzl MS, de Kloet ER.
Facilitation of feedback inhibition through
blockade of glucocorticoid receptors in the
hippocampus. Neurochem Res 1997;22:
1323-8.
30. De Kloet ER, Vreugdenhil E, Oitzl MS,
Joels M. Brain corticosteroid receptor bal-
ance in health and disease. Endocr Rev
1998;19:269-301.
31. Herman JP, Prewitt CM, Cullinan WE.
Neuronal circuit regulation of the hypo-
thalamo-pituitary-adrenocortical stress
axis. Crit Rev Neurobiol 1996;10:371-94.
32. Pego JM, Sousa JC, Almeida OF, Sousa N.
Stress and the neuroendocrinology of anx-
iety disorders. Curr Top Behav Neurosci
2010;2:97-117.
33. Singh KB. Persistent estrus rat models of
polycystic ovary disease: an update. Fertil
Steril 2005;84 Suppl 2:1228-34.
34. Frye CA. Steroids, reproductive endocrine
function, and affect. A review. Minerva
Ginecol 2009;61:541-62.
35. Weiser MJ, Foradori CD, Handa RJ.
Estrogen receptor beta in the brain: from
form to function. Brain Res Rev
2008;57:309-20.
36. Weiser MJ, Foradori CD, Handa RJ.
Estrogen receptor beta activation prevents
glucocorticoid receptor-dependent effects
of the central nucleus of the amygdala on
behavior and neuroendocrine function.
Brain Res 2010;1336:78-88.
37. Tomihara K, Soga T, Nomura M et al. Effect
of ER-beta gene disruption on estrogenic
regulation of anxiety in female mice.
Physiol Behav 2009;96:300-6.
38. Gonzales KL, Tetel MJ, Wagner CK.
Estrogen receptor (ER) beta modulates
ERalpha responses to estrogens in the
developing rat ventromedial nucleus of the
hypothalamus. Endocrinology 2008;149:
4615-21.
39. Walf AA, Koonce CJ, Frye CA. Estradiol or
diarylpropionitrile decrease anxiety-like
behavior of wildtype, but not estrogen
receptor beta knockout, mice. Behav
Neurosci 2008;122:974-81.
40. Johnston AL, File SE. Sex differences in
animal tests of anxiety. Physiol Behav
1991;49:245-50.
41. Mitev YA, Darwish M, Wolf SS et al. Gender
differences in the regulation of 3 alpha-
hydroxysteroid dehydrogenase in rat brain
and sensitivity to neurosteroid-mediated
stress protection. Neuroscience 2003;120:
541-9.
42. Martin EI, Ressler KJ, Binder E, Nemeroff
CB. The neurobiology of anxiety disorders:
brain imaging, genetics, and psychoneu-
roendocrinology. Clin Lab Med 2010;30:
865-91.
43. Han F, Ozawa H, Matsuda KI et al. Changes
in the expression of corticotrophin-releas-
ing hormone, mineralocorticoid receptor
and glucocorticoid receptor mRNAs in the
hypothalamic paraventricular nucleus
induced by fornix transection and adrena-
lectomy. J Neuroendocrinol 2007;19:229-
38.
44. De Kloet ER, Vreugdenhil E, Oitzl MS,
Joels M. Glucocorticoid feedback resist-
ance. Trends Endocrinol Metab 1997;8:26-
33.
45. Charmandari E, Tsigos C, Chrousos G.
Endocrinology of the stress response.
Annu Rev Physiol 2005;67:259-84.
Article
N
on
-c
om
m
rc
ia
l u
e 
on
ly
[page 58] [Endocrinology Studies 2011; 1:e12]
46. Sarrazin N, Di Blasi F, Roullot-Lacarriere V
et al. Transcriptional effects of glucocorti-
coid receptors in the dentate gyrus
increase anxiety-related behaviors. PLoS
One 2009;4:e7704.
47. Tronche F, Kellendonk C, Kretz O et al.
Disruption of the glucocorticoid receptor
gene in the nervous system results in
reduced anxiety. Nat Genet 1999;23:99-
103.
48. Boyle MP, Kolber BJ, Vogt SK et al.
Forebrain glucocorticoid receptors modu-
late anxiety-associated locomotor activa-
tion and adrenal responsiveness. J
Neurosci 2006;26:1971-8.
49. Mitra R, Ferguson D, Sapolsky RM.
Mineralocorticoid receptor overexpression
in basolateral amygdala reduces corticos-
terone secretion and anxiety. Biol
Psychiatry 2009;66:686-90.
50. Trapp T, Rupprecht R, Castren M et al.
Heterodimerization between mineralocor-
ticoid and glucocorticoid receptor: a new
principle of glucocorticoid action in the
CNS. Neuron 1994;13:1457-62.
51. Liu W, Wang J, Sauter NK, Pearce D.
Steroid receptor heterodimerization
demonstrated in vitro and in vivo. Proc
Natl Acad Sci USA 1995;92:12480-4.
52. Ikeda Y, Nagai A, Ikeda MA, Hayashi S.
Neonatal estrogen exposure inhibits
steroidogenesis in the developing rat
ovary. Dev Dyn 2001;221:443-53.
53. Nakamura T, Katsu Y, Watanabe H, Iguchi
T. Estrogen receptor subtypes selectively
mediate female mouse reproductive
abnormalities induced by neonatal expo-
sure to estrogenic chemicals. Toxicology
2008;253:117-24.
54. Viau V, Meaney MJ. Variations in the hypo-
thalamic-pituitary-adrenal response to
stress during the estrous cycle in the rat.
Endocrinology 1991;129:2503-11.
55. Nugent BM, McCarthy MM. Epigenetic
underpinnings of developmental sex dif-
ferences in the brain. Neuroendocrinology
2011;93:150-8.
Article
N
on
-c
om
m
er
ci
al
 u
se
 o
nl
y
 
  53 
3. Discussion 
The present work illustrates three different aspects of the ontogenetic programming of the 
neuroendocrine stress response and adaptive behavior. We demonstrate that neonatal exposure 
to either stress or GC has profound and long-lasting effects on the structural and neurochemical 
organization of brain mechanisms which are essential for homeostasis. The experimental 
challenges (stress, glucocorticoid excess or sex-steroid application) we applied during the same 
period of early ontogeny (neonatal period) differentially alter the activity thresholds of 
homeostatic sensors and elicit adaptive responses of inappropriate magnitude throughout later 
life. As many of our observations suggest the existence of sex differences in the quality and 
degree of manifestation of symptoms of mal-adaptation, the examination of the contribution of 
sex hormones to neonatal organization and adult modulation of endocrine and behavioral 
responsiveness elucidates certain novel aspects of the interaction between neuroendocrine 
circuits in this context. Although the link between the three studies described above might 
appear elusive at first glance, they address three major facets of brain programming during 
early ontogeny: substrate morphogenesis, neurochemical properties, and editing of the 
sensitivity to physiological hormone secretions. The focus on the mal-programming of the HPA 
axis is justified by its paramount involvement in the pathophysiology of several disorders of ill-
adaptation, especially such affecting mood and cognition, which currently account for the 
greatest disability rates in industrialized countries (Kessler, 2012; Larson, 2010).  
3.1 Physiological programming of brain functions 
As already stated in the introduction, programming of physiological functions determines the 
bandwidth of homeostatic processes in later life. Especially during early, sensitive (and, thus, 
vulnerable) time windows of development endogenous and exogenous factors affect virtually 
every organ system and program its later functionality. Programming on the one hand 
represents the organization of biological functions by endogenous signals according to the 
genetic blueprint (e.g. sexual differentiation of the brain (Dörner, 1983; Arnold and Breedlove, 
1985), on the other hand it is a result of proper or impaired capacity to re-set a system 
following its response to an external stimulus (e.g. metabolic changes in response to 
intrauterine nutritional status (Hanson et al., 2011a; Gluckman et al., 2009). 
  54 
 Programming through exogenous stimuli pre-sets physiological sensory gauges and thresholds 
for elicitation of responses to external stimuli, thus warranting the ability to discriminate and 
evaluate the significance of sensory input and perform adequate responses. For instance 
intrauterine mal-nutrition in humans and animals will cause specific effects on feeding and 
metabolic functions to preserve energy homeostasis in a certain nutritional environment 
(Lillycrop et al., 2010; Gluckman et al., 2011; Kyle and Pichard, 2006).  
If assuming that programming through environmental factors represents focusing of 
physiological functions to ensure survival in a certain environmental setting, it is conceivable 
that the more demanding the programming environment is, the more restrictive the 
programmed phenotype will become at the cost of confined homeostatic flexibility and 
adaptability. The paradigm of programming through neonatal stress used in our studies would 
thus translate into endocrine and behavioral alterations which reflect re-definition of homeostatic 
set points, but are unnecessary and, even, pathogenic in a stress-free environment (Kaufman et 
al., 2000). Intriguingly, in  animals with a history of neonatal stress, exposure to chronic stress 
in adulthood results in apparent improvements in certain behavioral domains (anxiety, cognitive 
functions), as well as endocrine response to stress, indicating that these animals might be able 
to cope with certain stressors in adulthood better than those without stressful experience as 
neonates (Patchev, Sousa, Almeida, unpublished observations; Karatsoreos and McEwen, 
2011).  While from an anthropomorphic point of view this seems plausible (a larger stress-
coping repertoire in those who grew up on the “wrong side of the tracks”), from a biological and 
medical perspective the elucidation of the mechanisms which account for the apparent 
resilience towards stress represents a challenging issue. Indeed, the insensitivity and, often 
questionable, validity of behavioral readouts in rodents (Sousa et al., 2006; Anisman and 
Matheson, 2005; Matthews et al., 2005) do not allow a comprehensive examination of all facets 
of the stress-coping ability and, to even lesser extent, the conduction of comparisons between 
individuals with different neonatal history.  
Another open question (provided this phenomenon proves valid) is whether enhanced stress-
coping ability following neonatal stress becomes equally manifest in all stress modalities. In this 
context the possibility should be considered that individuals with a history of adverse experience 
in early life might be able to cope better with stressors of given modalities and/or high 
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intensities, while displaying deficits in situations or stressors where these conditions are not 
met.  
It should be pointed out that programming of neuroendocrine and behavioral responses is not 
limited to the intrauterine or neonatal period (Andersen, 2003). Many studies are showing that 
adolescence and puberty in rodents and primates are permissive windows of time for both 
endogenous and exogenous programming stimuli. Over the last decades we have learned, that 
sexual differentiation and organization in mammals is not “finalized” until the organism goes 
through puberty where certain behavioral and endocrine functions are subject to ultimate 
organization by physiological sex steroid secretions (Schulz et al., 2009; Vigil et al., 2011). 
Adolescence and puberty also represent critical periods of increased vulnerability to the 
programming effects of stress (Beardslee et al., 2012; Lupien et al., 2009; Koenig et al., 2011) 
and mal-nutrition (Pervanidou and Chrousos, 2012; Must and Strauss, 1999). We and others 
have shown that adolescent rodents respond differently to stress than adults  and that chronic 
stress during puberty has long-term effects on emotional and cognitive behaviors as well as 
neuroendocrine functions in later life (Patchev, Sousa, Almeida unpublished observations; 
Romeo, 2010).  
However, with increasing age of the organism, a higher intensity or duration of a stressor is 
required for the induction of sustained after-effects in adaptive capacity. For instance, a stressful 
challenge which produces life-long alterations in learning and coping style when applied during 
the peripubertal time window, elicits similar, but reversible effects when applied in adults, with 
spontaneous recovery after 6 weeks thereafter (Patchev, Sousa, Almeida unpublished 
observations; Sousa and Almeida, 2012). It cannot be ruled out, however, that during adulthood 
and senescence the brain may remain liable to the programming effects of stress, depending on 
its duration and intensity.  
Taken together, physiological programming of brain functions requires endogenous and 
exogenous stimuli of appropriate intensity and duration, acting at the proper target substrate 
within a defined period of time. This programming pre-sets the quality and magnitude of future 
endocrine, metabolic and behavioral responses to environmental challenges, thereby 
determining our homeostatic flexibility and adaptability. If the orchestrated sequence of 
programming processes is disturbed, the adaptability of the homeostatic rheostat might become 
insufficient and result in overt pathology (i.e. mal-adaptation as a result of mal-programming).    
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3.2 Consequences of mal-programming and their implication in mental 
disorders 
Mal-programming of the HPA axis and, consequently, the responsiveness to stress have been 
increasingly linked to disorders of the brain (Aguilera, 2011; Mesquita et al., 2009; Saveanu 
and Nemeroff, 2012). Many studies have demonstrated associations between stress and 
hypercorticism, and the prevalence, severity and susceptibility to therapeutic interventions of 
depression and other mood disorders (de Kloet et al., 2005). Importantly, correction of HPA axis 
dysfunction shows (albeit with major inter-individual variability and in still poorly defined clinical 
sub-forms of the disease) beneficial additive therapeutic effects to classical antidepressants 
(Schatzberg and Lindley, 2008).  
Stress during childhood and adolescence have been identified as risk factors for depression, 
and in these cases signs of hypercorticism are more common than in the general population of 
patients with a history of depressive episodes (Kaufman et al., 2000; Joyce et al., 2007; Penza 
et al., 2003). In view of the confirmed role of stress as precipitating factor in the pathogenesis 
of affective disorders, the identification of this cluster of patients points at a potential causality 
connection between, or a facilitating role of mal-programming of the HPA axis function by early 
life stress experience and the emergence of this mental condition.  
Stress and glucocorticoids also strongly affect cognitive functions and growing evidence 
suggests that both are risk factors for cognitive disorders such as Alzheimer’s disease 
(Sotiropoulos et al., 2008b; Yu et al., 2008).  Work from our labs and others has identified 
direct links between glucocorticoids and amyloidogenic pathways, resulting in 
hyperphosphorylation of Tau and the increased production and deposition of pathogenic 
amyloid  fragments, the hallmark of Alzheimer’s disease (Sotiropoulos et al., 2011; Catania et 
al., 2009). These findings suggest that a mal-programmed, hyperactive HPA axis could tilt 
neuronal homeostasis towards amyloid overproduction and thus increased risk of developing or 
faster progression of imminent AD (Sotiropoulos et al., 2008b). Importantly, both AD and 
depression show higher prevalence in women, thus implying the existence of sex-specific risk 
factors in these pathological states (Angst et al., 2002; Vest and Pike, 2012). Sex differences in 
HPA axis function appear plausible candidates for the role of such gender-specific predisposing 
factors, however scrutiny of human data fails to show association between sex-specific 
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dichotomies in cortisol secretion and the expression of depressive behavior (Hinkelmann et al., 
2012).   
Although female rodents display a behavioral repertoire that seems to reflect lower incidence of 
anxiety- and depression-related behaviors (Dalla et al., 2011), the large fluctuation of test 
endpoints in the course of the ovarian cycle make experimental work in female rodents more 
bias-prone (e.g. task acquisition which requires several days of training and the fulfillment of the 
learning criteria shows large variations in female mice, with the outcome strongly depending on 
the gonadal endocrine milieu at the time of retrieval testing) (Patchev, Almeida, Sousa 
unpublished).  Research in non-human primates has also failed to reproduce the observation of 
higher vulnerability to stress-related disorders in human females (Willard and Shively, 2012). 
Furthermore, with the incidence of both depression and Alzheimer’s disease increasing with 
age, the contribution of menopausal sex hormone deficiency has been vigorously debated in the 
past (Llaneza et al., 2012). The involvement of gonadal hormones in the regulation of mood, 
cognition and stress-related endocrine functions is well known (Dalla et al., 2011; Luine, 2008; 
Patchev and Almeida, 1998), and it is conceivable that life stages with abrupt changes in sex 
hormone secretions might be associated with increased incidence of depression in both sexes 
(Bebbington et al., 2003).  
This allows for the speculation that the interactions between gonadal hormones and stress-
related behavioral and endocrine functions throughout the lifespan might represent a vulnerable 
homeostatic set-point at which stress might exert mal-programming effects. Our studies on the 
programming effects of estrogens on the HPA axis function and anxiety suggest that, rather than 
perinatal organization, endogenous gonadal secretions might exert a stronger leverage on these 
outcomes. Still, speculations on the revenant issue of the interplay between the adrenal and 
gonadal axes in humans are, nonetheless, incongruous, also in view of the scarcely elucidated 
importance of progestins as endogenous buffers of glucocorticoid effects in the brain (Patchev 
and Almeida, 1996).  
Evidence in support of the organizing capacity of ER isoform-selective ligands on neural circuits 
controlling gonadal and, secondarily, adrenal functions prompts the question of mental health 
consequences of exposure to endocrine disruptors. Endocrine disruptors (e.g. compounds with 
xenoestrogenic activity) are ubiquitous in form of environmental pollutants but also items of 
every-day use and affect human and wild-life health (Flint et al., 2012; Yang et al., 2006). 
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Epidemiological evidence hints at a possibility that teratogenic effects of xenoestrogen exposure 
during early life might represent risk factors for affective disorders in adulthood (Crews and 
McLachlan, 2006; Weiss, 2011). The well-known potential of these compounds to disrupt adult 
gonadal function extends the question of xenoestrogen significance in the pathogenesis and 
neuroendocrine epiphenomena of mental disorders to life phases beyond sexual maturity.  
3.3 Mechanisms of programming and mal-programming 
Programming of the stress-sensing threshold, response capacity and endurance to noxious 
challenges can occur at any level of the HPA axis.  
Here we show that stressful experience during early ontogeny leads to epigenetic marking 
(hypomethylation at specific CpG islands of the enhancer region) of the AVP gene, a key trigger 
of the neuroendocrine stress response (Volpi et al., 2004). We also gathered preliminary 
evidence (manuscripts in preparation) that such epigenetic alterations with functional relevance 
possibly affect other genes, whose products comprise almost the entire effector cascade (e.g. 
CRH and POMC), as well as the gauge which accounts for the efficient reset of the system (e.g. 
GR).  
Epigenetic mechanisms comprise, amongst others, posttranslational histone protein 
modifications, as well as DNA methylation (Jaenisch and Bird, 2003). Initially it was suggested, 
that while histone modifications are transient, DNA-methylation changes are persistent (Razin, 
1998; Razin and Riggs, 1980). Recent evidence, however, reveals that DNA-methylation is a 
rather dynamic process (Métivier et al., 2008; Unternaehrer et al., 2012), with DNA and histone 
modifications being highly interdependent in terms of regulation of gene expression (Razin, 
1998; Bird, 2001; Jaenisch and Bird, 2003). While mechanisms of active DNA de-methylation 
at CpG islands have not been shown in mammals yet, recent findings indicate that DNA 
methylation has to be actively maintained, e.g. by a restrictive histone confirmation that also 
leads to the site-specific recruitment of DNA methyl trasnferases (Chen and Riggs, 2011). Taken 
together these findings evince that programming through epigenetic mechanisms is unlikely to 
act in an “on-off” fashion, but rather comprises orchestrated signaling processes that maintain 
methylation marks depending on the cell type and its paracrine and endocrine milieu.  
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One intriguing observation in our study was that neonatal stress-induced upregulation of AVP 
mRNA became manifest on postnatal day 10 (last day of stress exposure), while no measurable 
alteration in CpG methylation could be documented at that time point. Since, however, 
inactivation of MeCP2 was observed at this time in AVP neurons, we presume that the 
increased AVP expression might represent (at least in part) a process of Ca2+ - CamKII- driven 
phosphorylation. At 6 weeks of age hypomethylation of the AVP enhancer region was clearly 
present; this finding indicates that the intracellular mechanisms that had been set off by the 
stressful experience required several weeks to “establish” the epigenetic footprint on that 
particular gene locus. Similar (and even longer) time courses were observed also with regard to 
other HPA axis-related genes (CRH, POMC, GR). At this stage we can only speculate about the 
control of the temporal pattern of the AVP enhancer CpG hypomethylation. One possibility is 
that the chromatin structure has been transiently altered in a mode that would allow passive de-
methylation of critical gene loci through signaling mechanisms that also contribute to MeCP2 
phosphorylation at Serine 438 (Zhou et al., 2006); similar mechanisms have been described in 
cancer and pluripotent stem cells (Shoemaker et al., 2011). 
An alternative assumption is that neonatal stress exposure results not only in transient changes 
of intracellular signaling, but also in altered neuronal “hard wiring”. Pertaining to the 
parvocellular AVP neurons, this would mean that the afferent input into these neurons has been 
changed by the neonatal stress procedure, leading to persistent activation of AVP gene 
expression and also allowing for passive demethylation of the AVP gene. Several studies have 
demonstrated that neonatal stress leads to lasting alterations in the monoaminergic input to the 
hypothalamus (Liu et al., 2000), which in turn could prompt altered activity and, ultimately, 
epigenetic changes in parvocellular CRH and AVP neurons (Pacak et al., 1995). This 
assumption would suggest that the epigenetic marking seen in neuroendocrine cells are 
secondary to stress-induced alterations in distant neural sensors of stress (Liu et al., 2000; 
Kaufman et al., 2000).  
The question of the substrates affected by mal-programming of the HPA axis by neonatal stress 
is not resolved by the identification of the hypomethylated AVP gene enhancer: even with the 
proof of functional significance, it might represent merely one of several candidates. With regard 
to rodent models, however, it is prudent to remark that it is highly unlikely that these effects of 
neonatal stress are a direct consequence of altered glucocorticoid secretions during the 
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neonatal period. Mechanisms of endocrine regulation in rodents undergo substantial maturation 
ex utero, with adrenal glands becoming functional only around postnatal day 14 (Sapolsky and 
Meaney, 1986). Basal and stress-induced GC secretions in newborn rodents are barely 
detectable, a phenomenon which coined the term "stress hypo-responsive period" (Vázquez, 
1998; Sapolsky and Meaney, 1986). It is pertinent to mention that this term is to a certain 
extent misleading, as neonatal mice and rats respond to stress in several modalities (e.g. 
ultrasonic vocalizations (Hofer, 1996) and catecholamine release (Sullivan, 2003) in response 
to maternal separation) except for the inability of their immature adrenal cortex to mount a full-
scale secretory response. Still, the importance of GC in the process of mal-programming of the 
HPA axis responsiveness merits further attention. Exaggerated secretory responses to stressful 
challenges are a hallmark of disturbed HPA function. While impairment of the neonatal 
organization might not depend on GC secretions, the resultant sustained adrenal hypersecretion 
in adulthood is associated with structural, behavioral and endocrine aberrations which are 
ascribed to the phenotype induced by early life stress, but may reflect the consequences of 
sustained adrenocortical activation (Murgatroyd et al., 2009; Sousa and Almeida, 2012).  The 
distinction between such “bystander” effects from those laid down during neonatal mal-
programming remains a challenging issue.  
Neonatal stress and exposure to non-physiological glucocorticoid doses seem to produce 
divergent, even partly opposite, effects. We here show that neonatal treatment with the GR 
agonist dexamethasone leads to hippocampal atrophy and growth retardation in later life, due to 
reduction of the neural precursor cell pool. In contrast, neonatal stress has been shown to 
increase hippocampal neurogenesis in adulthood (Hays et al., 2012). While the consequences 
of the pharmacological impact are readily explicable, the mechanisms which account for 
increased neurogenesis remains elusive. It can not be ruled out that they are due to 
compensatory mechanisms which are set off by the neonatal adverse experience. Still the 
possibility remains that the mal-programmed phenotype might reflect impaired efficacy of such 
compensatory mechanisms. It remains intriguing that neonatal stress is associated with 
impaired hippocampal function on the one hand (Patchev, Sousa, Almeida unpublished 
observations; Marco et al., 2012; Mesquita et al., 2009), and increased neurogenesis on the 
other (Hays et al., 2012). This prompts questions of the functional features of the post-stress 
newborn neurons, of their capacity to integrate into functioning hippocampal circuits or whether 
hippocampal deficits in neonatally stressed animals would be augmented if their adult 
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neurogenesis is blocked. These open questions also indicate that, while morphogenic aspects 
(e.g. cell numbers, proliferation, migration, cell death, cell plasticity) are subject to neonatal 
programming (Kaufman and Charney, 2001; Kaufman et al., 2000), the structural alterations 
might have long-term consequences (and, even, exert programming themselves) in distant and 
not immediately affected brain regions.  
Dealing with programming of complex neuroendocrine systems and neuronal circuits one might 
be mislead in terms of non-justified emphasis on singular processes (i.e. “hens and egg” issue). 
This is exemplified by our studies on sex-specific and estrogen-dependent differentiation of 
reproductive (Patchev et al., 2004) and HPA axis functions (Patchev et al., 2011). We and 
others have shown that estrogens with ER activity have the ability to produce defeminization of 
sexually dimorphic brain areas by either inducing apoptosis (Kato et al., 2012; Tsukahara, 
2009; Lephart et al., 2003)  or increasing proliferation and migration (Jacobson and Gorski, 
1981), whereas compounds with ER selectivity affect only certain morphological sex-specific 
features (Patchev et al., 2004). These findings offer a plausible explanation of how neonatal 
exposure to estradiol (a non-selective ER ligand) or ER-specific agonists leads to a 
defeminization of structures accounting for both, cyclic operation mode of the GnRH pulse 
generator (AVPV) and proceptive sexual behavior (SDN-POA), whereas exposure to ER agonists 
is capable to abolish only cyclic gonadotropin secretion, but not female sexual behavior. The 
fact that animals neonatally treated with ER agonists displayed residual ovarian secretions and 
intact behavioral responsiveness to estrogens was interpreted merely as corroboration of the 
differential organizing efficacy of isoform-selective estrogens (Patchev et al., 2004). However our 
recent study on the contributions of ER isoforms to the sex-specific programming of the HPA 
axis (Patchev et al., 2011) shows that the consequences of neonatal estrogenization on HPA 
axis activity in adulthood are secondary to the degree of impairment of gonadal function, rather 
than to specific organizational effects of estrogens on brain areas of relevance in HPA axis 
regulation.  
The differential (and, in some aspects, opposite) effects of selective ER agonists on HPA axis 
function and emotional behaviors cannot be ascribed to "once-and-forever" consequences of 
structural alterations, especially in view of the different adult sex steroid milieu in rats treated 
neonatally with ER- and ER-selective ligands. Residual (albeit not genuinely cyclic) ovarian 
estrogen and progestin production and, most important, preserved sensitivity to estrogens in 
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several brain areas of behavioral relevance in rats neonatally exposed to ER agonists support 
the view that sex-specific features of HPA and behavioral responses to stressful challenges are 
decisively shaped by the adult gonadal secretions, thus pointing at the importance of the so-
called activational effects of sex hormones. Certainly, direct teratogenic effects of neonatal 
estrogenization at some levels of HPA axis cannot be ruled out and deserve further attention. 
Notwithstanding this, sex-dimorphic endocrine and behavioral responsiveness to stress is 
apparently based on programming (organizing) effects which target primarily the gonadal 
neuroendocrine axis and its responsiveness to estrogens, thus preparing the ground for 
differential modulation of HPA axis activity by adult (activational) actions of physiological sex 
hormone secretions (Arnold and Breedlove, 1985). It is pertinent to underline that in earlier 
studies sex-specific programming of the HPA axis (Patchev et al., 1999; Patchev and Almeida, 
1998) might have erroneously exaggerated the importance of neonatal organization, while 
neglecting the superimposed effects of adult sex hormone secretions. These conclusions, 
however, were all based on experiments using the non-selective ER agonist estradiol, which acts 
in an all-or-none fashion in this model and precludes the preservation of residual ovarian 
function in adulthood; the insight presented in our last study was made possible by the 
discovery of novel pharmacological tools and thus have added to our understanding of the 
mechanisms of establishing a sex-specific HPA axis phenotype.  
In summary, we demonstrate that programming of the HPA axis occurs at many morphological, 
biochemical and systemic function levels, e.g.  
- at the epigenetic level, where stable or dynamic epigenetic alterations (DNA methylation 
and histone modifications) lead to sustained alteration of gene expression. The 
mechanisms leading to the establishment and maintenance of these changes, as well 
as the possibilities of their reversibility (e.g. pharmacological or behavioral) still need to 
be explored in greater detail.  
- at the structural level, where neonatal glucocorticoid exposure can affect neuronal 
survival and neurogenesis by altering the availability of neural precursors. Still, the 
possibility that neuronal cell death or birth might result from sequential activation (or 
failure) of pre-existing compensation mechanisms and associated cell programs 
deserves future exploration.  
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- at the systemic functional level, where the structural and epigenetic changes might lead 
to differential responsiveness of neuronal populations to external or endogenous 
signals, which in turn might lead or contribute to the expression of the mal- 
programmed phenotype.  
 
3.4 Ongoing and future studies  
The present work has assessed different mechanistic components of programming of the brain 
during the neonatal sensitive period. The focus of the work, due to personal interest, medical 
relevance and institutional bias was laid on the programming and mal-programming of HPA axis 
function and its emotional behavioral correlates. This work has raised several interesting 
questions, which should be subject of future studies.  
3.4.1 Methylation marks and HPA axis function – cause or consequence? 
As discussed above, the question remains whether the “epigenetic footprint” of neonatal stress 
is a cause or a consequence of the observed HPA axis phenotype. In our observations, the 
establishment of DNA-methylation marks on genes expressed in the PVN and involved in the 
HPA axis regulation required several weeks to become manifest. This suggests the existence of 
a time lag between the “funneling” of neonatal stress effects into the neuroendocrine neurons 
of the PVN and the occurrence of epigenetic changes. Another possible explanation could be 
that the neonatal stress-induced hyperactivation of the HPA axis leads to a sustained 
hypersecretion of glucocorticoids which, in turn, affect plasticity, hard-wiring and ultimately DNA-
methylation in relevant brain areas following discrete spatio-termporal patterns.  
One way to dissect these interdependent effects would be to adrenalectomize neonatally 
stressed animals at the youngest possible age (e.g. around 3-4 weeks) and to supplement the 
animals with low physiological doses of corticosterone. This would allow to differentiate 
behavioral and molecular (i.e. neurochemical and epigenetic) changes that occur as direct 
responses to neonatal stress and not to the hypercorticism that results from it.  
While such an experiment would add more to our knowledge of the mechanisms triggered by 
neonatal stress, it is also burdened by certain bias. For one, adrenalectomy at such young age 
  64 
is not only a procedural challenge in mice, but might also lead to disruption of maturational 
processes. Recent studies suggest that adrenarche also occurs in rodents and, like in primates, 
precedes physiological pubertal transition (Pignatelli et al., 2006).  
Furthermore, the lack of circa- and ultradian oscillations of corticosterone secretion over long 
periods might per se affect neuronal morphology and neurochemistry and, ultimately, behavior.  
An alternative approach, albeit bearing similar difficulties, would be the targeted deletion of GR 
in specific brain areas, e.g. by means of stereotactic virus-delivered shRNA. Such a GR 
knockdown in the PVN would allow the distinction between direct effects of hypercorticism and 
the “paracrine” effects of other brain areas projecting to the PVN.  
Currently we presume that the neonatal stress-induced alterations in the quality of these 
projections are responsible for the initiation of the epigenetic changes in the PVN, with GR 
signaling in response to a hyperactive HPA axis supporting the establishment or maintenance of 
the DNA-methylation in the AVP and CRH genes.  
Similarly, as we suspect that neonatal stress-induced methylation-marks need to be actively 
maintained, one could hypothesize that if they were to be artificially induced in an otherwise 
healthy organism, they would disappear with time. For instance, using a combination of 
conventional and conditional transgenic approaches, it could be possible to insert a 
hypomethylated CpG island in the AVP enhancer region (similarly to our in vitro studies 
(Murgatroyd et al., 2009)) in the parvocellular division of the PVN of an otherwise completely 
healthy control adult animal (not exposed to neonatal stress). It would then be interesting to 
study the time course during which the artificially inserted methylation mark will be changed 
back to the physiological level, assuming that the maintenance of neonatal stress-induced 
methylation marks results from other effects of neonatal stress on brain structure and function.  
3.4.2 What does not kill you makes you stronger? 
Similar mechanistic studies would also appear important in the context of the programming of 
adult neurogenic capacity of those cells of the NPC pool that survive neonatal GC treatment. 
Although we show that the majority of NPC express GR in vivo and in vitro, not all NPC are 
forced into apoptosis by dexamethasone treatment. This indicates that there are subpopulations 
of NPC that are not sensitive to the pro-apoptotic effects of GC.  
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Also neurons derived from these NPC surviving neonatal GC treatment might be less sensitive to 
deleterious effects of GC exposure in adulthood.   
To answer these questions neonatal animals could be injected with detectable synthetic 
nucleoside analogues (e.g. Bromodeoxyuridine (BrDU) and Iododeoxyuridine (IrDU)) at different 
time points of the dexamethasone treatment (e.g. at the beginning and the end) in order to label 
cells that have been born under and after GC exposure. Tissue sampling at different ages and 
subsequent analysis of the cellular phenotype of all cells that have incorporated BrDU and/or 
IrDU will allow for identification and characterization of these cells and their life span (e.g. 
whether neurons born from NPCs that have survived neonatal GC treatment die earlier or later 
and how do they react to subsequent challenges like stress or GC exposure).  
The later question seems important also in terms of epigenetic marking. For instance, it is 
possible that in NPCs that survive neonatal GC treatment, methylation marks which determine 
the epigenetic status of GC responsiveness are established on critical fragments of the GR gene 
or GR responsive genes. If this is the case, it would be important to scrutinize the emergence, 
maintenance and stability of these epigenetic marks in the NPCs, as well as in their postmitotic 
daughter cells. 
Both, the responses to neonatal stress and GC exposure might be differentially expressed 
depending on the sex of the individual. The sex hormone milieus in neonatal males and females 
are very likely to differentially affect the consequences of stress and GC during this period of 
ontogeny. We have recently documented sex-specific methylation patterns of the CRH promoter 
in parvocellular PVN neurons (Menger, Patchev, Spengler, Almeida; unpublished observations). 
Although our work on the role of isoform-selective ER activation suggests that activational sex 
steroid effects during adulthood largely account for the sex-specific differences observed in HPA 
axis and emotional behaviors, we can not rule out the contributions of direct organizational 
effects during early life.  
It appears important to scrutinize the roles of different sex steroids (e.g. estrogens, androgens 
and progestins) in the establishment of ELS-induced sex-specific methylation marks. Using 
pharmacological and surgical tools, as well as conventional and conditional transgenesis, it 
could be assessed whether the sex-specific effects of ELS on DNA-methylation can be reversed 
or, even, blocked. Similarly, the effect of sex and sex steroids should be evaluated in the context 
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of neurogenesis, e.g. are neonatal females more or less sensitive to the pro-apoptotic effects of 
GC on NPC?  
The cross-talk between steroid receptor signaling cascades is well known, and there are many 
possible points of interaction between ER, progesterone receptor (PR, which is strongly induced 
by ER-activation ) and GR signaling (Uht et al., 1997). Mechanistic dissection and 
understanding of these interactions and their relevance for structural, neurochemical, epigenetic 
and, ultimately, endocrine and behavioral outcomes might help to unravel the basis of sex-
differences in the prevalence of psychiatric and neurological disorders.  
3.4.3 Stress during different stages of early life – programming vulnerability 
or resilience?  
Another related question which has attracted our attention is the analysis of the programming 
effects of stress during later life stages, e.g. puberty, adulthood and senescence, and the 
cumulative effects of several stress episodes throughout critical stages of life.  
Our hypothesis is that stress during different critical windows of time will differentially (age-
specifically) program or damage endocrine and behavioral outcomes.  
We have shown that neonatal stress does not seem to affect anxiety-related behaviors in 
adulthood, whereas stress exposure during puberty leads to increased anxiety. Other behavioral 
traits, e.g. mood (depression-like behavior) and cognition (spatial learning) are similarly affected 
by neonatal and peripubertal stress.  
A history of stress exposure during neonatal life produces clear symptoms of HPA axis 
dysregulation: increased basal GC secretion, hyperreactivity to acute stress and delayed shut-off 
of the endocrine stress response, due to impaired GC negative feedback. In ongoing studies we 
are trying to identify the most vulnerable control point within the HPA axis, at which the 
impairment of GR signaling translates into reduced negative GC feedback efficacy in both 
models.  
Interestingly, animals exposed to neonatal stress do not show a down-regulation of GR mRNA 
expression at any supra-pituitary level of HPA axis regulation. In the PVN these animals actually 
show increased GR mRNA. Functional tests of GR sensitivity demonstrated a dose-dependent 
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increase in the expression of SGK-1 and FKBP5 (GR responsive genes) in the PVN of animals 
with a history of neonatal stress, indicating that GR signaling in the PVN of these animals is, in 
reality, increased (Bockmühl, Kuczynska, Patchev, et al.; in preparation). Ongoing studies aim 
to understand the reasons for the discrepancy between impaired GC negative feedback efficacy 
and enhanced GR expression and signaling in the PVN of these animals. One of the present 
assumptions that increased GR signaling in the PVN is a sign of an effort to compensate for 
reduced GR efficacy at a higher neural level of HPA axis regulation.  
It is conceivable that the (mal-)adaptive endocrine and behavioral responses induced by 
neonatal or peripubertal stress exposure might render the organism more vulnerable to the 
detrimental consequences of stress in adulthood. This assumption was originally supported by 
our finding of increased endocrine and behavioral responsiveness to acute stress in animals 
with a history of neonatal or peripubertal stress.   
Surprisingly, however, animals with a history of neonatal or peripubertal stress failed to show 
symptoms of aggravated emotional or cognitive deficit when exposed to chronic unpredictable 
stress in adulthood. Unexpectedly, when exposed to CUS in adulthood, animals with an early-life 
stress history displayed improved spatial learning, indistinguishable from that of controls with no 
history of ELS. In contrast, in animals with peripubertal, but not neonatal, stress experience 
exposure to CUS in adulthood resulted in depression-like behavior in the forced swim test.  
The hyper-reactive HPA axis phenotype resulting from early-life stress exposure was not further 
altered by subsequent adult CUS challenge.  
Taken together these findings indicate that the animals with a history of ELS show a differential 
behavioral response to chronic stress in adulthood, depending on the age at which ELS was 
applied. The apparent behavioral improvement following adult CUS exposure, however, cannot 
be associated with amelioration of the ELS-induced HPA axis disturbance.  
Future studies should address the mechanisms which account for the differential programming 
of behavioral phenotype by neonatal and peripubertal stress. Another challenging task would be 
to understand why adult chronic stress differentially affects mood and cognitive functions 
depending on the individual ELS-history of the animal (e.g. neonatal vs. peripubertal stress).  
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Figure 4  Summary of behavioral and endocrine phenotypes of combinatorial stress 
exposure 
The figure shows a summary of behavioral and endocrine outcome in adult animals which have undergone neonatal, 
peripubertal or adult chronic stress and combinations thereof. Adult chronic stress in animals with a history of neonatal stress 
exposure does not alter depression-like behavior, however improves spatial learning back to levels displayed by control animals. 
In contrast the same adult CUS procedure in animals with a history of chronic stress during puberty leads to apparent 
improvement in spatial learning, but also reduces depression-like behavior to levels below those of control animals. The question 
remains, if those apparent improvements are reflecting a better coping of the animals with stressful situations, or are 
epiphenomena of increased vulnerability, which are erroneously interpreted as improvements.  
In the rows, where only one stressor is applied (either neonatal, peripubertal or adult) arrows indicate change vs. controls. In the 
two lower rows (combinatorial stress procedures) arrows indicate change vs. the phenotype induced by ELS. Question marks 
indicate either inconclusive findings or parameters that have not been assessed yet.  
STRESS BEHAVIOR HPA axis function
neonatal peripubertal adult anxiety depression-like cognition basal acute stress response GC feedback efficacy
a      
a      
a      
a a ?     ?
a a ?     ?  
At this stage, we cannot denote the apparent improvement in certain behavioral outcomes that 
results from adult CUS exposure as “resilience”; however, we also cannot exclude that animals 
with a history of ELS cope better (or at least differently) with adult chronic stress. For instance, 
the strong increase in active behavior in the FST (an apparent reduction of depression-like 
behavior) after CUS exposure of peripubertally stressed mice, might actually reflect increased 
arousal, locomotion drive or, merely, general hyperactivity in these animals.  
We also cannot generalize the apparent beneficial effects of CUS in animals with ELS history to 
all other stress modalities. Perhaps other forms of superimposed stress (e.g. social defeat or 
isolation, chronic pain, infections etc.) may cause stronger deleterious effects in animals with an 
ELS background.  
As both, early life traumas, as well as repeated stress exposure over the lifetime have been 
identified as major risk factors for depression, and depression itself is a recognized risk factor 
for cognitive disorders, the dissection of the above-described, complex phenotypes resulting 
from our combinatorial stress models represents an issue of major medical interest.  
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Abstract
Studies into the mechanisms of corticosteroid action continue to be a rich bed of research, spanning the fields of
neuroscience and endocrinology through to immunology and metabolism. However, the vast literature generated,
in particular with respect to corticosteroid actions in the brain, tends to be contentious, with some aspects suffer-
ing from loose definitions, poorly-defined models, and appropriate dissection kits. Here, rather than presenting a
comprehensive review of the subject, we aim to present a critique of key concepts that have emerged over the
years so as to stimulate new thoughts in the field by identifying apparent shortcomings. This article will draw on
experience and knowledge derived from studies of the neural actions of other steroid hormones, in particular
estrogens, not only because there are many parallels but also because ‘learning from differences’ can be a fruitful
approach. The core purpose of this review is to consider the mechanisms through which corticosteroids might act
rapidly to alter neural signaling.
The protagonists and their roles
Corticosteroids are the main humoral mediators of
stress and their increased secretion in response to
adverse stimuli normally results in a cascade of physio-
logical and behavioral homeostatic mechanisms that
allow survival and the activation of defense mechanisms
against future insults. They facilitate arousal and the
appropriate channeling of physiological resources; pri-
marily, corticosteroids act to conserve essential salts, sti-
mulate gluconeogenesis and lipid metabolism,
cardiovascular and pulmonary function and erythropoei-
sis and bone turnover, while inhibiting, among others,
reproductive and ingestive behaviors as well as immune
responses [1]. Thus, corticosteroids are well suited to
serve the fight-or-flight response (first described by
Walter B. Cannon in 1915).
Corticosteroids (CS) are primarily produced by the
adrenal glands although recent studies suggest that they
may also be synthesized in the brain [2,3]. The term
‘corticosteroids’ embraces two prototypic steroids with
distinct biological functions: glucocorticoids (cortisol in
most large mammals, corticosterone in rodents and
other taxa), named because of their gluconeogenic prop-
erties, and mineralocorticoids (primarily aldosterone),
named for their role in the regulation of the salt-water
balance. Like other steroid hormones, corticosteroids
are small, lipophilic molecules (ca. 300 Da) that are
derived from cholesterol. Their physical properties facili-
tate their passage across the blood brain barrier where
they act to maintain brain structure (they are implicated
in the regulation of neuronal cell birth, differentiation
and apoptosis, as well as dendritic arborization and
synaptic function), and integrate a variety of behavioral
and physiological processes, including their own secre-
tion. In this respect, they serve as messengers between
the periphery and brain, but also between the external
and internal environments and the brain.
The hypothalamo-pituitary-adrenal axis embraces the
feedforward and feedback neuroendocrine mechanisms
that regulate CS production and synthesis (Figure 1).
Neural inputs trigger the release of adrenocorticotrophic
hormone (ACTH) from the pituitary which, in turn, sti-
mulates adrenocortical synthesis and secretion of CS.
Although CS are not stored in a readily-releasable pool,
it is estimated that adequate amounts of CS can be
released into the bloodstream within minutes of appro-
priate neural stimuli. Noxious (stressful) stimuli are the
primary triggers of neural firing that result in increased
CS release. On the other hand, CS are secreted accord-
ing to strictly-regulated circadian rhythms that are dic-
tated by the central nervous system. More recently, CS
have been found to have ultradian rhythmic patterns of
release. Such patterns are most likely maintained
through dynamic cross-talk between the peripherally-
produced CS and centrally-driven regulatory
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mechanisms; they are also likely important integrators of
normo-physiological functions [4].
Since corticosteroids come on stage within 3-7 min-
utes of first perception of a stressor [5], they may be
considered to be secondary or auxiliary players in com-
parison to monoamines (in particular, epinephrine and
norepinephrine) whose actions are initiated within milli-
seconds to seconds [6] i.e. corticosteroids are secreted
during the first stage of the ‘general adaptation syn-
drome’, a concept introduced by Hans Selye in 1946.
However, since corticosteroids act against the back-
ground of increased monoamine secretion, it is thought
that they act to fine-tune the organism’s response to
stress [7] and to facilitate signal-to-noise discrimination.
Moreover, unlike the transient monoamine response,
corticosteroids exert sustained actions on cellular activ-
ity and behavior, and therefore are essential for ensuring
the orchestration of a coordinated adaptive response as
well as ‘preparedness’ of the organism to cope with
future challenges.
Although corticosteroids are often thought of in nega-
tive terms because of their causative role in diseases
such as diabetes, hypertension, osteoporosis and
immune suppression, they are essential for adaptation to
stress and for maintaining physiological processes. With
respect to brain structure and function, corticosteroids
play an important role in maintaining hippocampal cell
numbers under basal conditions; this is illustrated by
robust observations that removal of corticosteroids by
extirpation of the adrenal glands results in massive
apoptosis, with parallel increases in neurogenesis, within
the granule cell population of the hippocampus [8]. On
the other hand, stress and elevated levels of glucocorti-
coids inhibit the generation of new granule neurons [9].
Another aspect that suggests an important role of corti-
costeroids in normo-physiology is the well-pronounced
Figure 1 Schematic representation of the hypothalamo-pituitary-adrenal (HPA) axis and its neuronal inputs. Corticotropin-releasing
hormone (CRH)- and arginine vasopressin (AVP)-expressing parvocellular neurons in the paraventricular nucleus (PVN) project to pituitary (via the
median eminence) where they stimulate adrenocorticotrophic hormone (ACTH) synthesis and secretion, subsequently triggering corticosteroid
synthesis and release from the adrenal cortex. Besides acting in the brain to regulate various behaviours, corticosteroids fine-tune the
subsequent pattern (amplitude and duration) of corticosteroid secretion; they activate their cognate receptors in the pituitary, hypothalamus and
hippocampus and bed nucleus of the stria terminalis (BNST, a relay between the hippocampus/amygdala and the PVN) to restrain, and in the
amygdala to enhance, adrenocortical secretion. Monoaminergic transmitters, namely, norepinephrine, serotonin and dopamine released from
midbrain nuclei (the locus coeruleus [LC], raphé and ventral tegmental area [VTA] and substantia nigra [SN], respectively) exert modulatory
effects on all brain regions involved in the control of the HPA axis. ‘Plus’ signs (green) indicate positive drive on the HPA axis; ‘minus’ signs (red)
represent sites of corticosteroid negative feedback; ‘clock’ signs denote neuronal populations known to respond rapidly to corticosteroids.
Corticosteroids are secreted rhythmically, displaying ultradian and circadian patterns. The circadian peak coincides with the onset of the daily
activity cycle (dark phase in rodents, light phase in humans). While the physiological and behavioural significance of the ultradian rhythms of
corticosteroid secretion is still unclear, it is plausible that they serve to dynamically fine-tune the regulation of the HPA axis and thus, to facilitate
adaptive processes. LD, light-dark cycle.
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circadian pattern of corticosteroid secretion. These
rhythms are robust and bi-directionally tightly coupled
to the individual’s sleep-activity and feeding cycles,
while being entrained and maintained by the daily light-
dark cycle.
The magnitude and duration of the humoral response
to stress is tightly coupled to the nature (quality, inten-
sity and duration) of the stressor, as well as the context
in which it occurs. Depending on context (e.g. the pre-
vailing physiological or psychological state, as well as
history of the individual), stressors may trigger excessive
corticosteroid secretion over an extended duration; in
such cases, the response switches from being an adap-
tive one into a maladaptive one, marked by transient or
chronic pathology. Major depression and cognitive
impairment are two conditions that represent the so-
called stress-induced disorders of the brain. The first of
these seems to reflect a sub-optimal stress-coping strat-
egy and may largely originate from impairments of the
mechanisms contributing to the homeostatic negative
feedback processes that act to protect the organism
against excessive exposure to corticosteroids; frequently,
depressed mood is accompanied by impaired cognition
and hyperemotionality, indicating that stress impacts on
multiple, inter-related neural circuits. A number of
human and animal studies have demonstrated the dis-
ruptive effects of excessive corticosteroid secretion on
cognition [10-12]. There is now strong evidence that the
latter involve structural changes, including severe reduc-
tions in the dendritic arborization of hippocampal and
prefronto-cortical neurons [13-15]. and synaptic loss
[16-18]. In addition, recent studies indicate that stress
may initiate neurodegenerative processes that increase
the risk for severe cognitive deficits such as those seen
in dementia of the Alzheimer type [19]. Lastly, chroni-
cally elevated levels of corticosteroids interfere with cen-
tral and pituitary integrators and regulators of the
hypothalamo-pituitary-adrenal (HPA) axis, resulting in
impaired corticosteroid negative feedback and sustained
corticosteroid secretion [20].
The soliloquy we’ve come to know and love
Glucocorticoids and mineralocorticoids fulfill their char-
acteristic biological functions through the mediation of
glucocorticoid receptors (GR) and mineralocorticoid
receptors (MR), respectively. Both of these receptors are
present in the brain; while GR are expressed ubiqui-
tously (most strongly in the hippocampus), MR are
more discretely distributed (strongly expressed in certain
hippocampal subfields and the septum, and moderately
expressed in the amygdala and hypothalamic paraventri-
cular nucleus) [21]. The MR has a 7-10-fold greater affi-
nity for corticosterone as compared to the GR [22]. It is
thus estimated that the MR is some 80% occupied
under basal conditions, and that the GR only becomes
activated when corticosterone levels rise during the daily
circadian peak of corticosterone secretion or after stress.
Although aldosterone may be synthesized in the brain
[2,3], it should be noted that brain MR do not normally
‘see’ their prototypic endogenous ligand; aldosterone is
produced in the periphery at concentrations that are too
low to have a direct impact on the brain and in any
case, the hormone does not easily cross the blood-brain
barrier. On the other hand, it should be mentioned that
ligand availability is subject to local regulation through
activation/deactivation of cortisol/corticosterone through
the actions of 11b-hydroxysteroid dehydrogenase [23].
The MR and GR belong to the phylogenetically
ancient superfamily of nuclear receptors, all of which
are transcriptional factors. For the sake of clarity, we
will herein refer to nuclear MR and GR as nMR and
nGR, respectively. Whereas the unliganded nMR is pri-
marily localized in the nucleus, the unoccupied nGR
resides in the cytoplasm and only translocates to the
nucleus upon ligand activation. This process depends on
the dissociation of a host of chaperone and co-chaper-
one molecules, including heat shock protein 90 (hsp90)
as well as on the inclusion of a nuclear translocation
signal in the receptor protein [24]. Like other nuclear
receptors, nMR and nGR are organized according to
canonical modules, including a ligand binding domain
(LBD), a DNA binding domain (DBD), and two activa-
tion functions (AF-1 and AF-2) at their N- and C-term-
inals, respectively. The various domains share
considerable homologies (homology between nMR and
nGR: ~57% in LBD; ~94% in DBD). Interactions of the
DBD with hormone response elements (HRE) in the
promoters of specific genes result in the induction or
repression of gene transcription and subsequently,
changes in the expression of proteins that influence cel-
lular functions. Homologies also exist within the HRE
sequence of various nuclear receptors, and receptor
recruitment and interactions with specific co-regulator
proteins (co-activators/-repressors) may endow these
structurally similar receptors with differing specificities
and potencies.
Stage props
Transcriptional and translational effects of corticosteroid
receptor activation have been demonstrated using drugs
such as actinomycin D and cycloheximide, respectively.
On the other hand, demonstration that nGR mediate
corticosteroid effects have relied on the use of the
antagonist mifepristone (RU 38486, also a potent
antagonist of progesterone receptors), while spironolac-
tone or oxoprenoate (RU28318) have been used to
demonstrate mediation through nMR. Other potentially
useful additions to the pharmacological toolbox for
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studying events mediated by nGR and nMR include
established chaperone inhibitors of hsp90 (e.g. cisplatin
and geldanamycin; [25]) and of the FK506-binding pro-
teins (e.g. GPI1046; [26]).
Drop sceneb
The mode of action of corticosteroids summarized
above, i.e. involving gene transcription and translation,
may be generalized to all steroid hormone receptors,
including those for estrogens. Since nuclear receptors
become transcriptionally active upon ligand activation,
their actions are, by definition, slow in onset and poten-
tially long-lasting (hours to days, or even months); at
best, gene transcription and translation require a mini-
mum of 20-30 minutes (translation takes longer than
transcription) [27]. However, steroids have been impli-
cated in the elicitation of a number of ‘rapid’ or ‘fast’
physiological and behavioral responses to external sti-
muli; some examples of fast steroid-mediated responses
and the mechanisms thought to underlie their actions
are presented in Additional File 1. Historically, the idea
that steroids can rapidly alter neuronal excitability and
conduction stemmed from work on the actions of sex
steroids by Kawakami and Sawyer in 1959 [28] and
Woolley and Timiras in 1962 [29].
As a rule, fast responses are considered to be those
that occur within the first 20 minutes of increased ster-
oid secretion, i.e. in a much shorter timeframe than that
required for effects on gene transcription and protein
synthesis. Somewhat erroneously, these fast actions are
referred to as ‘non-genomic’; in fact, rapidly triggered
signaling cascades may ultimately converge in the
nucleus to regulate gene transcription and protein
synthesis. Distinction between the ‘fast’ and ‘slow’
actions of steroid hormones is more of mechanistic than
of behavioral or physiological importance, since the lat-
ter are the integrated manifestations of sequential
events. Viewed from this perspective, the rapid actions
of steroids may be considered as ‘primers’ of the sub-
strates responsible for the manifestation of transcrip-
tional events triggered by nuclear receptors; kinase
cascades activated during early phases of steroid action
and which lead to the phosphorylation of regulatory
sites of nuclear receptors [30-32] are a good example of
such priming functions.
Many of the changes in behavior and brain physiology
that are listed in Additional File 1 reflect rapid
responses of the hippocampus to steroid hormones. For
example, corticosteroids have been consistently shown
to influence cognition and their effects are thought to
result from their ability to directly or indirectly alter the
excitability of hippocampal neurons. The hippocampus
has been extensively studied for a number of pragmatic
reasons. The input-output connections of the different
hippocampal subfields are well defined, making their
electrophysiological study convenient. Of all brain areas,
the hippocampus has been best studied in the context
of long-term potentiation (LTP) and long-term depres-
sion (LTD), the electrophysiological correlates of learn-
ing and memory, functions in which the hippocampus is
strongly implicated [[33-35]; see Figure 2 and Additional
File 2]. The hippocampus also serves as an important
homeostatic regulator of the HPA axis upon which it
exerts a strong negative drive [36,37] through the med-
iation of nMR and nGR [38].
Although the attention paid to the hippocampus is justi-
fiable because of its role in the regulation of many beha-
vioral and physiological processes, it should be
remembered that it constitutes only part of a complex
neuronal network that underpins physiology and beha-
vior in normal and pathological states. For example,
although the hippocampus plays an important role in
the regulation of the HPA axis, it should be noted that
other brain areas such as the prefrontal cortex [39],
amygdala and bed nucleus of the stria terminalis, under
the modulatory influence of monoamines from the hind-
brain [40], contribute to the control of corticosteroid
secretion; all these areas have reciprocal connections
with the hippocampus and express nGR.
Several studies have begun to define how corticoster-
oids and other steroids act on different brain structures
to produce integrated and adaptive behavioral and phy-
siological responses, e.g. the prefrontal and orbito-fron-
tal cortices (executive functions, including attention,
behavioral flexibility, declarative memory, decision mak-
ing [41,13,14,42]), thalamus (processing and gating of
sensory input [43], amygdala (evaluation of emotional
load of sensory input and regulation of fear [44], ventral
striatum (motivation and reward [45] and decision-mak-
ing [42]), and the cerebellum (learning of motor tasks
[46]. Of these, the amygdala, involved in the control of
fear, aggression and cognition (see Additional File 1),
has been the most intensively studied. Interesting work
by Roozendaal and colleagues has demonstrated a cross-
talk between rapid GC and noradrenergic signaling in
contextual memory consolidation [44,47] and suggests
that endocannabinoids are key mediators of this cross-
talk [48].
Putative membrane receptors - pirates with legs
to stand on?
The message that emerges from the previous section is
that nuclear receptors, acting as transcriptional factors,
are unlikely to mediate rapid actions of the sort listed in
Additional File 1. Nevertheless, the identity of the mole-
cular entity that allows rapid transduction of steroid sig-
nals remains elusive. Interestingly, some of the fast
responses to corticosteroids are reportedly attenuated in
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the presence of pharmacological antagonists of nGR (RU
38486 [49] or nMR (spironolactone [50,51]). These find-
ings suggest certain homologies between the classical
nuclear receptors and the putative receptors mediating
the rapid actions of these steroids. Nevertheless, the
existence of another class of receptors, with distinct che-
mistries and cellular localizations, and that are not sen-
sitive to the above-named antagonists, cannot be
dismissed.
Several mechanisms that may account for membrane-
mediated transduction of the rapid actions of estradiol
have been proposed (see Figure 3). Substantial evidence
supports the view that classical nuclear estrogen recep-
tors (nER of which there are two isoforms, ERa and ERb)
are integrated into, or in close proximity of, the cell
membrane. One hypothesis is that palmitoylation facili-
tates the interaction of these receptors with caveolins, a
family of proteins that associate with cholesterol and
sphingolipids to form caveolae within the plasma mem-
brane and which are implicated in signal transduction.
While some authors describe protein-protein interactions
of such membrane-associated nER with other membrane
proteins as a mechanism to explain rapid estrogen signal-
ing [52-54], others propose mediation by a membrane-
Figure 2 Schematic representation of induction and recording of long-term potentation and long term depression in the
hippocampus. Long-term potentiation (LTP) and long-term depression (LTD) can be induced by applying an electrical stimulus by placing an
electrode placed in the Schaffer collateral-commissural (SCC) pathway and recording from the CA1 subfield. Upper panel shows a coronal section
through the dorsal hippocampus, with schematic representation of intra-hippocampal connectivity. The CA1 pyramidal cell layer receives input
from the entorhinal cortex through the dentate gyrus [DG] and the CA3 pyramidal layers and the SCC; the subiculum carries hippocampal
efferents. Lower left-hand panel illustrates measurements of LTP as excitatory postsynaptic potentials (EPSP, peak amplitude or slope of the latter).
Initially, low-frequency stimulation (LFS, usually less than 0.1 Hz) is applied to the Schaffer collaterals to establish a stable baseline (usually for 20-
30 min), after which LTP is induced by high-frequency stimulation (HFS; usually 100 Hz), followed by LFS. Successful induction of LTP can be
assumed when the post-HFS EPSP peak amplitude (or slope) exceeds that seen before HFS and is maintained for at least 60 min. ① depicts a
single evoked EPSP; ② represents a potentiated EPSP after HFS. Lower right-hand panel shows that EPSP recordings also serve to detect LTD.
After initial baseline recording, low-frequency stimulation (LFS, usually 1 or 5 Hz) is applied to the SCC; successfully induced LTD can be assumed
when the post-LFS EPSP peak amplitude (or slope) is smaller than that observed before LFS. ① shows a single baseline EPSP; ② depicts a
example of a depressed EPSP after LFS.
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bound ER (mER) that is coupled to a Gaq protein. Evi-
dence for the latter includes the observation that estra-
diol induces activation of the phospholipase C- protein
kinase A (PLC-PKC-PKA) pathway in nER knockdown
mice [55]. The same investigators demonstrated rapid
electrophysiological effects of STX, a diphenylacryla-
mide-based selective estrogen receptor modulator, in
nER knockout animals; STX, which does not bind to
either isoform of the nER, proved to be more potent than
estradiol in their in vitro and in vivo test systems [55,56].
While no mER has been cloned and characterized to
date, GPR 30, an orphan G protein-coupled receptor
(GPCR), has been identified as a potential transducer of
estrogen signals that originate at the cell membrane
[57,58]. GPR 30 was shown to display similar structural
characteristics to other membrane receptors [57], but
was nevertheless viewed with a certain amount of skepti-
cism. For example, the nER antagonist ICI 182,780 exerts
agonistic effects on this receptor [59] and neurons from
GPR 30 knockout mice still display rapid responses to
Figure 3 Schematic representation of corticosteroid-triggered multiple tentative rapidly influencing neuronal function. Corticosteroids
are represented by red triangles. Nuclear GR (nGR) interact with caveolins [cf. [81]]; the interaction probably depends on posttranslational
modifications of nGR to yield so-called membrane corticosteroid receptors (mCR). Alternatively, CS-initiated intracellular signaling cascades may
result from corticosteroid binding to proteins embedded in the plasma membrane, e.g. G-protein-coupled receptors (GPCR) [75] which, upon
activation, activate protein kinase A (PKA) and protein kinase C (PKC) in turn. Other evidence points to membrane-bound corticosteroid binding
proteins that interact with members of the src family of kinases (SFK) to activate the mitogen-activated protein kinase (MAPK) pathway and/or
modulate the activity of other membrane-associated proteins, e.g. NMDA receptors and other ion channels with potential steroid binding sites
[76,85,86,222]. Under basal conditions, nGR are tethered in the cytoplasm in the form of a protein complex that includes the chaperone heat
shock protein 90 (hsp90) which itself may directly interact with Src kinases and the MAPK kinase, MEK [cf. [83]]. Additionally, direct interactions
between the nGR and Ras which may be functionally relevant have been described [84]. Finally, MAPK-mediated phsophorylation of nGR may
influence the transcriptional activity of nGR [32]. Thus, corticosteroid actions at the plasma membrane can converge and prime or potentiate
hormonal actions on gene transcription.
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estradiol [60], the latter finding suggesting that GPR 30
may co-exist alongside (an)other mER with unique phar-
macological properties. Notably, in an extension of their
earlier work, Revankar et al. [61] exploited chemical biol-
ogy to explore the subcellular localization of GPR 30 and
its signaling potential; on the basis of observations in 4
cancer cell lines, they discarded the notion that sufficient
GPR 30 is localized at the plasma membrane and rather
suggested that GPR 30 localized in the endoplasmic reti-
culum serves as an intracellular transmembrane receptor
for estrogen.
Interestingly, Toran-Allerand and colleagues [62,63]
described a high affinity (KD for estradiol: 1.6 nM)
caveolin-associated protein in the plasma membranes of
neonatal (but not adult) neocortical and uterine tissues.
This so-called ER-X seems to come closer to meeting
the expectations of a distinct mER insofar that it cannot
be blocked by ICI 182,780 [62]; moreover, these authors
found that experimentally-induced ischemic stroke in
adult animals is accompanied by an upregulation of ER-
X in the brain, suggesting that the ER-X mediates the
neuroprotective actions ascribed to estrogens.
It is tempting to hypothesize, that the mediators of
rapid corticosteroid effects may share similar basic prop-
erties and mechanisms with the proposed membrane-
associated estrogen receptors. The existence of a mem-
brane-bound receptor for corticosteroids (herein
referred to as mCR) was postulated by Willmer in 1961
[64]. Willmer’s suggestion that steroid hormones inter-
digitate with, and alter the permeability of, lipids in the
plasma membrane, lost currency as evidence that ster-
oids bind to intracellular proteins (nuclear receptors)
and stimulate protein synthesis began to accumulate
from 1961 onwards [65,66]. However, in 1974 Satre and
Vignais described corticosterone binding to mitochon-
drial preparations from the adrenal and kidney [67], a
finding that eventually extended to other cell types [68].
A series of authors provided evidence for membrane-
bound steroid recognition sites in the brain [69-71];
among these, Towle and Sze demonstrated specific cor-
ticosterone binding to plasma membrane preparations
from rat brain synapses [72]. These membrane binding
sites had a relatively high affinity for corticosterone (KD
10-7 M vs. 10-9 M in the case of cytosolic binding sites)
and treatment with phospholipase A2 or phospholipase
C led to complete dissociation of membrane-bound cor-
ticosterone. Similarly, Orchinik et al. described the pre-
sence of mCR in brain synaptosomal fractions obtained
from the amphibian Taricha granulosa (rough-skinned
newt) [69]. These receptors showed pharmacological
specificity for corticosterone and cortisol (KD 10
-9 M),
and lesser affinities for aldosterone and other natural
and synthetic steroids (such as dexamethasone and RU
38486). Importantly, Orchinik et al. reported a linear
relationship between the potencies of various com-
pounds (corticosterone being the most potent) in inhi-
biting male reproductive behavior (inhibition by
corticosterone within 8 minutes of application) and
their ability to bind the putative mCR [69]. In subse-
quent studies, these authors described similar neuronal
mCR in mammalian [73] and bird [74] brains and sug-
gested a role for guanine nucleotide-binding proteins in
the formation of a ternary complex of corticosterone
and the putative neuronal mCR, i.e. the mCR appears to
be coupled to G proteins [75]. Additional evidence for
the existence of a mCR was eventually provided by
Orchinik’s colleagues who solubilized and partially puri-
fied membrane-bound corticosterone binding sites from
the amphibian brain [76]; the assumed mCR had a
molecular weight of about 63 kDa, as compared to 97
kDa and 110 kDa in the case of the nGR and nMR,
respectively. More recently, studies by Johnson et al.
[77] provided anatomical evidence for the existence of
nGR within the postsynaptic density of neurons in the
rodent amygdala. At present it is unclear as to whether
there are any homologies between the mCR and either
the nGR or nMR.
Ultrastructural studies with an antibody against puri-
fied rat nGR revealed immunoreactivity associated with
the plasma membrane of rat hippocampal and hypotha-
lamic neurons [78]. Notably, membrane-associated
immunoreactive nGR sites were observed in or near
membranes covering the dendrites and somata of pyra-
midal neurons; nGR immunoreactivity was also seen in
the vicinity of the Golgi complex. With regard to the
plasma membrane, Liposits and Bohn [78] noted that
nGR immunoreactivity was associated with coated vesi-
cles which, together with their localization along the
membrane, suggested that nGR might either be trans-
ported and inserted into the plasma membrane, or
coupled to mediators of transduced signals. In this
respect, parallels may be drawn with what was reported
above with respect to the membrane-bound mediators
of estrogen actions. Palmitoylation of the nER has been
suggested as a mechanism that facilitates integration of
the nuclear receptor into (or the proximity of) the cell
membrane, thus providing access to BSA-conjugated
steroids and interactions of the receptor with mem-
brane-associated signaling proteins [79]. While it
remains to be shown that classical corticosteroid recep-
tors can be palmitoylated and trafficked to the plasma
membrane, recent studies have identified a highly con-
served 9-amino acid motif in the ligand binding domain
of estrogen, progesterone, androgen and glucocorticoid
receptors that could serve as a substrate for palmitoyla-
tion [80]; these observations suggest that palmitoylation
may be a general mechanism that allows nuclear recep-
tors to double up as bona fide membrane receptors.
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Supporting the plausibility of this view, Matthews et al.
have shown that nGR interacts with caveolin [81].
Many unliganded nuclear receptors (e.g. nGR), are
tethered in the cytoplasm through their association with
chaperone proteins such as heat shock protein 90
(hsp90); this complex is dissociated upon arrival of the
ligand [24]. Interestingly, hsp90 is known to interact
with src kinase [82], a membrane-proximal kinase
thought to mediate the rapid activation of the MAPK
pathway by corticosteroids. In addition, hsp90 interac-
tions with MEK2, another kinase upstream of MAPK,
has been shown to mediate MAPK pathway activation
by estradiol [83]. In fact, nGR itself reportedly interacts
with Raf-1, a downstream effector of Ras, and upstream
regulator of the MAPK pathway [84].
Receptors for several neurotransmitters (some of
which are ion channels) have been shown to bind CS
[76,85,86]. Although it remains unclear as to whether
these interactions serve as a conduit of the rapid actions
of CS, the latter seems plausible given the evidence that
neurosteroids can modulate chloride flux and thereby,
neuronal excitability, by binding to an allosteric site on
the GABAA receptor [87].
In summary, there is growing support for the view
that CS can initiate signaling at the plasma membrane
through one or more of the following mediatory
mechanisms: (i) G protein-coupled membrane-bound
CS receptors, (ii) steroid modulatory sites on plasma-
bound neurotransmitter receptors, (iii) interactions
between cytoplasmic CS receptors and kinase family-
interacting chaperone molecules, and/or (iv) palmitoyla-
tion. Elucidation of the mechanisms underlying the
rapid actions of CS will require a stepwise analysis of
the contributions of each member of this ‘interactome’ -
a major challenge.
From the sightlines - peeping on a rapidly
changing stage
This section will focus on the cellular endpoints that
can be used to support the view that corticosteroids
rapidly influence neuronal activity, focusing on altera-
tions in membrane excitability and signaling cascades
that originate at or close to the plasma membrane.
However, attempts to summarize the existing literature
are confronted with the fact that the results derive from
disparate protocols and experimental models in different
laboratories. For example, a wide range of corticosteroid
doses and exposure times have been applied to studying
synaptic transmission in either rat or mouse dissociated
hippocampal neurons or hippocampal slices. We will,
however, first consider early studies on hypothalamic
neurons by Kasai and colleagues and Saphier and Feld-
man, using in vitro ionotophoresis. Kasai and colleagues
showed that cortisol excited tuberoinfundibular neurons
in the paraventricular nucleus (PVN) which project to
the median eminence from where their neurosecretory
products reach the anterior pituitary; however, these
authors also reported inhibitory effects of cortisol in the
PVN, suggesting this to result from inhibition of nora-
drenergic inputs [88-90]. Saphier and Feldman, observed
a significant reduction in the spontaneous firing rates of
similar hypothalamic neurons after the application of
corticosterone [91,92]; these changes had a rapid onset
and were maintained even after iontophoresis of the
hormone was stopped. Further, they reported on a sub-
set of neurons whose activity was not altered by corti-
costerone; glutamate-induced excitation of these
neurons was however suppressed in the presence of
corticosterone.
Together, the studies described above represent a
hypothalamic electrophysiological correlate of the nega-
tive feedback control of adrenocortical secretion, and
illustrate that corticosteroids can elicit different
responses from different brain areas or neuronal popula-
tions within an anatomical region or specific neuronal
phenotypes within a given subfield; moreover, the
responses depend on neural inputs to the particular set
of neurons under investigation [91,93]. Given the sug-
gested importance of the hippocampus in mediating glu-
cocorticoid negative feedback (see above), it is surprising
that Barak [94] failed to observe any changes in the
activity of hippocampal neurons upon applying corticos-
terone. As will become evident below, despite a large
number of studies that focussed on the CA1 subfield of
the hippocampus, it is difficult to compile a consensus
view of how corticosteroids impact on the activity of
this region.
Examining spike accommodation in hippocampal neu-
rons, Vidal et al. reported that corticosterone (1 μM)
decreases spike numbers [95], whereas Joëls and de
Kloet [96] and Beck et al. [97], using 1 nM, observed
the steroid to increase spike numbers and decrease the
after-hyperpolarisation (AHP) amplitude; these effects
were abolished in the presence of spironolactone (nMR
antagonist). Importantly, 30 nM of corticosterone, which
activates nGR (as well as nMR), decreased spike num-
bers and increased AHP amplitude, leading the authors
to conclude that the bifurcating actions of low and high
doses of corticosterone reflect the activation of nMR
and nGR, respectively [96]. Further, given the gradual
rise in corticosterone levels upon arrival of a stimulus
(e.g. stress), they proposed a concentration-dependent
biphasic cellular response to corticosterone, i.e. an initial
increase in neuronal excitability, followed by suppression
of neuronal excitability. Similar findings were reported
earlier by Rey et al. (effects observed between 0.2 and
10 nM corticosterone; peak increase in spike amplitude
at 2 nM corticosterone) [98].
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Given that the amplitude of the AHP is determined by
Ca2+ and Ca2+-dependent K+ transients [99,100], it is
interesting that Landfield and colleagues reported that
high doses of the synthetic GR agonist RU28362 (7 μM)
enhance the amplitudes of voltage-dependent calcium
channel (VDCC)- mediated Ca2+ spikes in a protein
synthesis-dependent manner [101]. In contrast, Tian et
al. suggested that the increase in the slow after-hyperpo-
larization amplitude seen after exposure to high doses of
corticosterone may involve cAMP-dependent phosphor-
ylation and Ca2+-activated K+ channels [102]: dexa-
methasone (1 μM), a synthetic glucocorticoid with high
selectivity for the nGR, blocked PKA-mediated inhibi-
tion of Ca2+-activated K+ channels without influencing
VDCC-mediated Ca2+ currents in a mouse pituitary cell
line (AtT20). It should be noted that Tian et al. treated
their cells with dexamethasone for 2 h and that these
effects required de novo protein synthesis for their mani-
festation [102,103]. Because activation of NMDA recep-
tors results in an influx of Ca2+ and, as mentioned
above, Ca2+ determines the AHP amplitude [99], corti-
costeroid-NMDA receptor interactions have been ana-
lyzed in a number of studies using electrophysiological
recordings as the endpoint. For example, Wiegert et al.
showed that exposure of mouse hippocampal slices to
corticosterone (100 nM) for 20 min resulted in NMDA
receptor-mediated suppression of primed-burst potentia-
tion and synaptic potentiation [104] (induced by stimu-
lation at 10 Hz, in contrast to the more commonly-used
100 Hz LTP regimen). In contrast, theta-burst potentia-
tion (see Additional File 2 for information on different
stimulation protocols), which requires activation of both
NMDA receptors and voltage-dependent Ca2+-channels
was not affected by corticosterone treatment. The same
authors also described a role for L-type Ca2+ channels
in the synaptic actions of corticosterone [105]. In the
context of the question of whether corticosterone can
rapidly alter synaptic function, it is important to note,
however, that Wiegert et al. [104] and Chameau et al.
[105] made their electrophysiological recordings
between 1 and 6 h after initial exposure to the steroid.
On the other hand, Chameau et al. [105] found by
quantitative PCR that corticosterone did not change the
mRNA expression of the pore-forming Cav1 subunit of
the L-type Ca2+ channel, and ruled out transcriptional
mechanisms in the effects they observed.
Wiegert et al. [104] showed that RU 38486 blocks cor-
ticosterone-induced impairments of synaptic plasticity,
implying mediation of the effects by nGR. A similar
conclusion was drawn from their previous work on
GRdim/dim mice, a strain carrying a point mutation of
the DNA binding domain of the nGR which precludes
transcriptional effects; briefly corticosterone did not
influence VDCC-mediated Ca2+ currents in hippocampal
slices from GRdim/dim mice [106]. To address the ques-
tion of how glucocorticoids enhance Ca2+ currents on
the one hand, and reduce synaptic efficacy on the other,
Joëls’ laboratory examined synaptic efficacy 1-4 h after a
brief exposure to corticosterone (1 μM CORT for 20
min) [107]. Their investigations revealed that synaptic
transmission was potentiated when VDCCs were acti-
vated, and impaired only when NMDA receptors were
activated; moreover, they found that these effects were
RU 38486-sensitive, indicating their mediation by nGR.
Together, these observations point to the importance of
considering all of the individual components that contri-
bute to the overall response in field recordings. In this
respect, it is worth recalling that the magnitude of LTP
and LTD is a function of the number of AMPA recep-
tors that are present at the synaptic surface (see Addi-
tional File 2). Miniature excitatory postsynaptic currents
(mEPSCs, which represent the spontaneous release of
neurotransmitter quanta from presynaptic terminals) are
mediated by AMPA receptors and changes in the
mEPSC amplitude represent postsynaptic changes in
AMPA receptor properties and/or numbers. Indeed,
Martin et al. observed that corticosterone increases the
amplitude (but not frequency) of miniature excitatory
postsynaptic currents and demonstrated that corticoster-
one increases trafficking of the GluR1 and GluR2 subu-
nits of the AMPA receptor to the synaptic surface,
apparently through an nGR-dependent mechanism
[108]. This last study is in good agreement with that by
Karst and Joëls, who also reported nGR-mediated
increases in mEPSC amplitude [109].
Despite the overwhelming amount of data implying a
role for nGR and/or nMR in mediating the effects of
corticosterone on synaptic transmission, other evidence
indicates that the rapid actions of corticosterone are
mediated by mCR. For example, corticosterone was
shown to dose-dependently (0.1, 1, 10, 100 μM) inhibit
inward NMDA receptor-mediated currents, within sec-
onds, in primary hippocampal cultures [110]. This effect
faded upon wash-out of the hormone and was not
reversible with RU 38486; assuming that RU 38486
binds specifically to nGR, the latter finding precludes
mediation through nGR. The latter interpretation is sup-
ported by the finding that the effects of corticosterone
were reproducible with membrane-impermeable BSA-
conjugated corticosterone. Results from Takahashi et al.
also dismissed a mediatory role for nGR or nMR in the
mediation of corticosterone effects; however, they
reported that the steroid prolongs the elevation of
NMDAR-mediated Ca2+ influx in dissociated hippocam-
pal neurons independently of VDCC and mobilization
of intracellular Ca2+ stores [111]. In contrast, other
authors reported that corticosterone and BSA-corticos-
terone (30 min) inhibit the peak amplitude of NMDA
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receptor-mediated Ca2+ currents in the CA1 subfield of
the mouse hippocampus [93], that bath application of
corticosterone to hippocampal slices inhibits VDCC-
mediated Ca2+ currents within minutes [112], and that
corticosterone increases synaptosomal uptake of Ca2+
upon K+-induced depolarization [113].
At this stage, it is important to note that some of the
discrepant reports on corticosterone-induced changes in
NMDAR-mediated Ca2+ currents may reflect the differ-
ent durations of exposure to the steroid used by differ-
ent groups. In fact, Wiegert et al. defined a narrow time
window (10 min before high frequency stimulation) dur-
ing which corticosterone facilitates synaptic potentiation;
longer bath applications of the hormone were found to
impair synaptic potentiation [114].
Most of the evidence reviewed above presumes post-
synaptic sites of corticosterone action. New studies of
CA1 neurons also report changes in the frequency of
mEPSCs, thus implying presynaptic sites of action.
Thus, Karst et al. [50] and Olijslagers et al. [51] showed
that corticosterone increases the frequency of AMPA
receptor-mediated mEPSCs. Both studies show that
application of BSA-conjugated corticosterone produced
similar effects to those obtained with corticosterone,
and interestingly, that de novo protein synthesis was not
essential for their manifestation. Together, these results
hint at the involvement of receptors other than nGR
and nMR; nevertheless, nMR antagonism by spironolac-
tone resulted in a blockade of the corticosterone-
induced increases in mEPSC frequency. [50,51] [but see
[114]]. On the other hand, since RU 28362, a synthetic
nGR agonist, did not reproduce the effects of corticos-
terone, and because the effects were not antagonizable
with RU 38486, Karst et al. [50] and Olijslagers et al.
[51] proposed that the putative mCR might share iden-
tity with the nMR. The latter suggestion is supported by
experiments in mice with targeted mutations of nGR
and nMR [50,106] and work by Groc et al. [115]. Using
dissociated hippocampal cells to visualize AMPA recep-
tor trafficking, the latter authors observed increased
synaptic surface expression of GluR2 subunits of the
AMPA receptor within minutes of exposure to corticos-
terone, BSA-conjugated corticosterone or aldosterone
(the prototypic nMR agonist).
Related to the electrophysiological measures summar-
ized in the last few paragraphs, Olijslagers et al. demon-
strated that activation of the MAP kinase ERK1/2 is
crucial for the corticosterone-induced increase in
mEPSC frequency [51]. Interestingly, their experiments
showed non-dependence on postsynaptic G protein
activity on mEPSC frequency. Rather, by using the H-
Ras G12V strain of mouse which displays strong presy-
naptic activation of ERK1/2 due to constitutively high
expression of the H-Ras transgene, they suggested that
the actions of corticosterone are initiated at presynaptic
sites, increasing the probability of presynaptic neuro-
transmitter release [50,51]. Moreover, in agreement with
other studies [111], Olijslagers et al., reported that intra-
cellular Ca2+ stores do not influence mEPSC frequency
upon exposure to corticosterone [51]. Lastly, it should
be noted that although the involvement of G proteins in
corticosterone-induced changes in mEPSC frequency
were excluded [51], direct infusion of GDPbS into the
postsynaptic cell prevented the decrease of the peak
amplitude of IAcurrents (postsynaptic K
+ conductance)
by corticosterone [51]; this finding points to mediation
through a postsynaptic mCR-dependent mechanism.
A number of studies suggest a role of G proteins in
the mediation of the rapid actions of corticosterone. For
example, ffrench-Mullen showed that the inhibition of
Ca2+ currents by cortisol in guinea pig CA1 neurons
depends on pertussis toxin-sensitive G-proteins [112].
The same author also showed that the effects of cortisol
are significantly diminished in the presence of PKC inhi-
bitors (BIS and PKCI 19-31), and ruled out a role for
PKA in the mediation of the actions of cortisol [112].
Similarly, Chen and Qiu showed that corticosterone
rapidly inhibits VDCC-mediated Ca2+ currents in a
phaeochromocytoma cell line of neural origin (PC12
cells), and that inhibition of G proteins by application of
either pertussis toxin or GDPbS significantly attenuates
the ability of either corticosterone or BSA-corticosterone
to stimulate the influx of Ca2+ [116]. They also demon-
strated that activation of PKC with phorbol 12-myristate
13-acetate results in an inhibition of Ca2+ entry though
VDCC after depolarization with K+, and that the appli-
cation of corticosterone activates PKC within 5-15 min-
utes. Lastly, like Qi et al. [117] who obtained similar
results in primary hippocampal neurons, Chen and Qiu
[116] showed that both, corticosterone and BSA-conju-
gated corticosterone trigger the activation of PKC and a
series of MAP kinases (ERK1/2, p38MAPK and c-Jun)
in PC-12 cells; maximum kinase activation occurred
within 15 min of application of the hormone and the
effects could not be attenuated by RU 38486.
Reality
Blood (and brain) corticosteroid levels rise and fall in a
pulsatile manner under basal (unstimulated) conditions,
and the circadian and stress-induced rises in corticoster-
one secretion occur gradually, taking minutes or even
hours to reach peak levels. This raises the question of
whether corticosteroid levels above a certain threshold
have an impact on physiology and behavior and pro-
vokes curiosity about the mechanisms that could under-
pin the rapid biological actions of corticosteroids.
Original interest in the fast actions of corticosteroids
was awakened by attempts to understand the ‘fast’ and
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‘slow’ negative feedback actions of corticosteroids at the
level of the pituitary and the brain. Pioneering research
by Mary Dallman used ingenious experimental designs
which eventually provided evidence for the rapid actions
of corticosteroids in reducing their own secretion [118]
and, as already mentioned, the search for electrophysio-
logical correlates was pursued in the hypothalamus in
parallel. Today, predominantly based on work from the
laboratories of Stafford Lightman and colleagues [4], it
would appear that the ultradian rhythmic secretion of
relatively high-amplitude corticosterone may serve to
ensure low levels of adrenocortical activity during the
organism’s resting phases; these brief pulses presumably
act rapidly to suppress brain-pituitary drive of adrenal
secretion.
At the behavioral level, Orchinik et al. [69] elegantly
demonstrated the potency of corticosterone in inhibiting
male reproductive behaviour in newts, within 8 min of
application. In mammals, Jozsef Haller and colleagues
have shown that corticosterone injections elicit aggres-
sive and anxiety-related behavior (latency of 7 min) in
rats whose endogenous adrenocortical activity is sup-
pressed by inhibition of 11b-hydroxylase activity with
metyrapone [119-121]. Several authors have also
described the ability of corticosterone to rapidly alter
locomotor behavior in rodents; for example, acute sys-
temic injections of corticosterone to rats (placed in a
novel environment) were shown to stimulate locomotion
within 7.5 minutes of administration [122].
Rhythms in the secretion of corticosteroids and other
neuromodulatory molecules can influence experimental
outcomes, even in in vitro settings. For instance, Ca2+
currents into hippocampal CA3 neurons in in vitro pre-
parations are highest during the subjective night, when
corticosterone levels are highest [123]. Similarly, Brunel
and de Montigny [124] reported that the firing rate and
pharmacological responsiveness of CA3 neurons is high-
est during the nocturnal peak in corticosterone secretion
in vivo. Importantly, using hippocampal slice cultures,
Chaudhury et al. demonstrated that the amplitude of
LTP is greatest during the subjective night [125]. Addi-
tionally, Eckel-Mahan and colleagues reported circadian
dependency in the efficiency of consolidation of long
term memory [126].
Many studies support the idea that stress, a large part
of whose actions are mediated by corticosteroids, influ-
ences learning and memory. Besides the quality and
intensity of the stressor, the context in which the stress-
ful stimulus is perceived, is an important determinant of
the behavioral outcome. The latter is more easily
explained in terms of ‘intrinsic’ and ‘extrinsic stress
[127]; ‘intrinsic stress’ refers to situations in which stress
is either elicited by, or directly associated with, the cog-
nitive experience (e.g. spatial learning), whereas
‘extrinsic stress’ describes situations in which the stress
occurs outside the context of the momentary stress
situation (e.g. foot shock stress before spatial learning).
According to a model developed by Sandi and Pinelo-
Nava [127], learning and memory will be facilitated by
stressors that activate the same (or similar) neural cir-
cuitries that are required for interpreting and respond-
ing to a particular cognitive challenge. Supporting this
view, Cahill and McGaugh [128] and Sandi [129]
reported that emotionally arousing experiences are bet-
ter remembered than neutral ones. In fear conditioning
experiments, Cordero et al. noted that post-training cor-
ticosterone levels correlate with the strength of stimulus
required to encode memories [130,131]. Moreover, the
importance of corticosterone in information acquisition
and consolidation of memory is well known, even if still
poorly understood [132-135]. The relative importance of
nMR and nGR in these processes are elegantly discussed
by Schwabe et al. [136], and Revest et al. [134] have
demonstrated a mediatory role of the MAPK pathway in
the facilitation of hippocampus-dependent contextual
fear conditioning by corticosteroids. In the previously-
cited work on long-term contextual fear memory by
Eckel-Mahan and colleagues [126], rhythms of MAPK
(ERK1/2) activation were shown to coincide temporally
with the degree of persistence of memory. Given that
corticosterone acutely increases ERK1/2 phosphorylation
[51,116,117,134], the results presented by Eckel-Mahan
and colleagues [126] should be considered in the con-
text of the hypothesis proposed by Sandi and Pinelo-
Nava [127] and the pioneering work by Oitzl and de
Kloet [137]; in addition, since the amygdala plays a
major part in the regulation of fear and has reciprocal
interactions with the hippocampus and other cognition-
regulating brain areas, future interpretations of the work
by Eckel-Mahan and colleagues [126] should embrace
the idea that corticosteroids can exert actions on a net-
work of interconnected brain structures, whose indivi-
dual responses will determine the ultimate behavioral
output.
Besides the acute behavioral and physiological actions
of corticosteroids, much research has been focused on
understanding the influence of chronically elevated cor-
ticosteroid secretion. Notwithstanding the above-men-
tioned fact that corticosteroids may exert acute effects
during the rising phase of the endocrine response to
stress, it is important to note that the latter is, generally,
a protracted one. Thus, while the acute rises in corticos-
teroid secretion may shape the overall long-term
response, the longer duration of corticosteroid exposure
after stress allows recruitment of an array of intracellu-
lar responses (including nuclear receptor-mediated
events) and cellular, physiological and behavioral adapta-
tions. It is important to note that, although the
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adrenocortical response to stress primarily serves an
adaptive purpose, in certain circumstances, it may
switch to being maladaptive, marked by transient or
chronic pathology, as discussed earlier in this article.
The physiological and behavioral responses to stress
depend on myriad molecules and processes, with an
important contribution by corticosteroids; effects of the
latter are often studied in isolation at the cost of other
contributory factors and the neural networks which reg-
ulate, or may be regulated by, corticosteroids. This can
be exemplified by considering our earlier discussion of
corticosteroid interactions with glutamatergic transmis-
sion and reports that the direction and/or magnitude of
LTP and LTD are influenced by the intensity and emo-
tional value of a given stressor; for example, LTP is only
reduced in animals exposed to uncontrollable stress
[138], but not in animals that can escape from the stres-
sor [139]. Using the paradigm of foot-shock stress,
Wang et al. reported that stress induces a shift in synap-
tic plasticity; thus, whereas stress facilitates LTD induc-
tion, it impairs LTP induction [140]. Besides showing
that these effects of stress can be blocked by RU 38486,
these last authors showed that blockade of the NMDA
receptor restores LTP inducibility in stressed animals;
further they demonstrated that stress-induced changes
in synaptic efficacy can be abolished by prior adminis-
tration of Ro25-6981, a specific antagonist of the NR2B
subunit of the NMDA receptor. A role for the NR2B
subunit in the synaptic plasticity thought to be essential
for the orchestration of the behavioral response to stress
was also suggested by Wong et al. who showed that
Ro25-6981 reverses elevated platform stress-induced
deficits in spatial learning and memory, as tested in the
Morris water maze (MWM) [141].
The NR2B subunit is predominantly associated with
extrasynaptic NMDA receptors whose activation
depends on glutamate “spill-over”, a phenomenon that
can be mimicked with threo-b-benzyloxyaspartate
(TBOA), a blocker of glutamate re-uptake. Wong et al.
[141] found that TBOA application to animals 5 min
before low frequency stimulation resulted in the suc-
cessful induction of LTD, indicating that stress leads to
glutamate “spill-over”. Linking LTD with stress-induced
memory impairment, the authors showed that prevent-
ing LTD induction by infusion of a GluR2 peptide ana-
logue that cannot be internalized abolished the ability of
stress to cause memory deficits in the MWM test; these
findings add to the evidence that acute stress results in
the internalization of AMPA receptors, followed by
synaptic depression and learning and memory deficits.
We previously discussed how the MAPK signaling
pathways may be linked with LTP and LTD (and learn-
ing and memory). In this respect, it is interesting to
note that this pathway is concomitantly activated by
stress, presumably due to activation of nGR [142,143],
believed to be essential for the phosphorylation of
ERK1/2 [134]. Moreover, the observation that tail shock
and restraint stress robustly activate ERK1/2 and impair
synaptic potentiation in the CA1 subfield suggests a
major role for the MAPK pathway in mediating the
actions of stress [144]. In addition to inducing the phos-
phorylation of ERK1/2, stress activates other kinases (e.
g. p38 MAPK, CaMKII) and pCREB within 2 min of
swim stress [145]. Surprisingly, however, the latter
responses are accompanied by a reinforcement (rather
than impairment) of LTP in the dentate gyrus of the
hippocampus. This finding indicates that different stres-
sors may elicit quite different electrophysiological
responses and/or, that the synaptic effects of stress differ
from one hippocampal subfield to another. Since the
effects of stress on biochemical and electrophysiological
signalling in the dentate gyrus were found to be subject
to modulation by serotonin [145], it is plausible that dif-
ferential monoaminergic innervation of the different
hippocampal subfields defines the ultimate cellular
response.
We summarize some potential mechanisms that may
account for the rapid and slower effects of corticoster-
oids on neuronal physiology, with a focus on synaptic
events, in Figure 4. An attempt is made to show how
signals originating at the neuronal surface are integrated
both at the synaptic and transcriptional levels.
Critique
From the preceding, it appears safe to assume that,
irrespective of the behavioural or physiological out-
comes, acute and chronic elevations of corticosteroid
secretion initiate common mechanisms and biochem-
ical processes; convergence of these events will depend
on parameters such as exposure dosage and time, as
well as the context in which they occur. Given the
potential for convergence (as well as potentiation),
improved knowledge of the initial stages of corticoster-
oid signalling, whether membrane- or nuclear recep-
tor-mediated, is clearly desirable. Studies on the rapid
neural actions of corticosteroids are likely to gain
further interest, especially as newer analytical tools
become available and knowledge about the fast actions
of other steroid hormones grows. It therefore seems
appropriate to list some critical issues and needs, the
consideration of which may foster progress through
cautious reflection:
• definition of the terms “rapid” or “fast” actions
of corticosteroids in terms of the timeframe within
which a clearly defined (electro)physiological, bio-
chemical and/or behavioural response is elicited in
animals or neuronal cell and brain slice preparations;
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• standardized test protocols (steroid dose, animal
or cellular models, and sexcof animals); in in vitro
studies, drug diffusion times and active concentra-
tions achieved at target cells should be controlled;
similarly, in in vivo research, pharmacokinetic fac-
tors, including solvent and route of administration,
should be considered; age of animals, but also of
material used for in vitro testing, is important
because of dynamic age-related changes in the
expression of key partners such as glutamate recep-
tor subunits [146]; since corticosteroids are secreted
according to a strict circadian rhythm, both the
Figure 4 Working model of sequential corticosteroid influences on synaptic physiology. Corticosterone-mediated changes in synaptic
transmission occur at different levels and in different sequential steps. ① depicts synaptic transmission under basal conditions. Neuronal
excitation results in glutamate secretion from synaptic vesicles at presynaptic sites into the synaptic cleft. Glutamate binds to postsynaptic
glutamate-gated ion channels (in particular, AMPA receptors), which open to permit ion fluxes (Na+ influx, K+ efflux) across the AMPA receptor,
resulting in a depolarization of the postsynaptic cell. Due to a voltage-dependent Mg2+ block in its membrane domain, the NMDA receptor
remains inactive under basal conditions, and is activated when a certain transmission threshold is reached. ② Exposure to corticosteroids (e.g.
during stress) may lead to activation of ERK1/2 in the presynaptic terminal (possibly through membrane corticosteroid receptors [51]); increased
glutamatergic stimulation of postsynaptic AMPA receptors results in an increase in the frequency of AMPA receptor-mediated miniature
postsynaptic currents (mEPSCs). ③ Enhanced activation of AMPA receptors in the previous step further depolarizes the postsynaptic membrane
and activates NMDA receptors. Activated NMDA receptors (Na+ and Ca2+ influx, K+ efflux) lead to further depolarization of the postsynaptic cell,
resulting in the opening of voltage-dependent Ca2+ channels (VDCC) and high postsynaptic concentrations of Ca2+. Corticosteroids may
stimulate glutamate secretion so strongly, causing glutamate “spill-over” which activates not only synaptic, but also extrasynaptic, glutamate
receptors [141]; the latter are mainly NMDA receptors of the NR2B subtype. The increased intracellular levels of Ca2+ trigger a cascade of Ca2
+-dependent signaling pathways in the postsynaptic cell, which may, in turn, induce the phosphorylation and de-phosphorylation of
postsynaptic glutamatergic receptors and of nuclear corticosteroid receptors (nMR and nGR). Activation of extrasynaptic NMDA receptors is
thought to trigger NR2B-dependent kinases, which might initiate trafficking of extrasynaptic NR2B receptors into the postsynaptic surface.
Furthermore, Ca2+-dependent signaling pathways in the postsynaptic cell participate in the regulation of AMPA receptor trafficking to and from
the synaptic surface, as indicated in ④. Phosphorylation of nuclear corticosteroid receptors, influences their translocation to the nucleus and
therefore, their transcriptional activity [32], as indicated in ⑤.
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availability of endogenous corticosteroids as well as
of primary and secondary downstream effectors will
vary over the day - this demands testing at a given
circadian time to ensure comparable measurements
[123-125].
• while surgical adrenalectomy is a useful approach
to ensure that only the actions of exogenously-admi-
nistered steroids are being recorded, the operation
requires anaesthesia and may involve potentially
confounding post-operative pain; chemical adrena-
lectomy is a good alternative (e.g. blockade of corti-
costeroid synthesis with metyrapone), but it may
have (indirect) non-selective effects on the produc-
tion of other steroids; adrenalectomy, in general,
induces massive apoptosis and stimulates neurogen-
esis in the dentate gyrus within just a few hours,
changes that probably result in reorganized neuro-
nal circuits and measurable outputs [147].
• attention to the fact that acute and chronic corti-
costeroid exposures differ significantly, and that
administration of corticosteroids only mimics an
intermediate phase of the organism’s response to
stress;
• clear exclusion of transcriptional and transla-
tional events initiated by activation of cognate
nuclear receptors;
The show must (will) go on
While the nuclear receptor-mediated actions of corticos-
teroids are well established, those that appear to be
mediated through non-classical, possibly membrane-
bound receptors, have perhaps not received sufficient
appreciation. The lack of consistent results (see need for
standardization in previous section), compounded by the
relatively fruitless hunt for putative membrane receptors,
accounts for the scepticism that haunts this area of
research. Increased respectability might be gained by
initially seeking answers to some of the following ques-
tions:
• How can the neural actions ascribed to peripher-
ally-produced corticosteroids be distinguished from
those that result from those elicited by corticoster-
oids thought to be produced in neural tissue?
• Can the rapid actions of corticosteroids observed
predominantly in the CA1 subfield of the hippocam-
pus be generalized to other hippocampal subfields,
or indeed other brain regions?
• Do the endpoints assessed after application of cor-
ticosteroids reflect actions exclusively at the hippo-
campus? In vitro, do we get only a partial (or
perhaps, false) picture? In vivo, are we monitoring
responses from a network of corticosteroid-sensitive
brain regions? How are the outputs modulated by
other neurochemical states and inputs?
• Do corticosteroids directly interact with membrane
proteins? What is the chemical identity of these
molecules? Are they distinct from the known nuclear
receptors and if not,
◦ Do they represent post-translational modifica-
tions (e.g. palmitoylated versions of the nuclear
receptors, as suggested for the mER)?
◦ Is there biochemical evidence for interactions
with other known membrane receptors (e.g. glu-
tamate receptors); do these receptors have allos-
teric binding sites for corticosteroids as well as
for pharmacological antagonists of nMR and
nGR? (cf. estrogens, progestins)
• How do events that are triggered by corticosteroids
at the membrane funnel into long-term cellular and
organismic adaptations (e.g. by positive or negative
priming of the gene machinery regulated by nMR
and nGR)?
• How do the rapid actions of corticosteroids contri-
bute to their longer-lasting actions (e.g. ‘priming’ of
nuclear receptor-mediated events?)
• Is it possible to define corticosteroid actions - fast
and slow - in terms of spatio-temporal maps, keep-
ing in mind that damage induced in a relatively
short time in one area may take longer to spread to
other interconnected areas [cf. [13]]?
• Is it feasible to generate genetic or pharmacological
tools that will facilitate acceptance and further study
of mCR?
Appendix
a) Corticosteroids: way upstream - the title of this
article is adapted from Alan Ayckbourne’s stage play
Way Upstream in which two couples on a boating
holiday run into some strange happenings.
b) A painted cloth in front of which a short scene is
played while the main stage set is changed.
c) Research on the rapid actions of corticosteroids
has mainly exploited male rodents or tissues derived
from them. Corticosteroid secretion is strongly influ-
enced by sex, as are physiology and behaviour. Many
of the physiological and behavioural readouts moni-
tored in such studies reflect the prevailing sex ster-
oid milieu; in females, sex steroids are secreted in a
cyclical fashion.
Additional file 1: Summary of rapid effects of corticosteroids and
estrogens on the central nervous system [148-181].
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1756-6606-3-2-
S1.PDF ]
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Additional file 2: Synaptic plasticity and learning and memory [182-
221].
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1756-6606-3-2-
S2.PDF ]
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